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Introduction
The endothelium is a specialized cell layer that forms the inner lining of blood vessels 
and is the key regulator of vascular homeostasis [1]. Endothelium functions not only as 
a barrier but it actively engages in the inflammatory process by recruiting leukocytes 
from the blood via the production of cytokines, chemokines and adhesion molecules 
[2]. Endothelial cells are therefore an attractive target for anti-inflammatory therapy 
specifically by virtue of their pivotal role in the pathology of (chronic) inflammatory 
diseases, including atherosclerosis, diabetes and sepsis [3, 4]. Various pharmacological 
approaches to counteract (endothelial) cell activation are already applied in the clinic 
and improve disease status, including corticosteroids, nonsteroidal anti-inflammatory 
drugs (NSAIDs), and inhibitors of NFκB signaling, but existing therapies often carry a 
substantial risk of systemic toxicity due to the lack of cellular and molecular specificity 
[5].
Small interfering RNAs (siRNAs) are a class of new molecular drugs that offer 
high molecular specificity and potent silencing of disease associated genes [6]. The 
physicochemical properties of siRNAs demand their formulation into a delivery system 
that enables modification of the pharmacokinetic profile of the siRNA, reduces off-target 
toxicity, and improves the therapeutic index, thereby generating potent therapeutics [7, 
8]. Lipid-based drug delivery has become an established technology platform and has 
gained considerable clinical acceptance due to its remarkable flexibility. Lipid-based 
carriers such as liposomes, can be manufactured in various sizes, tailored on demand 
to introduce cell specificity, can efficiently encapsulate small or macromolecules, and 
show low toxicity in clinical trials [9]. Among cationic lipids, SAINT-C18 (1-methyl-
4-(cis-9-dioleyl)methyl-pyridiniumchloride) is a promising candidate for designing an 
efficient siRNA delivery system due to its capability to transfect cells in the presence of 
serum and with low toxicity [10]. Addition of SAINT-C18 amphiphile into formulation 
of conventional liposomes can potentially enhance their ability to efficiently encapsulate 
and intracellularly deliver siRNA with low toxicity, without reducing liposomes 
stability and target-specificity in vivo.
Aims of the thesis
This thesis focuses on the development of a lipid-based carrier suitable for 
endothelial-specific in vivo delivery of siRNA. We aimed to:
• design and characterize a liposomal targeted siRNA carrier system applying the 
cationic amphiphile SAINT-C18,
• study suitability of vascular cell adhesion protein 1 (VCAM-1) and E-selectin 
for targeted siRNA delivery into inflamed endothelium and validate molecular 




targets for siRNA mediated anti-inflammatory intervention, 
• investigate the potential of the developed siRNA carriers to interfere with 
disease associated endothelial activation by knocking down relevant target 
genes in vivo and to demonstrate proof-of-concept of endothelial specific 
siRNA based anti-inflammatory therapy.
Outline of the thesis
Upon inflammatory stimulation, each organ displays a vascular bed specific 
expression pattern of cell adhesion molecules providing challenging opportunities 
to deliver drugs or siRNAs to organ specific (micro)vascular endothelial subsets. 
In chapter 2 we introduce the general concept of endothelial heterogeneity and its 
consequences for targeted therapeutic intervention and discuss the key challenges for 
the development of an efficient and endothelial-specific siRNA delivery system that can 
effectively silence engagement of endothelial cells in the patho(physio)logy of disease.
Recently, the transcription factor Egr-1 was demonstrated to be upregulated 
in experimental neointimal pulmonary arterial hypertension (PAH) [11], that is 
characterized by the development of neointimal lesions in small pulmonary arteries, 
leading to increased right ventricular (RV) afterload and -failure [12]. In chapter 3, we 
aimed to uncover a novel role for Egr-1 as a molecular inducer for PAH development 
using catalytic oligodeoxynucleotides (DNAzymes) that bind to target RNA sequences 
resulting in specific RNA degradation. The effects of Egr-1 downregulation on 
pulmonary vascular remodeling were studied in experimental flow-associated PAH 
rats by i.v. administration of DNAzymes formulated with cationic lipid 1,2-dioleoyl-
3-trimethylammonium-propane (DOTAP) and by application of the PPAR-γ ligand 
pioglitazone.
Despite significant progress with regard to the development of drug delivery 
devices, so far only a few types of carriers for siRNA delivery into endothelial cells 
have been developed. In chapter 4 we embarked on an attempt to develop a targeted 
carrier for selective delivery of siRNA into inflamed endothelium by combining the 
cationic SAINT-C18 amphiphile with conventional liposome technology (so-called 
SAINT-O-Somes). To create specificity for inflamed endothelial cells, SAINT-O-Somes 
were harnessed with antibodies against VCAM-1 respectively E-selectin. Specificity 
of siRNA delivery and efficacy of VE-cadherin gene silencing was tested in TNFα 
activated primary endothelial cells in vitro. VE-cadherin gene expression is restricted 
to endothelial cells and maintained under TNFα stimulation making it a suitable model 
gene for our studies. Since little is known about the intracellular fate of siRNA delivery 
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systems internalized via VCAM-1 and E-selectin, we studied the intracellular trafficking 
of both siRNA and SAINT-O-Somes in the activated endothelial cells. SAINT-O-
Somes were further characterized with regard to their physicochemical properties 
and suitability for in vivo siRNA delivery. Finally, we studied their pharmacokinetic 
behavior in C57Bl/6 mice.
In chapter 5, we continued to explore the potential of SAINT-O-Somes for in vivo 
application. We studied whether anti-VCAM-1 SAINT-O-Somes carrying siRNA were 
able to cell specifically downregulate gene expression in inflamed endothelium in 
vivo. Pharmacokinetic behavior, biodistribution, and in vivo toxicity of intravenously 
administered anti-VCAM-1 siRNA SAINT-O-Somes were investigated in a simple 
inflammation model, in mice challenged with TNFα. Focusing on kidneys as our 
organ of interest, we demonstrated the potential of anti-VCAM-1 siRNA SAINT-O-
Somes to deliver VE-cadherin and NFκB p65 (RelA) specific siRNAs to the inflamed 
renal microvasculature of TNFα challenged mice. Effects of endothelial specific RelA 
downregulation on the endothelial inflammatory response towards LPS were studied 
by laser microdissection of different vascular beds prior to analysis of gene expression.
To achieve effective gene silencing, siRNAs need to be released from the carrier 
into the cytoplasm, where it associates with the RNA-induced silencing complex 
(RISC). In chapter 6, we designed and characterized new SAINT-based siRNA carriers 
incorporating protamine, a small cationic protein used as a transfection enhancer, 
with the aim to improve the efficacy of in vivo gene silencing in endothelial cells by 
improved siRNA release. So called SAINT-liposome-polycation-DNA (S-LPD) and 
SAINT-liposome-polycation (S-LP) were formulated by combining SAINT:DOPE 
liposomes and protamine, complexed with siRNA and carrier DNA, or siRNA only. 
These particles were examined for size, stability and the influence of polyethyleneglycol 
grafting. In vitro Toxicity and VE-cadherin gene silencing efficacy of S-LPD and S-LP 
in endothelial cells was compared to conventional  liposome-polycation-DNA particles 
based on DOTAP : Cholesterol liposomes [13].
Finally, in chapter 7, we summarize the results of the research presented in this 
thesis and discuss implications and perspectives for future development of targeted 
siRNA-based anti-inflammatory therapy.
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Summary
Increased insight in the role of endothelial cells in the pathophysiology of cancer, 
inflammatory and cardiovascular diseases, has drawn great interest in pharmacological 
interventions aiming at the endothelium in diseased sites. Their location in the body 
makes them suitable targets for therapeutic approaches based on targeted drug delivery. 
Functional heterogeneity of the microvascular bed in normal organ homeostasis has 
been appreciated for a long time, and more recent studies have revealed heterogeneity 
in endothelial reactivity to inflammatory stimuli as well. Upon stimulation, each 
organ displays a vascular bed specific pattern of cell adhesion molecules providing 
challenging opportunities to deliver drugs or small RNAs to organ specific (micro)
vascular endothelial subsets. In this review we introduce general concepts of 
endothelial heterogeneity in relation to disease state and its consequences for targeted 
therapeutic interventions. Furthermore, we will describe novel approaches to interfere 
with endothelial cell engagement in disease with a main focus on siRNA therapeutics 
and currently used nonviral lipid and polymer-based siRNA delivery systems. The last 
part of this review addresses some technical issues that are essential in proving the 
concept of target mRNA knockdown in a vascular bed specific manner, and the further 
development of effective endothelial cell specific drug delivery devices.





The endothelium is the cell layer that forms the inner lining of blood vessels. It is 
a spatially distributed system that extends to all organs and tissues of the body. The 
endothelium is a key regulator of vascular homeostasis and functions not only as a 
barrier but also acts as an active signal transducer for metabolic, hemodynamic and 
inflammatory input that modifies the function and morphology of the vessel wall [1]. 
Moreover, the smallest blood vessels engage in angiogenic processes that accompany 
wound healing, tissue repair, and solid tumor growth [2]. Depending on the location in 
the body, endothelial cells (ECs) display their own molecular make up that drives basic 
behavior as well as responses to inciting stimuli [3]. Along the vascular tree, major 
differences are observed in EC phenotype, permeability, endocytosis and transcytosis 
capacities, and responsiveness to activation. For example, brain microvasculature 
is an integral part of the impermeable blood brain barrier, whereas liver sinusoidal 
endothelial cells form a densely fenestrated sieve with support of a discontinuous 
basement membrane and engage in clearance of a variety of molecular entities from the 
circulation [4, 5]. Furthermore, endothelial cells aligning the postcapillary venules are 
primarily responsible for mediating leukocyte trafficking, whereas arteriolar endothelial 
cells regulate vasomotor tone [2].
Being a keeper of internal homeostasis, ECs are continuously sensing and 
responding to changes in the extracellular environment. They are the first cells 
exposed to proinflammatory stimuli associated with systemic diseases such as 
atherosclerosis, sepsis, diabetes, vasculitis and other (chronic) inflammatory disorders. 
The proinflammatory stimulus leads to activation of ECs, the status of which varies 
according to the nature of the activating factor and the location of the vascular bed [6]. 
For example, significant differences in response to proinflammatory stimuli such as 
tumor necrosis factor (TNF)-α are observed between venous and arteriolar endothelial 
cells [7]. Activated endothelium also accompanies the outgrowth of many tumors, 
where sustained formation of new blood vessels is one of the key factors leading to 
progression of the disease [8].
A variety of pharmacological approaches to counteract endothelial activation are 
already applied in the clinic, tested in clinical trials, or in preclinical development, 
including the potent inhibitors that affect receptor tyrosine kinase activation as well as 
specific kinases involved in the various signal transduction cascades [9]. Besides kinase 
inhibitors, drugs based on RNA interference (RNAi), i.c., small interfering RNAs 
(siRNAs), offer increased specificity and efficient gene silencing of diseaseassociated 
genes. Formulation of such drugs in a targeted delivery system would create potentially 
powerful gene silencing therapeutics with diminished side effects, and hold a great 
promise for successful treatment of chronic inflammatory diseases and cancer. In the 
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current review, we will focus on recent developments in the design of siRNA delivery 
approaches with the aim to therapeutically affect abnormal endothelium. We will 
introduce general consideration of endothelial heterogeneity in relation to disease 
state and its consequences for targeted therapeutic interventions. Next we will focus 
on drugs based on RNA interference, on their mechanisms of action and obstacles 
limiting application of siRNA in the clinic. We will provide an overview of currently 
used siRNA delivery systems designed to interfere with endothelial cell engagement in 
disease, with emphasis on nonviral approaches including lipids and polymers. In the 
last part, we will discuss the in vivo complexity of endothelial cell behavior and the 
difficulties encountered when attempting to mimic this in an in vitro setting. This calls 
for the use of new technologies that allow for endothelial gene expression analysis and 
studying targeted drug delivery devices in the complex environment of an organ.
Endothelial Heterogeneity and Abnormal ECs as Therapeutic Target
In recent years, the endothelium has become an attractive target for therapeutic 
intervention by virtue of its association with the pathophysiology of many diseases, 
its prevalence throughout the body, and its accessibility to intravenously administered 
agents [10]. Much effort has been dedicated to the development of drugs that inhibit 
endothelial cell activation to treat chronic inflammatory diseases, to disrupt tumor 
vasculature, or to halt angiogenesis. However, most of the drugs lack specificity for 
the endothelium, giving rise to adverse effects in other cells in the body. Formulation 
of highly potent drugs in EC specific delivery devices will be essential to provide these 
drugs with a potential for future clinical application [9, 11]. Critical for success of these 
approaches is the identification of target epitopes on the diseased endothelial cells as 
well as choosing the proper drug target and concurrent molecular entity for therapeutic 
effects. This justifies an approach in which knowledge of microvascular endothelial cell 
biology and pharmaceutical sciences are combined, as we do in our own research as 
well as in outlining the content of this review.
Endothelial cells are differentially regulated in diverse (micro)vascular beds and 
in time, giving rise to the phenomenon of endothelial cell heterogeneity. Structural 
and functional heterogeneity of endothelial cells is evident between arteries and 
veins as well as between the capillaries in the different organs. Not only do different 
endothelial cell subsets in one organ have a different phenotype and function related 
to organ physiology, they also behave differently under pathophysiologic stress. As 
a consequence, endothelial cells in various (micro)vascular beds express different 
proteins at different moments in time during disease initiation and development [4].The 
differentially expressed determinants on the surface of disease-activated endothelium 
are excellent targets for drug delivery towards abnormal endothelium, and include 
molecules involved in leukocyte rolling and adhesion to the vascular wall during 




the inflammatory process, and in other disease–related processes [12]. It should be 
noted, however, that many of these proteins are not homogeneously expressed by 
the endothelium but rather are (micro)vascular bed specific. Moreover, the kinetics 
of disease-induced target epitope expression may spatiotemporally differ between 
endothelial cell subsets in the diseased sites [13]. This could have either an advantageous 
or a detrimental effect with regard to specificity and/or extent of local accumulation of 
the drug delivery formulation.
Endothelial Adhesion Molecules as Targets for Inflamed Endothelium
Their position in the body makes the ECs one of the first cells to be exposed to 
systemic proinflammatory stimuli such as bacterial endotoxin (lipopolysaccharide, 
LPS), or systemically released cytokines such as TNF-α, interleukin (IL)-1, and IL-6.
Exposure to these proinflammatory conditions leads to EC activation and expression of 
cell adhesion molecules and various other molecules associated with proinflammatory 
activation. Several of them can serve as molecular targets for siRNA delivery in 
pathologies such as atherosclerosis [vascular cell adhesion molecular-1 (VCAM-





 integrin, E-selectin [17, 18]), and pulmonary inflammatory 
diseases (intercellular adhesion molecular-1 (ICAM-1), [19]).
Ideally, target epitope expression should be restricted to diseased endothelium, 
thereby preventing accumulation of a drug in nondiseased endothelium. E-selectin 
is one of the few molecules that meet this criterion. Moreover, it is not present on 
nonendothelial cells and its expression is dramatically upregulated during inflammation 
in vivo. The endothelial adhesion molecule expression induced by systemic stimuli 
varies between organs according to the nature of the stimulus and the origin of the 
vascular bed. Each organ displays a unique pattern of molecules providing further 
challenging opportunities to deliver drugs or small RNAs to organ specific (micro)
vascular endothelial subsets (Fig. 1A). For example, van Meurs et al., observed 
E-selectin expression primarily in glomerular ECs in a study on microvascular 
activation following induction of systemic inflammation in a hemorrhagic shock mouse 
model. In contrast, VCAM-1 expression was induced in all vascular segments except 
in glomerular ECs [20]. 
Furthermore, it is important to note that target epitopes should reside at the exterior of 
the cell membrane of the target cells, that they are not avidly shed, and that they become 
internalized upon ligand binding and intracellularly processed when intracellular drug 
release is a prerequisite. E-selectin is an internalizing receptor that routes its ligands 
including antibodies and antibody modified-liposomes to the lysosomal compartment 
[21–23]. This feature substantially contributes to its outstanding quality as a target to 
be exploited for intracellular delivery of small RNAs. Also VCAM-1 and ICAM-1 are 
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Figure 1. Simplified scheme of disease-associated cellular events that lead to endothelial cell activation and 
provide challenging opportunities for targeted siRNA delivery. (A) Microvascular endothelial cells (EC) are 
exposed to microenvironmental factors that differ from one vascular bed to the other, as a consequence of 
which their basic phenotype may vary. Exposure to proinflammatory conditions (e.g., TNFα or IL-1b) leads 
to activation and expression of a variety of cell adhesion molecules and other determinants associated with 
disease which may vary between endothelial subsets. (B) The differentially expressed determinants on the 
surface of disease-activated endothelium are excellent targets for drug delivery to abnormal endothelium. The 
targeted siRNA carriers (e.g., lipoplexes, polyplexes, or liposomes) interact with cell surface receptors and 
are taken up into the target cells via receptor-mediated endocytosis. The resulting endocytotic vesicles fuse 
to form early endosomes. These mature into late endosomes which ultimately become part of the lysosomes,
where proteins and nucleic acids are degraded by acid hydrolases. To achieve target gene silencing, siRNAs 
need to be released from the carrier and escape from the endosomes into the cytoplasm, where it associates 
with the RNAi machinery and directs the cleavage of target mRNAs. 1 The activated intracellular signal 
transduction cascade controls transcription factor activation and proinflammatory gene expression. 2. 
Once escaped from the endosomes, the siRNA incorporates into the RNA-induced silencing complex, is 
subsequently unwound, and next guided to the complementary site in the target mRNA. This leads to specific 
gene silencing of, for example, (2a) transcription factors (TFs) NFκB or AP-1 to block downstream signaling 
pathways regulated by these TFs, or (2b) other determinants associated with disease activity. 




internalizing receptors [24] and although their expression is not restricted to endothelial 
cells in inflamed sites, they can still be considered attractive targets, provided that the 
therapeutic advantages outweigh the undesired side effects of delivery of the drug into 
nondiseased endothelium.
Integrins αvβ3 and αvβ5 are interesting molecules to consider for targeted drug 
delivery to ECs as they are upregulated in physiological as well as pathological 
angiogenic vessels, and possess proangiogenic functions [11, 25, 26]. For example, 
peptides with the arginine glycine aspartic acid (RGD) amino acid sequence show high 
affinity for the αvβ3-integrin, as do αvβ3 specific antibodies. During the past decade, 
RGD-peptides have become an established tool for the targeting of drugs and imaging 
agents to αvβ3-integrin expressing ECs [27].
Small Interfering RNAs, a New Class of Therapeutics
Three decades ago, RNA was generally considered to be no more than just a passive 
intermediate transferring information from DNA to the protein-synthesizing machinery. 
The discovery of catalytic RNAs in the 1980s had a tremendous impact on this dogma. 
Small RNAs are key players in triggering post-transcriptional or translational gene 
silencing and nowadays they represent one of the most promising new classes of 
molecular target-specific therapeutics. There are two main groups of small RNAs, i.e., 
siRNA and micro RNA (miRNA), which are short double-stranded RNA (dsRNA) 
molecules generally composed of 21-23 (siRNA) or 18-25 (miRNA) nucleotides (nt). 
siRNA generally has perfect complementary sequence to its target messenger RNA 
(mRNA), leading to gene-specific degradation of the mRNA, in contrast miRNA has 
predominantly imperfect sequence complementarity in the 30 untranslated region of 
the target mRNA which leads to translational silencing without mRNA degradation [28, 
29]. Mostly chemically synthesized siRNA molecules are used to silence target gene 
expression, exploiting the cells’ endogenous RNAi processing machinery for further 
processing before hybridization with its target mRNA. Another method of mediating 
the RNAi effect involves exogenously administered vector-based short hairpin RNA 
(shRNA) which is transcribed in the nucleus, further processed and transported to the 
cytoplasm for silencing activity [30]. Although a vector-based shRNA system may 
have advantages such as robust and long term gene silencing in the transfected cell, its 
expression is hard to control with regard to length of time and efficiency. Moreover, 
vector-based shRNA require nuclear entry, which represents an additional hurdle in 
the overall mechanism of action. The use of exogenous siRNA results in direct gene 
silencing since it does not require additional processing. Furthermore, its effect is 
transient, which may be preferred in a therapeutic setting.
RNAi has become a widely used approach for silencing gene expression in vitro and 
in vivo, to study gene functions and elucidate molecular mechanisms in mammalian 
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cells. Both endogenously produced siRNAs and chemically synthesized siRNAs 
become assembled within a multisubunit ribonucleoprotein complex known as the 
RNA-induced silencing complex (RISC). Subsequently, the sense strand of the siRNA 
is removed, leaving the antisense strand to guide the ‘activated’ RISC to its site of 
action where it hybridizes with its target mRNA resulting in mRNA cleavage by the 
RNAi endonuclease Argonaute 2 [31]. This type of silencing occurs when siRNA 
molecules perfectly match their complementary target mRNA. The RISC complex 
can also guide and incorporate partially homologous siRNA strands to target mRNAs, 
causing translational repression of the particular mRNA present in the cytoplasm. In this 
case the siRNA acquires miRNA activity, and can control the expression of numerous 
target mRNAs at the translational level, which remains a critical issue for therapeutic 
applications of RNAi [32, 33]. The siRNA-loaded RISC is recycled for additional 
rounds of gene silencing activity. The rate of target cell divisions determines the 
persistence of siRNA, mediated gene silencing not of shRNA when stably incorporated 
in the DNA, since the siRNAs will be diluted after each cell division.
Apart from siRNA, gene silencing involving RNAi can also be achieved using so 
called DNA enzymes (deoxyribozymes) which can be perceived as molecular scissors 
containing a catalytic core of 15 deoxyribonucleotides that binds to and cleaves its 
target RNA (reviewed by [34]). Moreover, interference with miRNA pathways is 
possible by means of antisense oligonucleotides, which are complementary to the 
sense strand of the target miRNA duplex and block its processing (reviewed by [35]). 
RNAi based drugs may allow for specific silencing of a gene involved in downstream 
signaling of proinflammatory and pro-angiogenic stimuli, whereas interference with 
miRNA pathways may result in downregulation of multiple proinflammatory genes, 
both theoretically leading to suppression of inflammation. The recent discovery of 
miRNA involvement in tumor angiogenesis [36] furthermore paves the road for 
inhibitory miRNAs to be further developed for endothelium-specific therapy of cancer. 
For reasons of space limitations we will restrict ourselves in the next paragraphs to 
siRNA, although several of the concepts discussed may be applicable to other types of 
inhibitory RNAs as well.
siRNA Delivery Into Endothelial Cells
The first decade of targeted endothelial drug delivery research focused on the 
identification of molecular targets on the endothelial cells that are selectively expressed 
during disease development [27, 37]. Initially employed drugs include the cell 
death inducing molecules doxorubicin [38] and the proapoptotic heptapeptide dimer 
D(KLAKLAK)2 [39]. Moreover, anti-inflammatory enzymes that provide anti-oxidant 
protection [40] and corticosteroids that inhibit intracellular signaling and concomitant 
proinflammatory gene expression [16, 22] have been formulated and were shown to 




improve disease status. Also, targeted delivery of antisense oligonucleotides has been 
investigated in detail in the last 15 years [41]. The design of new siRNA delivery devices 
for future therapeutic application has benefitted and will continue to benefit from the 
knowledge gained by advancements in targeted delivery of these conventional drugs.
Unmodified and uncomplexed siRNAs (so-called naked si- RNAs) have a half-life 
in the blood of only a few minutes which limits their usefulness as a drug per se. They 
are rapidly eliminated by renal excretion and are also degraded with a t½ 1 h by serum 
RNases [42]. Due to its relatively large molecular weight (13 kDa), polyanionic nature 
(40 negatively charged phosphate groups), and high hydrophilicity, naked siRNA will 
furthermore not passively cross the membrane of unperturbed cells. To apply siRNA 
for in vivo gene silencing, it either needs to be chemically modified or formulated 
and delivered to protect it from rapid clearance and degradation by serum RNases, to 
prevent activation of the immune system and interactions with other nontarget cells, 
and to allow cellular uptake, finally leading to participation in the RNAi pathway [43]. 
Formulation of siRNA in an advanced drug delivery system has the advantage that it 
does not affect the pharmacological potential of the siRNA, contrary to various forms 
of chemical modification.
Ideally, for in vivo application the siRNA needs to be efficiently formulated 
in carrier systems to contain sufficient amounts of siRNA and be stable to resist 
degradation or disassembly in the circulation. At the same time, carrier systems 
should allow efficient release of the cargo once the carrier arrives in the endocytotic 
vesicles and/or in the cytoplasm of the cells (discussed in more details by [44]). 
Physicochemical characteristics of the carrier such as composition, size and surface 
charge can handicap pharmacokinetic behavior by engaging in interactions with serum 
proteins including serum albumin, lipoproteins and immunoglobulins, which leads to 
clearance by cells of the reticulo-endothelial system (RES) in the spleen and liver [45]. 
To limit these interactions and prolong circulation half-life, the surface charge can be 
masked by covering the carrier with a hydrophilic polymer such as (poly)ethylene 
glycol (PEG) [46]. Recent work revealed that lipid-based particles containing high 
levels of PEG (10 mol%) are not taken up by the liver after systemic administration 
[47]. Moreover, different types of polymers, such as pH-sensitive or diffusible PEG 
variants are available for shielding off the vesicle surface. Such alterations provide 
increased carrier responsiveness to low pH and enhanced cytoplasmic release of its 
cargo [48]. Furthermore, it is possible to control the circulation time of particles by time 
dependent diffusion-mediated release of PEG shielding which can reduce side effects 
of formulations containing toxic drugs [49, 50].
Size and shape of the carrier also determine its fate in vivo. Most of the systems 
used for targeting endothelial cells have size ranging between 100–200 nm to minimize 
clearance from the circulation by renal filtration and liver uptake [51, 52]. Moreover, 
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several groups reported that nano-sized particles are more effective than microsized 
particles in targeting microcapillary sized vessels, where red blood cells (RBCs) 
preferentially line up in the center of the blood stream, thereby increasing nanoparticle 
contact with the vessel wall. They may, however, not be adequate for targeting to 
medium-to-large size blood vessels due to RBC-hindered margination which may 
decrease particle contact with the vessel wall [53, 54] The shape of the carrier may also 
determine the extent and mode of interaction with the vascular wall and affect the rate of 
cellular uptake. Spherical nanoparticles are typically proposed for vasculature-targeted 
drug delivery by virtue of their relatively unrestricted capacity to navigate through the 
circulatory system bringing along minimal risk of vessel occlusion [10]. Furthermore, 
Muro et al., reported that in vitro endothelial ICAM-1-targeted 0.1 x 1 x 3 μm elliptical 
polystyrene disks exhibited four times slower uptake rates when compared to 0.1 and 5 
μm diameter spheres [55].
To achieve specific delivery of siRNA to the desired endothelial subsets, carriers 
can be surface-modified with monoclonal antibodies, peptides, small-molecule ligands, 
or for example, aptamers, to recognize determinants on the cell surface. Antibodies and 
small antigen binding fragments have been studied most extensively for this purpose. 
A good ligand needs to be specific for a target expressed on the surface of ECs and 
should bind with sufficient capacity to promote internalization of drug loaded carrier to 
deliver therapeutically effective amounts of drug into the cells’ interior. Furthermore, 
ligand-target molecule binding should avoid (prolonged) disruption or interference 
with normal functions of the target epitope [56]. Targeting endothelial cells can also 
be achieved by employing their basic functional heterogeneity without concomitant 
diseases activity. For example, liver sinusoidal endothelial cells, acting as scavengers 
specialized in the uptake of polyanionic macromolecules, could be efficiently reached 
by carriers conjugated with polyaconitylated human serum albumin, a ligand for 
scavenger receptors [57]. Moreover, pulmonary endothelial cells which function as a 
nonthrombogenic semipermeable barrier and provide a vast surface for gas exchange, 
readily express high levels of thrombomodulin and angiotensin-converting enzyme at 
the cell surface as compared to other ECs, allowing effective preferential targeting 
[58, 59]. In addition, delivery to endothelium does not always require harnessing the 
carrier with a targeting ligand. Santel et al. reported that systemic administration of 
an siRNA complexed with a lipid-based carrier, creating a so called lipoplex, led to 
significant uptake of siRNA by endothelial cells in different organs. siRNA-lipoplexes 
were extensively taken up by the vasculature of the heart, lung, and liver resulting in 
RNAi mediated silencing of endothelial cell restricted genes CD31 and Tie2 [60].




Intracellular Fate of Endothelium Targeted Delivery Systems and Their Cargo
When a delivery system has reached the target endothelial cells, the carrier has to 
be internalized by the cell and release its content into the cytoplasm. Many carriers 
conjugated with ligands for extracellular receptors are internalized via endocytotic 
pathways leading to degradation, transcytosis, or sorting of internalized material to 
different cell compartments [58]. The type of pathway utilized depends on the target 
receptor, and the size and the nature of the drug carrier [44]. Clathrin-mediated uptake 
and caveolae-mediated uptake are two main mechanisms involved in endocytosis 
in ECs. The clathrin-mediated pathway mainly guides the delivery system to the 
endosomes with subsequent degradation in the lysosomes, whereas the caveolae-
mediated pathway predominantly serves as an entry for transcytosis through endothelial 
monolayers that usually avoids lysosomal compartments [58]. Carriers targeting plasma 
membrane proteins like selectins are mainly taken up via clathrin-mediated endocytosis 
guiding the internalized content to the lysosomal degradation pathway within 2–4 h 
[22, 61]. On the other hand, ligands that bind to ICAM-1 were shown to enter ECs by 
a nonclassical endocytotic mechanism named cell adhesion molecule (CAM) mediated 
endocytosis. It requires formation of small multimeric complexes of the receptors and 
depends on target molecule clustering and size of the conjugates (100–300 nm). This 
mechanism also delivers materials to lysosomal compartments within 3 h [40, 62]. If 
the vesicular cargo enters the lysosomal degradation pathway, the initially formed early 
endosomes mature to more acidified (pH 5.0–6.0) late endosomes and eventually merge 
with lysosomes, rendering their content for degradation by lysosomal enzymes and low 
pH [63]. For siRNA delivery, however, endocytosis via the nondegradative route (e.g., 
caveolae-mediated pathway) likely leads to entrapment of the cargo in the endosomes 
[64].
We have shown that E-selectin targeted, lipid-based, conventional liposomes are 
extensively taken up by TNF-α activated HUVEC but also that they are degraded to a 
minor extent inside the endocytic vesicles of the endothelial cells [65]. Regardless of 
the entry pathway, a lack of endosomal escape generally leads to poor siRNA efficacy, 
thus carriers have to be able to release their siRNA before entering lysosomes and 
enable escape of intact siRNA from the endosomal compartment into the cytoplasm 
(Fig. 1B). To aid siRNA delivery, several mechanisms allowing penetration of the 
endosomal membrane before transfer to the lysosomal compartment have been 
proposed. Vesicle type carriers can be modified with pore forming peptides that are able 
to disturb the continuity of the bilayer by introducing a pore in the membrane, thereby 
facilitating release of endosomal contents. Those peptides are often based on naturally 
occurring toxins or venoms like diphtheria toxin or melittin, a major component of 
bee venom [64]. Cationic lipids can destabilize the endosomal membrane by inducing 
‘flipping’ of anionic lipids in the endosomal bilayer, leading to formation of ion pairs 
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which facilitates vesicle fusion with the endosomal membrane and release of the 
cargo into the cytoplasm [66, 67]. Moreover, addition of a helper lipid with fusogenic 
properties [e.g., 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)] to a carrier 
formulation can significantly improve content release and escape from the endosomes 
[68]. Furthermore, so called pH-sensitive carriers were developed by formulating 
DOPE with a pH-titrable lipid (displaying a pH-dependent charge) such as cholesteryl 
hemisuccinate (CHEMS) or by combination of cationic and anionic lipids in one lipid 
membrane. These formulations promoted content release by increased destabilization 
of the carrier in the endosomal compartment upon low pH [69]. In contrast, polymers 
like polyethylenimine (PEI) and polyamidoamine (PAM) can induce endosomolysis by 
the so called proton sponge effect. These polymers have a strong buffering capacity due 
to protonation of amino nitrogens upon endosome acidification. This invokes a high 
chloride ion influx into the endosome, causing osmotic swelling of the endosome and 
eventually endosome lysis [70].
Endothelial Cell Targeted siRNA Delivery Systems
Lipid-based systems have been used for the delivery of nucleic acids for over 20 
years, starting with studies by Felgner et al. [71]. Liposomes and lipoplexes are the 
two main categories of lipid-based systems, although novel types of carriers such as 
stabilized nucleic acid-lipid particles (SNALP), lipid polycation-DNA nanoparticles 
(LPD) and lipid like molecules called lipidoids (extensively reviewed by [72]) have 
entered the stage in recent years. For siRNA delivery, liposomes and lipoplexes are 
usually composed of a cationic lipid, helper lipid (e.g., DOPE and/or cholesterol) and 
a (poly)ethylene glycollipid [44]. Liposomes consist of an aqueous core enclosed in 
a phospholipid bilayer with nucleic acids mainly entrapped in the central aqueous 
compartment. Liposomes have generally stable physicochemical characteristics, while 
lipoplexes are spontaneously formed via interaction of positively charged lipids and 
negatively charged nucleic acids which makes them more unstable [73]. The advantages 
of lipid-based systems are their low toxicity (several liposomal formulations are FDA 
approved), easy sizing to below 200 nm, and great flexibility in tailoring them on 
demand with targeting ligands. Lipid structures can be easily modified by coupling 
targeting ligands to improve their delivery potential or by adding pH-sensitive or 
fusogenic moieties to aid intracellular release of siRNA [41].
So far only a few types of carriers suitable for systemic siRNA delivery into endothelial 
cells have been developed (Table 1). Successful siRNA delivery to tumor endothelial 
cells expressing integrin αvβ3 using RGD based homing peptides has first been reported 
by Schiffelers et al. [74]. In this study, the siRNA that inhibited vascular endothelial 
growth factor receptor 1 (VEGFR2) expression was incorporated into self-assembling 
nanoparticles constructed with RGD-harnessed PEGylated polyethyleneimine, after it 
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was shown that formulation into conventional liposomes did not lead to target gene 
silencing. We recently developed two novel lipid-based systems which show potential 
for systemic siRNA delivery to activated endothelial cells. The first system is based 
on a lipoplex composed of the cationic amphiphilic lipid SAINT (1-methyl-4-(cis-9-
dioleyl)methyl-pyridiniumchloride), a well established delivery agent of nucleotides 
and proteins, and the helper lipid DOPE [75]. To achieve specificity towards activated 
endothelium, SAINT was covalently coupled to a monoclonal anti-E-selectin antibody 
forming a construct referred to as SAINTarg. With this anti-E-selectin-SAINTarg we 
were able to substantially enhance siRNA uptake, transfection specificity and efficacy of 
VE-cadherin down regulation in activated endothelial cells, as compared to transfection 
with a nontargeted SAINT formulation [76].
In addition, we have developed a novel generation of liposomes called SAINT-
O-Somes, based on formulation of conventional long circulating liposomes by the 
addition of the cationic amphiphilic lipid SAINT. These liposomes harnessed with anti-
Eselectin antibody showed specific uptake by activated endothelial cells, and displayed 
good size stability (100 nm in diameter) in the presence of serum, but were destabilized 
at lower pH as occurs in the endosomes of endothelial cells, thereby showing superior 
intracellular release of their content. We were able to efficiently encapsulate low 
molecular weight compounds such as doxorubicin and siRNA in these carrier systems, 
rendering this formulation an interesting candidate for systemic application [65].
Issues to be Addressed for Further Development of EC Specific Delivery Devices
Significant progress has been made in the last decade with regard to the 
development of endothelial cell specific drug delivery devices. Increased knowledge 
of the molecular changes within these cells during the onset and progression of disease 
has spurred identification of new potential targets on the cell membranes, while new 
molecular entities give rise to the design of novel carriers with important added value 
over conventional ones. Knowledge of the molecular control and pharmacology of 
microvascular endothelial cells remains, however, scarce. Basic heterogeneity in the 
control of EC behavior makes it highly likely that their responsiveness to ‘drugs’ is also 
microvascular bed dependent, although data to support this are only slowly emerging. 
Moreover, the loss of microenvironment driven EC behavior upon culturing the cells 
in vitro requires solid validation of in vitro molecular control or responsiveness to 
stimuli and pharmacological observations in the in vivo context (Fig. 2). This is only 
occasionally pursued, which is mostly due to the limited availability of methods to 
assess kinase activity, gene and protein expression in tissue biopsies, and to locate them 
specifically in the endothelium. As such, the choice of molecular target(s) allowing 
successful therapeutic interference by means of targeted siRNA approaches remains 
somewhat elusive.




After a drug delivery system carrying siRNA has been developed and properly 
optimized and sufficient siRNA can be delivered inside the target cell leading to the 
desired down regulation of the disease-associated target gene, novel technologies 
should be used to bring siRNA as therapeutic tool closer toward clinical application. 
Laser microdissection (LMD) of endothelial cells from specific microvascular 
segments in tissues allows compartmentalized analysis of gene expression and hence 
the examination of local effects of the targeted drug treatment [77]. LMD can be applied 
to both animal and human tissues and it allows for enrichment of endothelial cells 
from (micro)vascular segments which can be prior assessed histologically for disease 
activity. Combining targeted drug delivery systems carrying siRNA to selectively down 
regulate disease-associated genes in restricted microvascular segments with LMD-
based validation of gene silencing in the target endothelial compartment represents not 
Figure 2. Experimental approaches to study the selectivity, intracellular delivery capacity and efficacy 
of endothelial targeted siRNA delivery systems in vitro and in vivo. Studying endothelial cell association, 
internalization and siRNA delivery using primary endothelial cell cultures (A) may be inadequate due to high 
rate of endothelial cell dedifferentiation upon in vitro culturing. This leads among others to loss of heterogenic 
behavior of ECs associated with the location of the microvascular bed in vivo. Laser microdissection (B) of 
ECs from specific microvascular segments in tissues is an essential technique to assist in the development 
of endothelial specific siRNA delivery devices, as it allows validation of local target gene knock down and 
studying downstream molecular consequences of gene knock down. The advantages and disadvantages of 
both approaches are summarized in (C). 
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just a powerful, but rather an essential strategy to provide proof of concept of in vivo 
siRNA delivery studies (Fig. 2).
Another technology that can significantly assist in further development of novel 
targeted delivery systems toward clinical application is precision-cut tissue slices. They 
closely resemble the organ from which it is prepared, with all cell types present in 
their original tissue-matrix configuration [78]. The circumstance that in tissue slices 
the architecture of the original organ is retained makes them an attractive tool for 
drug delivery studies. Using this system, we showed that anti-E-selectin-SAINTarg 
specifically associated with activated endothelial cells in human kidney tissue slices 
subjected to inflammatory conditions, exactly following the expression pattern of 
E-selectin [76].
Furthermore, one should take into account the differences in behavior between 
primary endothelial cells and endothelial cell lines. Endothelial cell lines, for example, 
are easier to transfect and hence are often chosen for protein overexpression studies, 
yet they display quite some differences in phenotype and responsiveness compared to 
primary cells. Moreover, their internalization machinery is often more tumor cell like 
and less relevant to the uptake features of primary cells. Since primary endothelial cells 
are closest, though not identical, to endothelial cells in vivo, they should at one point 
in the design of targeted drug delivery systems be used to further validate binding, 
internalization and intracellular drug release characteristics.
Conclusions
Increased insight in the role of endothelial cells in the pathophysiology of cancer, 
inflammatory and cardiovascular diseases, has drawn great interest in the design of 
pharmacological interventions aiming at the endothelium in diseased sites. The 
effectiveness of drugs intended to affect diseased endothelium is however limited 
which is likely partly due to the existence of endothelial subset specific responsiveness 
to proinflammatory cytokines [6]. This heterogeneity on the other hand provides an 
opportunity for identification of disease-associated target epitopes expressed by vascular 
segment restricted endothelial cells as well as for selection of the proper drug target and 
concurrent drugs for therapeutic effects. Emerging therapeutic strategies based on RNAi 
have a great potential for therapeutic application. siRNAs can, however, not be directly 
applied for in vivo treatment of diseased endothelium due to a short half-life of the 
molecules, in the circulation, inability to pass the cellular membrane, high toxicity, and 
low cell selectivity. Formulation of these therapeutic molecules into delivery devices 
such as lipidbased or polymer-based systems targeted to diseased endothelial cells can 
provide them with a potential for further clinical application. Target determinants like 
E-selectin, VCAM-1, ICAM-1, and integrins with expression restricted to endothelial 




cells and upregulated during inflammation or angiogenesis may help to achieve specific 
and safe delivery of drugs into EC subsets involved in diseases, thereby improving 
pharmacological efficacy. Widespread use of RNAi therapeutics for endothelial 
diseases requires a clinically suitable, safe and effective delivery vehicle. This can be 
achieved by developing new formulations and bio-materials (e.g., novel cationic lipids, 
polymers or pH-sensitive PEG) to avoid detection by cells of the RES and improve 
intracellular siRNA release properties of existing lipid or polymer-based systems. 
Combined research efforts in the field of microvascular endothelial cell biology and 
pharmaceutical sciences are crucial to achieve the final goal, that is, the development 
of an efficient and cell-specific siRNA drug delivery system that can be applied in the 
clinic to effectively silence endothelial cell engagement in the patho(physio)logy of 
disease.
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Abstract
Aims: Pulmonary arterial hypertension (PAH) is characterized by development 
of unique neointimal lesions in small pulmonary arteries, leading to increased right 
ventricular (RV) afterload and failure. Novel therapeutic strategies are needed that target 
these neointimal lesions. Recently, the transcription factor Egr-1 was demonstrated to be 
upregulated early in experimental neointimal PAH. Its effect on disease development, 
however, is unknown. We aimed to uncover a novel role for Egr-1 as a molecular 
inductor for disease development in PAH.
Methods and results: In experimental flow-associated PAH in rats, we investigated 
the effects of Egr-1 downregulation on pulmonary vascular remodelling, including 
neointimal development, and disease progression. Intravenous administration 
of catalytic oligodeoxynucleotides (DNAzymes) resulted in downregulation of 
pulmonary vascular Egr-1 expression. Compared to vehicle or scrambled-DNAzymes, 
DNAzymes attenuated pulmonary vascular remodelling, including the development of 
occlusive neointimal lesions. Selective downregulation of Egr-1 in vivo led to reduced 
expression of vascular PDGF-B, TGF-β, IL-6 and p53 resulting in a reduction of 
vascular proliferation and increased apoptosis. DNAzyme treatment further attenuated 
pulmonary vascular resistance, right ventricular systolic pressure and right ventricular 
hypertrophy. In contrast, in non-neointimal PH rodents DNAzyme treatment had no 
effect on pulmonary vascular and RV remodelling. Finally, pharmacological inhibition 
of Egr-1 with pioglitazone, a PPAR-γ ligand, attenuated vascular remodelling including 
of neointimal development.
Conclusions: These results indicate that Egr-1 governs pulmonary vascular 
remodelling and the development of characteristic vascular neointimal lesions in flow-
associated PAH. Egr-1 is therefore a potential target for future PAH treatment. 
Translational perspective
PAH is characterized by the development of unique neointimal lesions. PAH is 
regarded incurable when these neointimal lesions have formed. New therapeutic 
strategies are needed that target these neointimal lesions. Here we investigated whether 
Egr-1 could be such a target. We show that a) Egr-1 governs pulmonary neointimal 
development in experimental PAH and b) Egr-1 is a putative new treatment target for 
PAH patients.





Pulmonary arterial hypertension (PAH) is a fatal and progressive form of pulmonary 
hypertension with, so far, unknown origin [1]. It is characterized by the development 
of unique so called neointimal lesions that result vascular proliferation and apoptotic 
dysregulation [2]. PAH is considered irreversible when these neointimal lesions have 
formed [3], and eventually results in death due to right ventricular (RV) failure [4,5]. 
Current treatment strategies may beneficially affect disease progression but certainly do 
not result in curing of the disease. Therefore, new treatment strategies are needed that 
target this irreversible form of pulmonary vascular proliferation.
In PAH associated with congenital heart diseases, the role of increased pulmonary 
blood flow is seen as an important trigger [6,7]. In experimental PAH models the 
addition of increased pulmonary blood flow has extensively been shown to induce 
neointimal development that reflects human PAH more truly than the monocrotaline or 
chronic hypoxia PH models [6,8]. Still, the mechanism by which increased blood flow 
leads to neointimal development and subsequently RV failure is unknown.
For this study, we hypothesized that the transcription factor Egr-1 (early growth 
response protein 1) is an important pathogenic inductor for neointimal development 
in PAH. Recently, we identified Egr-1 to be upregulated by increased pulmonary 
blood flow in the pulmonary vessels [9,10]. Furthermore, we confirmed Egr-1 to be 
upregulated in human end-stage PAH [9].
The transcription factor Egr-1 is known to play a major role in a variety of 
cardiovascular processes including systemic arterial remodelling [11,12]. However 
it is unknown whether in vivo downregulation of Egr-1 will beneficially affect 
PAH progression. Targeting Egr-1 in vivo has previously been described using 
pharmacological treatment (including PPAR-γ ligands [13,14]) or using specific gene 
silencing methods, including so-called DNA enzymes (DNAzymes). DNAzymes are 
catalytic oligodeoxynucleotides that are able to bind to specific RNA sequences resulting 
in RNA degradation [15,16]. These DNAzymes exhibit greater catalytic efficiency than 
oligonucleotides such as ribozymes and are more stable in serum in vivo.  For this 
study we therefore investigated whether in vivo downregulation of Egr-1, using both 
DNAzymes and the PPAR-γ ligand pioglitazone, would prevent the development of 
pulmonary vascular neointimal lesions in rats with flow-associated PAH.
Materials and methods
DNAzyme preparation
DNAzymes (Double RP-HPLC purification, phosphodiester backbone and inverted 
T at 3’ terminus for increased stability; Trilink Biotechnologies, Santa Cruz CA, USA) 
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were sequenced as followed: Egr-1 DNAzyme (ED5; Figure 1): 5’-CCG CTG CCA 
GGC TAG CTA CAA CGA CCC GGA CGT Ti-3’; scrambled (inactive) DNAzyme 
(ED5scr): GCC AGC CGC GGC TAG CTA CAA CGA TGG CTC CAC Ti-3’, as 
described previously [17]. Based on our result from a pilot study, the cationic lipid 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) was used as the transfection 
carrier as described in the online supplement. 
PAH Animal model
The Institutional Animal Care and Use Committee approved animal care and 
experiments. One hundred twenty-three male Wistar rats (270-300g) were used. 
Experimental flow-associated PAH was created using a monocrotaline injection (60 
mg/kg) followed by an abdominal aortocaval (av) shunt one week later, as described 
previously [9,10,18].
Figure 1. ED5 in the pulmonary vasculature. A) Schematic representation of the DNAzyme sequence 
targeting Egr-1 (ED5). This molecule, with a phosphodiester backbone and an inverted T at 3’ terminus, 
consists of a catalytic core (underline) and 2 recognition arms that attaches to the Egr-1 translational start 
site [17]. B) Vascular localization of ED5 24 hours after injection. ED5 was commercially labelled with 
6FAM, combined with DOTAP and injected into the jugular vein. Positive fluorescent signalling was mainly 
seen in the vascular bed. Both pre- and intra-acinar vessels showed positive signalling for ED5. C) Single 
ED5 injection resulted in a decrease of vascular Egr-1 expression after 1 day. This effect was lost 3 days after 
injection. D) Localization of both ED5 signalling and Egr-1 expression in the intra-acinar vessels. Data are 
presented as mean values ± SEM. * P<0.05.  Scale bar represents 50µm.




Egr-1 downregulation in PAH animal model
For the main DNAzyme study 82 rats were used. Blood was drawn peri-operatively 
for baseline blood analyses. A pilot study revealed that rats needed to receive ED5 
treatment every 48 hours (Figure 1C and D and online supplement). Rats were randomly 
divided to receive intravenous treatment of either: 1) NaCl 0.9% (PAH_VEH; n=24), 
2) scrambled DNAzyme-DOPTAP solution (PAH_SCR; n=18), 3) DNAzyme ED5-
DOPTAP solution (PAH_ED5; n=20). Treatment started directly after shunt creation 
(=induction of increased flow) (Figure 2A). Rats received treatment every 48 hours 
through an externally fixed jugular vein catheter. Randomization was blinded for the 
investigators. Repeated ED5 delivery did not result in a systemic immune response or 
decreased liver function (Supplemental Figure E2). For each group, rats were sacrificed 
1 week (n=6-12 per group) or 3 weeks (n=10-12 per group) after shunt creation. Sham 
operated rats served as control and received either NaCl 0.9% (n=12) or ED5-DOTAP 
solution (n=8). Since no differences were seen between these groups, they were pooled 
as control (Supplemental Figure E3). 
Egr-1 downregulation in non-neointimal PH animal model
In addition, to investigate the effects of Egr-1 downregulation in a non-neointimal 
PH model, additional rats received a single injection of monocrotaline only. One week 
later, rats were randomly divided to receive either NaCl 0.9% (MCT_VEH; n=3) or 
DNAzyme ED5-DOPTAP solution (MCT_ED5; n=3) via externally fixed jugular vein 
catheters. Rats were sacrificed 3 weeks after monocrotaline injection.
Pioglitazon treatment in PAH animal model
To investigate the effects of the PPAR-γ ligand pioglitazon on pulmonary vascular 
Egr-1 downregulation in PAH, 24 additional flow-PAH rats were randomly divided to 
receive either: 1) vehicle treatment (n=6), 2) pioglitazon 20mg/kg (n=9), 3) pioglitazon 
100mg/kg (n=9). Treatment was mixed into rat chow and rats were fed ad libitum. Rats 
were sacrificed 1 day (n=3-5 per group) and 1 week (n=3-4 per group) after start of 
increased blood flow. Vehicle treated sham rats from the main study served as control.
Echocardiography, hemodynamic measurements, pathology and biomolecular 
analyses
Echocardiography, hemodynamic measurements, morphometric analyses, 
immunohistochemistry and RT-PCR technique were performed as previously described 
[9,10,18,19] and in more detail in the online supplement. 
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Statistics
Data are presented as mean ± standard error of the mean. Differences between 
groups were determined by one-way analysis of variance (ANOVA) with Bonferroni 
or Dunnet post-hoc test where applicable. For data not normally distributed, Mann 
Whitney U test was performed. A P-value below 0.05 was considered to be significant.
Results
Increased pulmonary blood flow resulted in progressive PAH with neointimal 
development
Rats that received monocrotaline administration and an aortocaval shunt (flow-
PAH) showed progressive pulmonary vascular remodelling over time (Figure 2A; 
Table 1). One week after shunt creation (PAH_1wk) intra-acinar vessels exhibited 
Figure 2. Development of flow-associated PAH. Pulmonary vascular remodelling and disease development 
in experimental flow-PAH. A) Typical examples of the progression of pulmonary vascular remodelling, 
including the formation of neointimal lesions after increased pulmonary blood flow. Note the degradation of 
the lamina elastica interna and the cellular luminal in these neointimal lesions. B) Progressive worsening 
of vascular remodelling, RV hypertrophy and hemodynamic measurements. C) Occlusive neointimal lesions 
consisted of ECs (staining positive for vWF) surrounded by SMCs (staining positive for αSMA). Data are 
presented as mean values ± SEM. * P<0.05. Scale bar represents 50µm.




   
PAH_1wk
   
PAH_3wks
 
 Con  VEH SCR ED5  VEH SCR ED5
Body weight at sac (g) 361±7  306±6* 304±11 309±6  327±5* 323±5 328±3
RV weight (mg) 0.19±0.00  0.25±0.01* 0.25±0.01 0.19±0.01†  0.49±0.02* 0.49±0.02 0.39±0.02†
LV+IVS weight (mg) 0.68±0.01  0.74±0.17 0.69±0.03 0.71±0.02  0.83±0.02* 0.81±0.02 0.66±0.03 †
RV/BW (mg/g) 0.53±0.01  0.83±0.01* 0.81±0.04 0.60±0.02†  1.49±0.07* 1.53±0.06 1.2±0.06 †
LV+IVS/BW (mg/g) 1.92±0.02  2.44±0.04* 2.33±0.14 2.30±0.05  2.53±0.07* 2.50±0.05 2.53±0.04
atria/BW (mg/g) 0.27±0.01  0.61±0.02 0.48±0.04 0.38±0.02†  0.71±0.04* 0.78±0.02 0.64±0.03†
CO (ml/min) 103±5  131±9* 134±16 135±11  108±9 123±5 127±10
PAAT (ms) 30±1  28±2 24±2 21±3  15±3* 15±2 17±1
TAPSE (mm) 3.0±0.2  3.5±0.1* 3.6±0.6 3.8±0.09  2.5±0.24 2.6±0.2 2.6±0.2
Vascular remodeling
 Pre-acinar          
  Outer diameter (µm) 101±8  96±15 104±11 106±10  124±16 115±13 110±10
  Wall thickness (µm) 6±1  6±1 5±1 6±1  14±1 13±1 9±1†
 Intra-acinar          
  Outer diameter (µm) 28±1  36±1* 37±1 35±1  34±1 36±1 35±1
  Wall thickness (µm) 0.3±0.0  2.3±0.4* 2.1±0.2 1.0±0.1†  5.6±0.7 5.8±0.7 3.0±0.4†
 Remodeling (% of total vessels)       
  Non-muscular (%) 79±1  22±3* 24±1 31±8†  13±3 10±2 18±2†
  Partially 
  muscularized (%)
26±1  35±3* 35±3 43±3†  13±2 12±2 22±5†
  Totally 
  muscularized (%)
6±1  35±3* 33±5 20±2.5†  39±5 41±4 48±4
  Occlusive lesions (%) 0±0  12±2* 11±1 2±1†  33±3 32±3 11±2†
PAH: Pulmonary arterial hypertension; Con: control; VEH: vehicle treatment; SCR: scrambled DNAzyme 
treatment; ED5: DNAzyme treatment; Sac: sacrifice; RV: right ventrile LV: left ventricle; IVS: intraventricular 
septum; BW: body weight; CO: cardiac output; PAAT: pulmonary artery acceleration time; TAPSE: tricuspid 
annular plane systolic excursion. * P<0.05 Con vs VEH; † P<0.05 SCR vs ED5. Data presented as mean 
± SEM.
muscularization, and sporadic neointimal lesions were observed. In end-stage disease 
(PAH_3wks) occlusive neointimal lesions were seen in the majority of intra-acinar 
vessels (Figure 2; Table 1). Vessel occlusion resulted in symptomatic PAH 3 weeks after 
induction of increased blood flow, including increased peak right ventricular systolic 
pressure (pRVSP), increased pulmonary vascular resistance, and right ventricular 
hypertrophy (RVH) (Figure 2B). These parameters correlated with pulmonary vascular 
remodelling (Supplemental Figure S4).
Four rats did not reach the endpoint of the study: 1 died perioperatively (ED5 
group), 3 rats were sacrificed (2 ED5 group; 1 SCR group) because of severe dyspnoea 
due to air emboli during intravenous injection. These rats were excluded from further 
analyses. 
Table 1. Animal characteristics
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Figure 3. Downregulation of pulmonary vascular Egr-1 expression. A) Schematic overview of the study 
design. B) Egr-1 expression in vehicle and scrambled DNAzyme treated rats showed similarities with Egr-
1 expression in human PAH associated with congenital heart disease. C) Egr-1 was located in both the 
medial and endothelial vessel layer in end stage disease (F). D) Chronic ED5 delivery (PAH_ED5) reduced 
pulmonary vascular Egr-1 protein expression without reducing the total number of Egr-1 positive intra-acinar 
vessels (E). G) Pulmonary vascular Egr-1 expression correlated with pulmonary vascular remodelling. Data 
are presented as mean values ± SEM. * P<0.05. Scale bare represents 50µm. VEH: vehicle treated rats, SCR: 
scrambled DNAzyme treated rats, ED5: DNAzyme treated rats.
Intravenous ED5 delivery reduced vascular Egr-1 expression in flow-PAH.
Compared to control, pulmonary vascular Egr-1 protein expression increased 1 
week after increased pulmonary blood flow (PAH_1wk) and progressed during disease 
development (PAH_3wks) (Figure 3). Chronic ED5 delivery (PAH_ED5) reduced 
pulmonary vascular Egr-1 protein expression with 35% and 43% at 1 and 3 weeks after 
increased flow, respectively (Figure 3D). Egr-1 was targeted throughout the vessels 
wall (Supplemental Figure S5). Pulmonary vascular Egr-1 expression correlated with 
pulmonary vascular remodelling (Figure 3G).
Egr-1 downregulation attenuated neointimal formation and flow-PAH development
Vascular Egr-1 downregulation due to ED5 delivery (PAH_ED5) reduced vessel 
occlusion and wall lumen ratio of the intra-acinar vessels at both 1 week and 3 weeks 
after induction of increased blood flow (Figure 4, Table 1). Egr-1 downregulation 




Figure 4. Effects of pulmonary vascular Egr-1 downregulation. At 1 and 3 weeks after increased flow, Egr-
1 downregulation using ED5 significantly attenuated both (A) pulmonary vascular remodelling and (B) PAH 
development as shown by a reduction in pulmonary vascular resistance, pRVSP and RV hypertrophy. Data 
are presented as mean values ± SEM. * = P<0.05 ED5 vs VEH and SCR.
Figure 5. Mechanisms of pulmonary vascular changes due to Egr-1 downregulation. A) Egr-1 
downregulation resulted in a significant reduction of vascular proliferation (KI67) 1 week after flow and 
a significant increase in vascular apoptosis (Caspase 3) 3 weeks after flow. B) Localization of Ki67 and 
Caspase 3 in the pulmonary vessel. Typical examples of Ki67 (C) and Caspase 3 (D) vascular expression. 
Data are presented as mean values ± SEM. * P<0.05. Scale bar represents 50µm.
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furthermore resulted in a reduction of the pRVSP, pulmonary vascular resistance and 
RVH (Figure 4B). Scrambled DNAzyme treatment (PAH_SCR) had no effect on any 
of the vascular remodelling or hemodynamic parameters. ED5 treatment had no effect 
on left ventricular mass (Table 1). 
Egr-1 downregulation attenuated neointimal development through early attenuation 
of vascular cell proliferation and end stage increase of apoptosis 
In vehicle and scrambled DNAzyme treated rats, both vascular proliferation and 
apoptosis peaked one week after the induction of increased flow (Figure 5A). Egr-
1 downregulation reduced early vascular cell proliferation and increased end staged 
vascular cell apoptosis, predominantly in the endothelial layer (Figure 5B and 
Supplemental Figure S6). 
Expression of PDGF-B, TGF-β IL-6 and p53, all downstream targets of Egr-1 and 
known to play a role in vascular proliferative remodelling in human PAH, was increased 
in the pulmonary vessels during neointimal development (PAH_VEH and PAH_SCR) 
at both 1 and 3 weeks (Figure 6, supplemental figure S6). Egr-1 inhibition (PAH_
ED5) resulted in a significant reduction of PDGF-B, TGF-β, IL-6 and p53 expression 
compared to vehicle and scrambled treatment (Figure 6, supplemental figure S6).
Figure 6. Pulmonary vascular expression of the Egr-1 downstream genes PDGF-B, TGF-β IL-6 and p53 
in the intra-acinar vessels. Egr-1 inhibition resulted in downregulation of PDGF-B, TGF-β IL-6 and p53 at 
both 1 and 3 weeks. Histological examples are shown in supplemental Figure S6. Data are presented as mean 
values ± SEM. * P<0.05. Scale bar represents 50µm.




ED5 delivery has no effect on vascular remodelling in non-neointimal non-flow PH
To further test whether the effects of Egr-1 downregulation are specific for flow-
induced neointimal formation, we investigated the effects of ED5 delivery in a 
non-neointimal, non-flow-associated model of pulmonary hypertension, namely 
monocrotaline only model (MCT_VEH vs. MCT_ED5) [9]. MCT injection (MCT_
VEH) resulted in a significant increase in vessel wall thickness, increased pRVSP and 
RVH compared to control (Figure 7C). Neointimal lesions were not observed (Figure 
7B). In MCT-only PH rats, vascular Egr-1 expression was only sporadically seen 
compared to its expression in flow PAH rats (Figure 7A). Also, ED5 treatment (MCT_
ED5) did not alter vascular remodelling, pRVSP or RVH (Figure 7C) in MCT-only PH 
rats. 
Figure 7. ED5 treatment in non-flow non-neointimal PH. A) Egr-1 protein expression and localization 
(B) in the intra-acinar vessels at 3 weeks. In rats where pulmonary blood flow was not increased (MCT-only 
rats), Egr-1 was only sporadically seen and no neointimal lesions were formed. C) In these non-flow non-
neointimal rats, ED5 administration had no effect on vascular remodelling, RV hypertrophy or pRVSP. Data 
are presented as mean values ± SEM. * P<0.05. Scale bar represents 50µm.
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Figure 8. Egr-1 downregulation using the PPAR-γ ligand pioglitazone. A) Egr-1 protein expression in the 
intra-acinar vessels 1 day and 1 week after increased flow. B) Typical examples of Egr-1 expression 1 week 
after increased blood flow. C) Preventive pioglitazone treatment attenuated pulmonary vascular remodelling, 
pRVSP and RV hypertrophy 1 week after increased flow. D) Schematic hypothesis of the role of Egr-1 and its 
downstream genes in the development PAH. Data are presented as mean values ± SEM. * P<0.05. Scale bar 
represents 50µm. PIO 20: 20mg/kg/d pioglitazone treatment, PIO 100: 100mg/kg/d pioglitazone treatment. 
Pharmacological downregulation of Egr-1 using pioglitazone also attenuates 
vascular remodelling in flow-PAH
Using the PPAR-γ ligand pioglitazone, we investigated whether Egr-1 could 
be pharmacologically inhibited. First, pioglitazone treatment activated PPAR-γ, as 
confirmed by increased PGC1a (co-activator of PPAR-γ) and MCAD (downstream 
gene of PPAR-γ) gene expression (Supplemental Figure S7). Pioglitazone reduced 
vascular Egr-1 expression in a dose dependent matter 1 day and 1 week after increased 
pulmonary blood flow (Figure 8A and B). This was accompanied with attenuation of 
pulmonary vascular remodelling (Figure 8C), including reduction of neointimal lesions 
and reduction of RVH compared to vehicle treated flow-PAH rats (Figure 8C).





This study in experimental flow-associated PAH demonstrates that in vivo Egr-1 
downregulation, both via intravenous administration of catalytic oligodeoxynucleotides 
(DNAzymes) and pharmacological intervention using pioglitazone, attenuates 
pulmonary vascular remodelling including the development of occlusive neointimal 
lesions, and reduced PAH progression. These results indicate that Egr-1 plays an 
important role in the induction and development of pulmonary vascular remodelling 
in flow-associated PAH. Egr-1 is therefore a putative target for future PAH treatment. 
Egr-1 is a transcription factor with pleotropic effects. Egr-1 is poorly expressed in 
the normal arterial wall but can be activated by various stimuli including changes in 
shear stress [12,20]. In systemic vessels, Egr-1, once activated, has been shown to act 
as an early ‘master switch’ during vessel wall remodelling including intimal thickening, 
vascular proliferation and vessel inflammation [21,22]. A role for Egr-1 in pulmonary 
vascular remodelling in PAH had not been described until now. 
Here we demonstrate, for the first time, a functional role for the transcription factor 
Egr-1 in pulmonary vascular remodelling in PAH. Our results indicate that Egr-1-
inhibition in vivo attenuates apoptotic dysregulation and reduces vascular proliferation. 
In human PAH development, vascular proliferation and apoptosis resistant endothelial 
cells are recognized hallmarks of pulmonary neointimal formation [2]. Egr-1 has 
been previously shown to induce neointimal formation in systemic arteries, in 
atherosclerotic disease and in-stent restenosis, mediated through both anti-apoptosis 
and pro-proliferative pathways [12,17,21]. PDGF-B and TGF-β1 are known to induce 
proliferation of both smooth muscle cells and endothelial cells and are upregulated 
in human PAH [2]. Egr-1 is known to bind to the promoter regions of these genes 
resulting in increased expression [12,23]. The results of the current study, showing 
increased PDGF-B and TGF-β1 expression in experimental PAH and its reduction 
through inhibition of Egr-1, support the working mechanism of Egr-1 induced vascular 
proliferation through PDGF-B and TGF-β1 (Figure 8D).  In addition we show that 
Egr-1 downregulation results in a reduction of IL-6 (vascular inflammation) and 
p53 (vascular apoptosis), both downstream targets of Egr-1 and known genes in the 
pathogenesis of human PAH [2,24].
Egr-1 could be a putative therapeutic target for future PAH treatment. We have 
previously shown that Egr-1 is upregulated in human end-stage PAH [9]. In these 
patients Egr-1 was located at sites that are of interest for treatment targeting, namely in 
vessels with media hypertrophy and in neointimal lesions [9]. The positive effects of 
Egr-1 inhibition on vascular remodelling and PAH progression in this study supports 
future outlook of Egr-1 as a treatment target. The fact that these effects were seen in the 
current PAH model that mimics 1) a human pathological trigger, 2) complex neointimal 
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development and 3) human PAH progression makes the critical role of Egr-1 in PAH 
development more convincing [25]. Combined, the observations in both human and 
now in experimental PAH justify future investigation in Egr-1 intervention either via 
gene silencing techniques or pharmacological treatment in human PAH. 
The rapid developments in the design of gene silencing agents could facilitate 
a novel approach for therapeutic intervention for the treatment of PAH. First 
antisense oligonucleotide-based drugs have reached the clinic and have proved to 
be effective against for instance CMV infections and hypercholesterolemia [26,27]. 
New generations of oligonucleotides such as DNAzymes or small interfering RNAs 
(siRNAs) have entered the clinical stage [15]. In the current study we demonstrated 
that in PAH Egr-1 can be interfered in vivo using RNA interfering agents. Several types 
of clinically suitable carriers for siRNA delivery into pulmonary endothelial cells have 
been developed [28] and could serve as an alternative for DOTAP mediated delivery in 
the future and increase specificity. ED5 could possibly have a direct effect on pressure 
induced RV hypertrophy. However, since we show Egr-1 downregulation 1) attenuates 
pulmonary vascular resistance in flow-PAH rats 2) has no effect on RV hypertrophy in 
MCT only treated rats and 3) has no effect on LV mass, it is most likely that the positive 
effects of ED5 treatment are to Egr-1 downregulation in the pulmonary vasculature.
Pharmacological downregulation of Egr-1 with clinically used drugs could also be 
an interesting pursuit. One of these pharmacological possibilities is the use of PPAR-γ 
ligands, such as pioglitazone. PPAR-γ ligands have previously shown to inhibit Egr-1 
expression in vivo [13,14]. These studies describe Egr-1 as a key repressive target gene 
of PPAR-γ in different pathophysiological mechanisms. Activation of PPAR-γ has been 
shown to prevent ERK phosphorylation in endothelial cells [29] and SMCs [30], which 
may affect Egr-1 activation pathways. In addition, recent studies have suggested that 
BMPR2 signalling dysfunction in PAH leads to failure of PPAR-γ activation resulting, 
in SMC proliferation in PAH [31]. PPAR-γ ligands are also shown to have a positive 
effect on vascular remodelling in other pulmonary hypertension models [32,33]. 
However, these studies were conducted in a hypoxic PH model that is known to fail 
to induce the typical neointimal lesions and progressive PAH development, which 
limits translation to human disease. Our results in a neointimal model of PAH show 
that pioglitazone prevents pulmonary vascular remodelling and that this positive effect 
is associated with a downregulation of vascular Egr-1 expression. This justifies further 
investigation of oral thiazolidinedione PPAR-γ ligands in both preclinical and clinical 
settings, also focusing on possible side effects.
This study was designed to investigate the mechanistic role of Egr-1 in the 
development of neointimal lesions. Therefore the question whether targeting Egr-1 also 
results in reversal of established PAH (when neointimal lesions are already present) 
should now be addressed. However, since Egr-1 is expressed in remodelled vessels 




of both experimental and human end-stage PAH, Egr-1 could very well be a target in 
established pulmonary vascular remodelling.
Conclusions
This study indicates that the transcription factor Egr-1 governs flow-induced 
pulmonary vascular remodelling and the development of the characteristic vascular 
neointimal lesions in flow-associated PAH. Egr-1 therefore is a potential target for 
future PAH treatment. 
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Supplementary material and methods
DNAzyme preparation and transfection carrier 
For in vivo DNAzyme administration we first tested 2 different transfection carriers – 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP; Avanti Polar Lipids, Alabaster, 
Alabama, USA) and polyethylenimine (in vivo jetPEI; Polyplus transfection, Illkirch, 
France) – known for targeting the pulmonary vasculature [1]. Sterile DOTAP solution 
(0.5 mg/ml) was prepared as follows. DOTAP stock solution in chloroform: methanol 
(9:1) was dried under reduced nitrogen pressure for 10 min and further dried under high 
vacuum for 30 min. Subsequently, dried lipid film was hydrated in sterile HN buffer 
(150 mM NaCl, 20 mM HEPES) pH 7.4 for 10 min and vortex vigorously. DOTAP 
solution was stored at 4 °C under argon gas and used within 4 days. DNAzyme-DOTAP 
complex was prepared by mixing DOTAP solution with DNAzyme in 1:1 ratio w/w 
(500ug DNAzyme/500ug DOTAP) and allowing complex to form for 10 min before 
use. ED5-jetPEI complexes were prepared in 5% glucose according to manufacturer’s 
protocol using 7:1 ratio w/w (DNAzyme/PEI).  
In this study we demonstrated that, compared to ED5-jetPEI, a single injection of 
ED5-DOTAP solution (500ug DNAzyme/500ug DOTAP) in the jugular vein resulted 
in a significant ED5 uptake in the pulmonary vasculature and a reduction of vascular 
Egr-1 expression after 24 hours (n= 4 rats; Supplemental Figure S1). For the detection 
studies of DNAzyme in vivo, 6FAM was used as fluorescent label on the 5’ terminus 
of ED5 (Figure 1).
Pilot study: Egr-1 DNAzyme (ED5) delivery to pulmonary vasculature
In a pilot study we aimed to determine whether intravenous administration of 
the DNAzyme ED5/DOTAP complex would lead to delivery into the pulmonary 
vasculature and downregulate pulmonary vascular Egr-1 protein expression. To test 
this, flow-PAH rats (n=4) received a single injection of ED5/6FAM-DOTAP solution 
(500ug DNAzyme/500ug DOTAP) directly after shunt creation, whereas 3 flow-PAH 
rats received saline injection. Rats were sacrificed after 1 and 3 days. In contrast to 
the saline-injected animals, the ED5/6FAM-DOTAP-injected rats, showed ED5 in the 
endothelial layer of the pulmonary vessels (Figure 1) at day 1 that had diminished at 
day 3. Accordingly, in these rats ED5 transfection indeed resulted in downregulation of 
vascular Egr-1 protein expression at day 1 and this effect was lost 3 days after injection 
(Figure 1C and D). Therefore, in the main study rats received treatment every 48 hours.
Echocardiography
Echocardiography was performed 1 and 3 weeks after start of increased pulmonary 
blood flow, and in sham operated animals using a Vivid Dimension 7 system and 




10S-transducer (GE Healthcare, Waukesha, WI, USA) as described previously [2]. 
Briefly, cardiac output (CO) was calculated using systolic aorta diameter and pulsed 
wave Doppler of aorta flow as (aorta diameter)2 × 3.14 × velocity time integral (VTI) x 
heart rate. Pulmonary artery acceleration time (PAAT) was measured in the RV outflow 
tract, and tricuspid annular plane systolic excursion (TAPSE) was measured in apical 
4-chamber view. 
Hemodynamic measurements
Rats were anesthetized with 3-5% isoflurane inhalation. A fluid filled pressure 
catheter was inserted into the right internal jugular vein and guided to the right ventricle 
under pressure waveform monitoring using a bedside monitor. Mean right atrial pressure 
and right ventricular systolic pressure were measured. Pulmonary vascular resistance 
was estimated by dividing the assessed mean pulmonary arterial pressure by the cardiac 
output as described previously [3].
Pathology and morphometric analysis 
Heart and lungs were excised and weighed separately. The right lung was frozen in 
liquid nitrogen for molecular analysis. The left lung was fixated by passive filling of the 
airways with 3.6% formalin and embedded in paraffin. Pulmonary vascular morphology 
(n=6-7 rats per experimental group) was qualitatively and quantitatively analyzed.
Intra-acinar vessels without a clearly defined internal lamina elastica combined with 
luminal occlusion were defined as occlusive neointimal lesions. Intra-acinar vessels 
with a double lamina elastica for more than half of its circumference were defined as 
completely muscular. Intra-acinar vessels with a double lamina elastica for less than 
half of its circumference were defined as partially muscular. Normal, non-muscular, 
intra-acinar vessels had a single lamina elastica and no luminal occlusion. 
Five-ten randomly chosen pre-acinar vessels (> 50 mm) and 40 randomly chosen 
intra-acinar vessels (< 50 mm) were assessed using Image Scope (Aperio Technologies 
version 10). Three different vascular areas were defined: outer vessel area, inner vessel 
area and luminal area. The outer vessel area was defined as the area within the lamina 
elastica externa. The inner vessel area was defined as the area within the lamina elastica 
interna. The medial area was defined as the outer vessel area minus the inner vessel 
area. 
The occlusion score for the intra-acinar pulmonary vessels was calculated according 
to the following formula: (outer vessel area – luminal area) / (outer vessel area) and 
presented as the mean (± SD) percentage of vessel occlusion per time point.
Muscularization per time point was assessed and presented as the percentage of 
vessels per degrees of muscularization (including neointimal formation).
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Immunohistochemistry 
Paraffin-embedded rat lung sections were microwave heated for antigen retrieval. 
To reduce non-specific staining, sections were preincubated in 0,3% hydrogen peroxide. 
Sections were then embedded for 1h at room temperature with primary antibodies for aSMA 
(DAKO, 1:50), von Willebrand Factor (vWF; Abcam, 1:300), Egr-1 (rat: Cell Signaling, 
1:50 dilution; human: Abcam, 1:100 dilution),  (PDGF)-B (Abcam, 1:100), TGF-β1 
(Abcam, 1:100), IL-6 (Abcam, 1:00), p53 (Abcam, 1:00), Caspase 3 (Cell Signaling, 1:100 
dilution) and Ki67 (Abcam, 1:50 dilution). Species-specific immunoglobulin G coupled to 
peroxidase was used as secondary and tertiary antibodies (DAKO, 1:100 dilution). Sections 
were stained with diaminobenzidine for 10 min and counterstained with hematoxylin. For 
immunofluorescence nuclei were stained with DAPI (Vector Laboratories Inc.). 
As an example for Egr-1 staining in human PAH, a human lung tissue sample was 
obtained from an explanted lung from a patient with PAH associated with congenital 
cardiac shunt (VSD+PDA) that underwent lung transplantation.
Egr-1 positive control staining was performed on prostate adenocarcinoma samples. In 
addition, bronchial staining of Egr-1 served as positive control within the sample. Negative 
controls for all secondary antibodies were tested. 
Staining was semi-quantified (n=4-6 rats per experimental group) to characterize 
spatiotemporal expression of the proteins Egr-1, Caspase 3 and Ki67, PDGF-B, TGF-β1, 
IL-6 and p53. Twenty intra-acinar vessels were randomly selected per rat. Vessels were 
scored as followed: a) positive Egr-1 expression (0: no staining; 1: positive staining), b) 
localization of Egr-1 expression (0: no staining; 1: positive staining mainly in endothelium, 
2: positive staining mainly in media and 3: diffuse positive staining) and c) amount of 
positive Egr-1 cells per vessel. Endothelium was defined as the cell layer bordering the 
vessel lumen. In non-neointimal vessels, media was defined as the layer between outer 
elastic layer the cell layer bordering the vessel lumen. 
Real-time RT-PCR
For PPAR-γ activation, gene expression of PGC1a (co-activator of PPAR-γ) and 
MCAD (downstream gene of PPAR-γ) were measured. For real-time RT-PCR of whole 
lung samples (n=3-5 per group), commercially available kits were used.  Total RNA 
was isolated from pulmonary tissue using TRIzol reagent (Invitrogen). Real-time RT 
PCR experiments were performed on a CXF384 real time system C1000 Thermal 
cycler (BioRad Laboratories, Veenendaal, The Netherlands). cDNA was synthesized 
using QuantiTect Reverse Transcription Kit (Qiagen, Benelux). Real-time RT PCR 
was conducted using SYBR Green PCR Master Mix according to the manufacturer’s 
instructions (Eurogentec, San Diego, CA). Primer sequences are available on request. 
Expression levels were obtained from a dilution standard curve and compared with those 
of cyclophilin or 36B4 RNA in order to calculate the relative expression levels.
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Supplementary data
Figure S1. Pilot study: targeting pulmonary vasculature with DNAzyme ED5
A) Pulmonary vascular localization of ED5 (6FAM fluorescent signaling) after a single injection combined 
with either DOTAP of PEI for facilitation of cell transfection. Note the strong presence of ED5 in the 
combination with DOTAP at 6 and 24 hours post injection. PEI did not result in pulmonary vascular cell 
transfection. B) transfection of ED5 with DOTAP (PAH_DOTAP) resulted in a reduced pulmonary vascular 
Egr-1 expression compared to saline injected rats (PAH_VEH). PEI (PAH_PEI) had no effect on Egr-1 
expression. Data are presented as mean values ± SEM. * P<0.05. Scale bar  represents 50µm.
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Figure S2. Peripheral blood work results 
ED5 treatment did not result in a systemic immune response (as measured by leucocyt count, hematocrit 
(Ht), hemoglobin (Hb) at 3 weeks) or decreased liver function (as measured by the liver enzymes aspartate 
transaminase (ASAT), alanine transaminase (ALAT); and albumin production at 1 week) measured in 
peripheral blood. Data are presented as mean values ± SEM. Dotted lines indicate normal range for each 
parameter.
Figure S3. Similarities in sham operated animals at 3 weeks
Pulmonary vascular remodeling (occlusion score, wall thickness), RV hypertrophy (RV/IVS+LV) and peak 
systolic right ventricular pressure (pRVSP) in sham operated rats that received either vehicle treatment of 
ED5. ED5 treatment had no effect on pulmonary vascular remodeling, RV remodeling or pRVSP in control 
animals. Data are presented as mean values ± SEM. 




Figure S4. Correlation between the wall thickness of the intra-acinar vesssels and hemodynamic 
parameters and right ventricular hypertrophy. Data are presented as mean values ± SEM. * P<0.05.
Figure S5. Localization of Egr-1 expression in pulmonary vasculature
At 1 week Egr-1 was found mainly in the intimal layer. At 3 weeks Egr-1 was found throughout the vessel wall. 
ED5 reduced the expression of Egr-1 throughout the vessel wall.
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Figure S7. PPAR-γ activation.
Expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and medium-
chain acyl-CoA dehydrogenase (MCAD) as a readout for PPAR-γ activation at 1 day and 1 week after flow. 
Pioglitazon treatment increased PGC1α (co-activator of PPARγ) and MCAD (downstream gene of PPARγ) 
expression in a dose dependent matter. Data are presented as mean values ± SEM. * P<0.05 PAH_PIO100 
vs PAH_VEH.
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Abstract
Activated endothelial cells play a pivotal role in the pathology of inflammatory 
diseases and present a rational target for therapeutic intervention by endothelial 
specific delivery of short interfering RNAs (siRNA). This study demonstrates the 
potential of the recently developed new generation of liposomes based on cationic 
amphiphile SAINT-C18 (1-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chloride) for 
functional and selective delivery of siRNA into inflamed primary endothelial cells. 
To create specificity for inflamed endothelial cells, these so called SAINT-O-Somes 
were harnessed with antibodies against VCAM-1 respectively E-selectin and tested 
in TNF-α activated primary endothelial cells from venous and aortic vascular beds. 
Both targeted SAINT-O-Somes carrying siRNA against the endothelial gene VE-
cadherin specifically downregulated its target mRNA and protein without exerting 
cellular toxicity. SAINT-O-Somes formulated with siRNA formed small particles 
(106 nm) with a 71% siRNA encapsulation efficiency. SAINT-O-Somes were stable in 
the presence of serum at 37 oC, protected siRNA from degradation by serum RNases 
and after i.v. injection displayed pharmacokinetic comparable to conventional long 
circulating liposomes. These anti-VCAM-1 and anti-E-selectin SAINT-O-Somes are 
thus a novel drug delivery system that can achieve specific and effective delivery of 
siRNA into inflamed primary endothelial cells and have physicochemical features that 
comply with in vivo application demands.





Gene silencing by means of RNA interference (RNAi) is a powerful technique 
with a potential for pharmacological application. Short interfering RNAs (siRNAs) are 
extensively investigated as a new class of molecular drugs due to their highly specific 
interference with gene expression. However, unmodified or uncomplexed siRNAs (so-
called “naked” siRNAs) are subjected to rapid clearance from the circulation by the 
liver and by renal filtration which limits their usefulness as a therapeutic per se [1, 2]. 
Moreover, the physicochemical properties of siRNAs, including their high molecular 
weight (~13-15 kDa), polyanionic nature (~40 negatively charged phosphate groups), 
and their susceptibility to degradation by serum RNases, enforce application of chemical 
modifications or proper formulation into a delivery system to create potent therapeutics 
[3, 4]. siRNA carriers have proven to be able of knocking down targets in various 
diseases in vivo including hypercholesterolemia [5], liver cirrhosis [6], and cancer [7]. 
Moreover, first evidence of successful siRNA mediated gene silencing in humans by 
systemically delivered siRNA nanoparticles has been published recently [8].
Increased insight in the role of endothelial cells in the pathophysiology of cancer, 
inflammatory and cardiovascular diseases, has drawn great interest in pharmacological 
interventions towards the endothelial cells at diseased sites [9, 10]. Their prevalence 
throughout the body, and accessibility for intravenously administered compounds make 
them attractive targets for targeted drug delivery approaches. Interfering with molecular 
processes in diseased endothelial cells by means of siRNA will advance to create novel 
endothelial cells directed therapies. Santel and Aleku et al. for example, demonstrated 
that in vivo silencing of protein kinase N3 (PKN3) in the tumor vasculature by siRNA 
containing lipoplexes significantly inhibited growth of various types of tumors as well 
as formation of metastases [11, 12].
Despite successful attempts of siRNA delivery to tumor endothelium, targeted 
delivery to endothelial cells in inflamed sites is still ill-addressed. Upon pro-
inflammatory stimulation, each organ displays a vascular bed specific pattern of cell 
adhesion molecules as E-selectin or VCAM-1, providing challenging opportunities to 
deliver drugs or small RNAs to organ specific (micro)vascular endothelial subsets [13]. 
E-selectin expression is restricted to endothelial cells and dramatically upregulated 
during inflammation [14, 15]. Also VCAM-1 is an attractive target as it is strongly 
upregulated upon inflammatory stimuli and during angiogenesis [16, 17]. In previous 
studies, we successfully employed immunoliposomes targeted to E-selectin for delivery 
of the anti-inflammatory drug dexamethasone and the cytotoxic drug doxorubicine to 
inflamed endothelial cells [18-20].
Limited processing of liposomes and subsequent release of their content displayed 
by primary endothelial cells remain a serious obstacle to achieve effective drug delivery 
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[19]. To address this, we recently developed a new generation of liposomes called 
SAINT-O-Somes, based on formulation of conventional long circulating liposomes 
and the cationic amphiphilic lipid SAINT-C18 (1-methyl-4-(cis-9-dioleyl)methyl-
pyridinium-chloride). SAINT-O-Somes showed superior intracellular release of their 
content in endothelial cells compared to conventional liposomes. Moreover, this system 
displayed the ability to efficiently encapsulate low molecular weight compounds and 
siRNA [19]. In the current study, we show that siRNA encapsulated in SAINT-O-
Somes targeted to VCAM-1 or E-selectin can be successfully delivered into inflamed 
primary endothelial cells originating from distinct vascular beds (venous and arterial). 
We investigated the potential of SAINT-O-Somes to specifically deliver siRNA into 
activated endothelial cells taking into account their physicochemical features (size, 
stability, protection of siRNA) and target cell conditions as appear in vivo. In addition, 
in vivo pharmacokinetic (PK) behavior of siRNA SAINT-O-Somes  was studied. Since 
little is known about the intracellular fate of siRNA delivery systems internalized via 
E-selectin and VCAM-1, we studied the intracellular trafficking of both siRNA and 
SAINT-O-Somes in the activated endothelial cells. Based on our results, we concluded 
that SAINT-O-Somes fulfill important requirements for successful targeted delivery of 
siRNA into inflamed endothelial cells and meet the requirements for in vivo application.
Experimental Section
Materials
Lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(poly-ethylene glycol)-2000]-ma-
leimide (DSPE-PEG2000-Mal), and 2-distearoyl-sn-glycero-3-phosphoethanolamine-N 
[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Avanti 
Polar Lipids (Alabaster AL, USA). The cationic lipid 1-methyl-4-(cis-9-dioleyl)
methyl-pyridinium-chloride (SAINT-C18) was obtained from Synvolux Therapeu-
tics (Groningen, The Netherlands). Cholesterol (Chol) and N-succinimidyl-S-acetyl-
thioacetate (SATA) were obtained from Sigma (St. Louis MO, USA). Nucleic acid 
stain Hoechst 33342 (trihydrochloride), lipophilic tracers 1,1′-dioctadecyl-3,3,3′,3′-
tetramethyl-indocarbocyanine perchlorate (DiI), 1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-
indodicarbocyanine perchlorate (DiD), and LysoTracker® Green DND-26 probe were 
purchased from Molecular Probes (Leiden, The Netherlands). LipofectamineTM 2000 
transfection reagent was purchased from Invitrogen (Breda, The Netherlands). All siR-
NAs were purchased from Qiagen (Venlo, The Netherlands).
The H18/7-acb (mouse IgG2a anti-human E-selectin) and E1/6-aa2 (mouse IgG1 
anti-human VCAM-1 antibody) monoclonal antibody-producing hybridomas were 
kindly provided by Dr. M. Gimbrone from Harvard Medical School (Boston, MA, USA).




Preparation of siRNA containing SAINT-O-Somes
SAINT-O-Somes were prepared as described previously with slight modifications 
[19]. In brief, lipids from stock solutions of POPC, SAINT-C18, Chol, DSPE-PEG2000 
and DSPE-PEG2000-Mal in chloroform: methanol (9:1) were mixed in a mol% ratio of 
37:18:40:4:1. To fluorescently label the liposomal bilayer, DiI or DiD was added to the 
lipid mixture in a 0.25 mol% ratio of Total Lipid (TL). We prepared SAINT-O-Somes 
containing VE-cadherin siRNA (Hu_CDH5_2 FlexiTube siRNA, cat No. SI00028483) 
or control siRNA (AllStars Negative Control, cat No. 1027281), with no homology to 
any known mammalian gene, with or without a fluorescent label. siRNA was dissolved 
according to the protocol of the manufacturer and mixed with dried lipids at a ratio 
of 1 nmol siRNA per 1 μmol TL. After extrusion through polycarbonate filters (50 
nm pore size) nonencapsulated siRNA was removed by ion exchange chromatography 
on a DEAE Sepharose CL-6B (Sigma, The Netherlands) column using HN buffer 
(135 mM NaCl, 10 mM HEPES) pH 6.7 as an eluent. The concentration of siRNA 
encapsulated in liposomes was measured using the Quant-iT™ Ribo-Green® assay 
(Invitrogen, Breda, The Netherlands) according to the protocol of the manufacturer. 
The efficiency of siRNA encapsulation into liposomes was calculated based on the 
measurements of encapsulated siRNA in the presence or absence of 1% (v/v) Triton 
X-100 (Sigma-Aldrich, Zwijndrecht, The Netherlands). The monoclonal anti-E-
selectin and anti-VCAM-1 antibodies were thiolated by means of SATA and coupled 
to a maleimide group at the distal end of the polyethylene glycol chain by sulfhydryl-
maleimide coupling as described before for albumin [21]. SAINT-O-Somes without an 
antibody were prepared from the same lipid mixture, but instead of being conjugated 
to the antibody, they were allowed to react with cysteine in a molar ratio twice that of 
DSPE-PEG2000-Mal to block reactive maleimide groups. The SAINT-O-Somes were 
characterized by determining the protein concentration using rat IgG as a standard 
and measuring the total lipid concentration by phosphorus assay [22]. Particle size 
and Zeta-potential were analyzed using a Nicomp model 380 ZLS submicron particle 
analyzer. Particle size was measured using dynamic light scattering (DLS) in the 
volume weighing mode (NICOMP particle sizing systems, Santa Barbara, CA, USA). 
The Polydispersity index (PDI) was calculated using a Malvern Zetasizer Nano ZSP 
(Malvern Instruments ltd., Worcestershire, UK). The number of antibody molecules 
coupled per liposome was calculated as described before [23]. SAINT-O-Somes were 
stored at 4 °C under argon gas and were used within 4 weeks.
Cryo-transmssion microscopy (Cryo-TEM)
Cryo-TEM analysis of SAINT-O-Somes was performed as described previously [19].
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Cell cultures
Human umbilical vein endothelial cells (HUVEC) were obtained from Lonza 
(Breda, The Netherlands). Cells were cultured in EBM-2 medium supplemented 
with EGM-2 MV SingleQuot Kit Supplements & Growth Factors (cat No. CC-3202, 
Lonza,). In all experiments, cells from passage 5 to 7 were used and they were plated on 
cultures plates (Costar, Corning, NY) at a density of 1.8 x 104 cells/cm2 one day before 
the experiment unless stated differently. Before seeding the cells, culture plates were 
incubated with EGM2 MV medium for 30 min.
Human aortic endothelial cells (HAEC) were obtained from Cascade Biologics 
Invitrogen cell culture (Life Technologies, Bleiswijk, The Netherlands). Cells were 
cultured in Medium 200 (Life Technologies) supplemented with Low Serum Growth 
Component (LSGS, containing fetal bovine serum, 2% v/v; hydrocortisone, 1 µg/
ml; human epidermal growth factor, 10 ng/ml; basic fibroblast growth factor, 3 ng/
ml) and heparin 10 µg/ml, streptomycin 100 μg/ml, and penicillin 100 IU/ml). In all 
experiments, cells from passage 5 to 10 were used and they were plated on cultures 
plates (Costar) at a density of 2 x 104 cells/cm2 one day before the experiment. All cell 
cultures were maintained by the endothelial cell facility of UMCG.
Influence of serum on particles size stability and siRNA integrity
To determine the influence of temperature and serum on the size of siRNA SAINT-
O-Somes, particles were incubated for 2, 4, 6 and 24 h at 37 °C in the presence or 
absence of 50% human serum. The size of liposomes was measured as described above 
by dynamic light scattering.
To investigate the integrity of encapsulated siRNA, SAINT-O-Somes containing 
160 ng of control siRNA were incubated in presence of 50% human serum for 0.5, 1, 4, 
6 and 24 h at 37 °C. An equal amount of naked control siRNA was incubated with human 
serum for the same period of time as SAINT-O-Somes. At the end of the incubation, 
1 % (v/v) Triton X-100 and the gel loading dye (BioLabs, Leiden, The Netherlands) 
were added to the samples. Subsequently, samples were loaded on 2% agarose gel 
containing ethidium bromide and run for 15 min at 110 V. Bands were visualized using 
the ChemiDocTM XRS system (Bio-rad, Veenendaal, The Netherlands). The integrity 
of encapsulated siRNA after eight weeks of storage at 4 oC under argon gas was also 
analyzed by agarose gel electrophoresis as described above.
Investigation of SAINT-O-Somes uptake by flow cytometry and fluorescence 
microscopy
For flow cytometry experiments, HUVEC and HAEC were seeded in 24-well 
plates. 10 ng/ml TNF-α (BioSource Europe, Nivelles, Belgium) was added to the cells 
2 h before addition of 80 nmol TL/ml of SAINT-O-Somes containing AlexaFluor
488 




siRNA. TNF-α remained present in the medium during further incubation with 
liposomes. To block E-selectin respectively VCAM-1 protein, a 75-fold excess over 
the amount of antibodies coupled to the liposomes of anti-E-selectin or anti-VCAM-1 
monoclonal antibodies was added to the cells, together with the liposomes. 4 or 24 h 
after addition of SAINT-O-Somes, cells were washed twice with PBS and detached 
from the surface using trypsin/EDTA (Sigma, Ayrshire,UK) after which they were 
immediately transferred to tubes containing 5% FBS (Fetal Bovine Serum, Thermo 
Scientific HyClone, Cramlington, UK) in PBS and kept on ice. Next, samples were 
centrifuged for 5 min at 500 g at 4 °C, followed by two washing steps with 3 ml of 
5% FBS in PBS, and resuspended in 0.2 ml PBS for flow cytometry analysis (Calibur, 
BD Biosciences, Franklin Lakes, NJ). When flow cytometry was performed the 
following day, cells were fixed with 0.5% paraformaldehyde in PBS and stored at 4 
°C.
For fluorescence microscopy HUVEC were cultured on Lab-TekTM Chamber Slides 
(Nunc, Rochester, NY, USA). Before seeding the cells, chamber slides were incubated 
with EGM2 MV medium for 30 min. Cells were activated with TNF-α and incubated 
with liposomes in a similar way as described for the flow cytometry experiments. 
Targeted and non-targeted SAINT-O-Somes labeled with DiI and containing 
AlexaFluor
488
 labeled siRNA were used at 80 nmol TL/ml. Nuclei of the cells were 
stained using Hoechst 33342. At the end of the incubation, cells were washed twice 
with ice-cold serum-free culture medium, placed on ice and subjected to imaging within 
45 min. Fluorescence images of cells were taken with a Leica DM/RXA fluorescence 
microscope (Wetzlar, Germany) using Quantimet HR600 image analysis software 
(Leica). Images were taken at excitation/emission wavelengths of 550/570 nm for DiI, 
490/520 nm for siRNA AlexaFluor
488
, and 350/461 nm for Hoechst 33342.
Investigation of Intracellular processing of siRNA containing SAINT-O-Somes by 
confocal microscopy 
For confocal laser scanning microscopy (CLSM), HUVEC were cultured on sterile 
cover glasses (Menzel-Gläser, Braunschweig, Germany) placed into the wells of a 
12-well plate. Before seeding the cells, the cover glasses were incubated with EGM2 
MV medium for 30 min. Prior to incubation with anti-E-selectin or anti-VCAM-1 
SAINT-O-Somes, HUVEC were activated for 4 h with 10 ng/ml of TNF-α. Liposomes 
containing membrane label (DiD) and/or fluorescent siRNA were incubated with the 
cells at concentration of 80 nmol TL/ml for the indicated time periods. For staining of 
acidic organelles, cells were incubated with LysoTracker at a concentration of 75 nM 
for the last 20 min of the incubation. To stain late endosomal/lysosomal compartments 
cells were plated at a density of 1.4 x 104 cell/cm2 and transfected with 2 µg/ml pLamp-
1-RFP plasmid (obtained from Dr. Walther E. Mothes from Yale School of Medicine, 
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New Haven, CT, USA) using Lipofectamine 2000, 48 h prior the experiment according 
to the manufacturer’s protocol. At the end of the incubation, cells were washed twice 
with ice-cold serum-free culture medium, placed on ice and subjected to imaging 
within 45 min. During this time, there was no change in cell morphology and images 
taken within this period were reproducible throughout the different experiments. For 
studying the internalization, cells were fixed with 4% formaldehyde in PBS for 15 
min at room temperature (RT) and subsequently slides were mounted with Citi-Fluor 
AF1 (Citifluor Ltd, London, UK) and kept at 4 oC until analysis. Images were taken 
with a confocal laser scanning microscope (True Confocal Scanner SP2-AOBS; Leica, 
Heidelberg, Germany) equipped with argon (Ar) and helium-neon lasers (HeNe) and 
coupled to a LeicaDM RXE microscope using an HCXPL APO CS 63 x 1.40 oil 
immersion objective. Continuing scans were taken for fluorophore pairs AlexaFluor
488
/
DiD and LysoTracker green/DiD, while sequential scans were obtained for fluorophore 
pairs AlexaFluor
488
/RFP to avoid bleed through. AlexaFluor
488 
was excited using the 
488 nm Ar laser line, AlexaFluor
546 
and RPF were excited using the 543 nm HeNe laser 
line, and DiD was excited using the 633 nm HeNe laser line. All images were recorded 
in the linear range, avoiding local saturation, and at an image resolution of 1024x1024 
pixels and with pinhole size of 1 Airy unit. A series of xyz-scans with a 0.3 µm step 
size were taken along the z-axis from top to bottom of the cells. Presented images show 
a single z-scan or maximum intensity projection of all z-scans from a single series as 
indicated. Images were analyzed and processed using Leica Confocal Software V2.61 
and ImageJ V1.45s.
Gene expression analysis by RT-qPCR
For gene expression analysis, HUVEC and HAEC were seeded in 24-well plates. 
After 2 h of activation with TNF-α (10 ng/ml), anti-E-selectin or anti-VCAM-1 SAINT-
O-Somes containing VE-cadherin specific siRNA or control siRNA were added to the 
cells at 1 µM siRNA concentration, and incubated for 48 h. TNF-α was present in 
the medium during the entire incubation period. After 48 h total RNA was isolated 
using the RNeasy® Mini Plus Kit (Qiagen, Venlo, The Netherlands) according to the 
protocol of the manufacturer. The amount of RNA was measured by a NanoDrop® 
ND-1000 Spectrophotometer (Wilmington, DE) and qualitative gel electrophoresis 
consistently showed intact RNA integrity. cDNA synthesis and quantitative (q) PCR, 
including data analysis, were performed as described previously [19]. The real-time 
PCR primers for human VE-cadherin (Hs00174344_m1) and GAPDH (Hs99999905_
m1) were purchased as Assay-on-Demand from Applied Biosystems (Nieuwekerk a/d 
IJssel, The Netherlands). Gene expression levels were normalized to the expression of 
the reference gene GAPDH and compared to cells treated only with TNF-α.




Protein expression analysis by Western blot and ELISA
HUVEC and HAEC were seeded in 6-well plates and after 2 h of activation with 
TNF-α (10 ng/ml), anti-E-selectin or anti-VCAM-1 SAINT-O-Somes containing VE-
cadherin specific siRNA or control siRNA were added to the cells at 1 µM siRNA 
concentration. After 48 h of incubation cells were lysed using RIPA buffer (Sigma-
Aldrich, Zwijndrecht, The Netherlands) and lysates were used for Western blot and 
ELISA. Western blot analysis was performed as described previously [24], with slight 
modifications. The membrane was horizontally cut through the 70 kDa pre-stained 
marker and the upper part of the blot was incubated overnight at 4 °C with polyclonal 
rabbit anti-human VE-cadherin antibody (cat No. #2158, Cell Signaling Technology, 
Inc, Leiden, The Netherlands). For loading control the lower part of the blot was 
incubated for 1 h at RT with monoclonal mouse anti-human GAPDH antibody (cat 
No. #mAbcam 9484, Abcam, Cambridge, UK). Antibody binding was visualized by 
horseradish peroxidase-conjugated anti-rabbit IgG (cat No. #7074, Cell Signaling 
Technology, Inc, Leiden, The Netherlands) and anti-mouse IgG H+L (cat No. 1010-05 
Southern Biotech, Birmingham, AL, USA). Chemiluminescence (Thermo Scientific, 
Rockford, IL, USA) signals were quantified by densitometric analysis using Quantity 
One software (Bio-Rad, Hercules, CA, USA). Protein expression from at least three 
independent experiments was quantified using DuoSet® IC Human Total VE-cadherin 
ELISA (R&D Systems, Abingdon, UK), according to the manufacturer’s protocol.
Investigation of cellular toxicity by MTS assay
To investigate the influence of anti-E-selectin and anti-VCAM-1 siRNA SAINT-O-
Somes on cell viability, HUVEC and HAEC were seeded in 96-well plates. Incubations 
with TNF-α and liposomes were performed as described for gene and protein expression 
analysis. After 48 h cells were washed twice with PBS followed by addition of 100 µl 
fresh culture medium and 20 µl CellTiter 96® AQ
ueous
 One Solution reagent (Promega, 
Leiden, The Netherlands). After 1.5 h, the absorbance at 490 nm was recorded with 
a Varioskan Flash Multimode reader (Thermo Scientific, Breda, The Netherlands). 
Absorbance of the activated endothelial cells without addition of SAINT-O-Somes was 
considered 100%.
Pharmacokinetics of (siRNA) SAINT-O-Somes 
Male C57bl/6OlaHsd mice (18-23 g) were purchased from Harlan (Zeist, The 
Netherlands) and randomly divided into experimental groups. To induce an acute 
systemic inflammation mice were i.v. injected with 0.2 mg of recombinant mouse 
TNF-α (mrTNF-α; Gibco, Camarilo, CA, USA) in 0.9% NaCl, 2 h prior to injection 
of liposomes. Subsequently, animals received i.v. a single dose (10 mmol TL/kg, 3 
mice/group) of [3H]Cholesteryl Hexadecyl Ether (PerkinElmer, Shelton, CT, USA) 
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labeled SAINT-O-Somes, empty or containing control siRNA. Blood was sampled at 
10 min, 30 min, 1 h, 6 h, and 24 h. 3H radioactivity was measured using a Packard Tri-
Carb 2500 TR liquid scintillation analyzer (PerkinElmer Life And Analytical Sciences, 
Waltham, MA). The total amount of radioactivity in the serum, separated from the 
blood by centrifugation, was calculated as described previously [21]. Pharmacokinetic 
parameters were calculated according to population analysis using the Interactive Two-
Stage Bayesian program [25]. All animal experiments were performed according to 
national guidelines and upon approval of the local Animal Care and Use Committee of 
Groningen University.
Statistical analysis
Statistical analysis of the results was performed by a two-tailed unpaired Student’s 
t-test, assuming equal variances to compare two replicate means, or One-Way ANOVA 
followed by Bonferroni post-hoc analysis to compare multiple replicate means. 
Differences were considered significant when P<0.05.
Results
Preparation and characterization of SAINT-O-Somes loaded with siRNA
In the present study we formulated SAINT-O-Somes containing 18 mol% of 
SAINT-C18 and investigated their potential for effective siRNA delivery into activated 
primary endothelial cells. The physicochemical properties of SAINT-O-Somes loaded 
with siRNA are given in Table 1. Using cryo-EM microscopy we demonstrated that 
siRNA SAINT-O-Somes mainly consist of liposomes. Additionally, disk-like micelles 
were observed in the population (Fig. 1A), the formation of which could have been 
induced by the presence of DSPE-PEG2000 >4 mol% TL in the liposome formulation as 
described by Johnsson et al. [26, 27]. However,  based on volume-weighted Gaussian 
distribution (data not shown) and the presented cryo-EM images, disc-like micelles 
comprises minor proportion (< 10 %) of  siRNA SAINT-O-Somes preparation. The 
average liposome size defined by DLS method was 106 nm with corresponding 
polydispersity index of 0.17 which according to multiple sources [28, 29]  is considered 
acceptable for the sample to be homogenous and monodisperse. siRNA SAINT-
O-Somes showed good size stability in the presence of 50 % serum and 37 oC (Fig. 
1B). Surface charge of targeted SAINT-O-Somes was neutral and particles displayed 
a siRNA encapsulation efficiency of 71% ± 15 (Table 1). Based on the Ribogreen 
measurements we estimated that additional 5-6% of siRNA was electrostatically 
attached to the surface of liposomes. To investigate whether encapsulation into SAINT-
O-Somes protects siRNA against RNases, we incubated particles with 50% human 
serum at 37 oC (Fig. 1C). Nonencapsulated siRNA was entirely degraded in serum 





POPC : SAINT : Chol  : DSPE-PEG : DSPE-PEG-Mal 












106 ± 48 0.17 ± 0,03 3.8 ± 5 24 ± 5 71 ± 15 
	  
Table 1. Physicochemical properties of siRNA containing SAINT-O-Somes.
Data are presented as means of 8 preparations ± SD. Ab, average amount for anti-E-selectin or 
anti-VCAM-1 antibody conjugated to liposome.
Figure  1. Characterization of siRNA containing SAINT-O-Somes. (A) Cryo-EM images of siRNA containing 
SAINT-O-Somes; (B) Size stability of siRNA SAINT-O-Somes in (●) presence or (○) absence of 50% serum. 
Particles were incubated for 2, 4, 6 and 24 h at 37 oC in HN buffer pH 7.4 or in 50% human serum. Data 
are presented as diameter (nm) ±SD of 3 preparations; Maintenance of siRNA integrity by encapsulation in 
SAINT-O-Somes was studied by comparison of equal amounts of nonencapsulated and encapsulated siRNA 
incubated in 50% human serum for 0.5, 1, 4, 6 and 24 h at 37 oC. (C) Agarose gel electrophoresis of 
nonencapsulated and encapsulated siRNA. (D) Agarose gel electrophoresis of siRNA encapsulated in anti-E-
selectin respectively anti-VCAM-1 antibody conjugated SAINT-O-Somes that were stored for 8 weeks at 4o 
C, intact naked VE-cadherin siRNA was used a control.
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within 4 h, whereas formulation into SAINT-O-Somes preserved the integrity of siRNA 
for 24 h. Moreover, we demonstrated that SAINT-O-Somes could be stored for at least 
8 weeks at 4 oC in HN buffer without loss of siRNA integrity (Fig. 1D) and without 
change of the particle size (data not shown). 
To demonstrate feasibility of SAINT-O-Somes for in vivo administration, we 
investigated the pharmacokinetic behavior of i.v. injected SAINT-O-Somes both empty 
and loaded with siRNA. Plasma concentration of the particles showed two-phase 
clearance kinetic with a short initial half-life ranging from 9-12 min and a secondary 
half-life of  > 11 h (Fig. S1 and Table 2). siRNA SAINT-O-Somes showed longer 
circulation time than empty SAINT-O-Somes, as indicated by longer secondary half-
life and significantly lower plasma clearance and steady state volume of distribution. 
Coupling of antibody to siRNA SAINT-O-Somes resulted in significantly prolonged 
secondary half-life from approximately 12 to 17 h and lower plasma clearance.
SAINT-O-Somes targeted to VCAM-1 and E-selectin specifically deliver siRNA into 
TNF-α activated primary endothelial cells
To achieve specific delivery of siRNA to activated endothelial cells we conjugated 
SAINT-O-Somes with antibodies directed against E-selectin or VCAM-1. Primary 
HUVEC and HAEC were used to investigate specificity and efficacy of siRNA 
delivery. Cells were activated with TNF-α and incubated with targeted SAINT-O-
Somes containing fluorescently labeled siRNA. As compared to resting cells, anti-E-
selectin and anti-VCAM-1 SAINT-O-Somes showed a 35-fold increase in association 
(binding and uptake) of siRNA with activated HUVEC and a 25-fold increase with 
activated HAEC (Fig. 2A, B). HUVEC and HAEC exhibited the highest association 
with anti-VCAM-1 SAINT-O-Somes after 24 h and comparable association between 
4 and 24 h with anti-E-selectin SAINT-O-Somes, which corroborated the protein 
Parameter 
SAINT-O-Somes 
empty siRNA siRNA + Ab 
CL, ml/h 2.87 ± 0.07 2.02 ± 0.11* 1.36 ± 0.04# 
Vss, ml/g  32.65 ± 0.53  25.92 ± 1.39*  26.09 ± 0.55 
t1/2 (1), h 0.15 ± 0.01          0.21 ± 0.02 0.21 ± 0.02 
t1/2 (2), h   11.33 ± 0.06  11.72 ± 0.01*  17.36 ± 1.67# 
	  
Table 2. Pharmacokinetic parameters of siRNA SAINT-O-Somes.
Data are presented as means values ± SD of 3 mice/group. CL, plasma clearance; 
Vss, steady-state volume of distribution; t1/2 (1), initial half-life;  t1/2 (2), 
secondary half-life. * P < 0.05 empty vs siRNA, # P < 0.05 siRNA vs siRNA + 
Ab (antibody)




expression kinetics of both adhesion molecules (data not shown). In HUVEC, SAINT-
O-Somes targeted to E-selectin or VCAM-1 showed comparable siRNA delivery, 
whereas in HAEC 50% more siRNA was delivered after 24 h by anti-VCAM-1 than 
by anti-E-selectin SAINT-O-Somes. To prove that association of siRNA in activated 
endothelial cells was mediated by E-selectin and VCAM-1, we co-incubated cells with 
an excess of antibodies against both target proteins. This led to a significant decrease in 
Figure 2. Selective delivery of siRNA to activated primary endothelial cells by targeted SAINT-O-Somes. 
Quiescent and TNF-α activated (A) HUVEC and (B) HAEC were incubated for 4 or 24 h with anti-E-selectin 
and anti-VCAM-1 SAINT-O-Somes containing AlexaFluor488 siRNA. Specificity of association to E-selectin 
respectively VCAM-1,  was determined by co-incubation with 75 times excess of anti-E-selectin or anti-
VCAM-1 monoclonal antibodies together with the liposomes. The association of siRNA with the cells was 
quantified by flow cytometric analysis. Data are presented as mean florescence intensity (MFI) values ± 
SD of three independent experiments. * P < 0.05, # P < 0.05 - 4h vs 4h + Ab, $ P < 0.05 - 24h vs 24h + 
Ab. (C) Fluorescence microscopy images of the uptake of targeted and non-targeted SAINT-O-Somes by 
cultured HUVEC. The liposome membrane was labeled with DiI (red) and encapsulated siRNA was labeled 
with AlexaFluor488 (green), the nuclei of the cells were stained using Hoechst (blue). The presented data 
set shows representative images, presented as merged pictures, of tree independent experiments. Original 
magnification 100x.
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the siRNA association with the activated cells (Fig. 2A, B). Additionally, in the absence 
of targeting antibody on the surface of SAINT-O-Somes no association of siRNA was 
observed either in resting or in activated cells (Fig. 2C and S2. A, B). The uptake of 
targeted SAINT-O-Somes by activated endothelial cells was confirmed by fluorescence 
microscopy using DiI (red) labeled liposomes containing fluorescent siRNA (green) 
(Fig. 2C). The two labels co-localized, indicating uptake of siRNA in conjunction with 
the carrier.
Intracellular trafficking of anti-VCAM-1 and anti-E-selectin SAINT-O-Somes in 
endothelial cells
Uptake and intracellular trafficking of the anti-E-selectin and anti-VCAM-1 SAINT-
O-Somes loaded with labeled siRNA in TNF-α activated HUVEC was investigated 
using CLSM. AlexaFluor
546 
siRNA (red) encapsulated in SAINT-O-Somes was binding 
to the surface of activated HUVEC at 4 oC (Fig. 3A a1, a5) and was internalized at 
37 oC (Fig. 3A a2-a4, a6-a8). siRNA SAINT-O-Somes endocytosed via E-selectin 
and VCAM-1 localized in acidic compartments (late endosomes/lysosomes) within 
4 h after start of the incubation with the cells (Fig. 3B, C), as demonstrated by co-
localization with LysoTracker (Fig. 3B) or lysosomally expressed Lamp-1-RFP (Fig. 
3C). By tracking simultaneously labeled SAINT-O-Somes and the encapsulated siRNA 
we demonstrated co-localization of the two labels after 4 h and partial dissociation of 
the siRNA label from the lipid label after 24 h (Fig. S3).
Anti-VCAM-1 and anti-E-selectin SAINT-O-Somes can effectively downregulate 
target genes in primary endothelial cells
Using anti-E-selectin or anti-VCAM-1 siRNA SAINT-O-Somes we aimed to knock 
down a gene that is expressed in the endothelial cells and would pose a model for 
studying the effects of the targeted system. VE-cadherin is an endothelial gene regulating 
formation of adherent cell junctions [30, 31], the expression of which is restricted to 
endothelial cells and maintained under TNF-α stimulation (Suppl. Table 1), making it a 
suitable target gene for this study. TNF-α activated HUVEC and HAEC were incubated 
for 48 h with SAINT-O-Somes containing VE-cadherin specific siRNA (VE) or control 
siRNA at 1 µM concentration. SAINT-O-Somes loaded with VE-cadherin specific 
siRNA caused up to 60% downregulation of VE-cadherin mRNA in both HUVEC 
and HAEC, while uncoupled SAINT-O-Somes (data not shown) and SAINT-O-Somes 
containing control siRNA were devoid of an effect (Fig. 4A, B). Moreover, VE-cadherin 
downregulation did not alter the expression of the unrelated endothelial genes CD31 or 
Tie2 in both HUVEC and HAEC (Fig. S4A-D). Furthermore, reduction in VE-cadherin 
mRNA resulted in up to 50% decrease in protein expression in HUVEC and 25 % in 
HAEC, as quantified by ELISA (Fig. 4C, D), while no effects were observed with 




Figure 3. Anti-E-selectin and anti-VCAM-1 targeted SAINT-O-Somes loaded with siRNA are directed to 
endolysosomal compartments. (A) Encapsulated siRNA labeled with AlexaFluor546 (red) internalized via 
E-selectin or VCAM-1 displayed perinuclear localization in vesicular structures within 4 h after addition of 
liposomes (a1-a8). After addition of liposomes, cells were kept at 4 oC to allow binding but inhibit formation 
of endocytic vesicles (a1, a5). Borders of the cells (white dotted lines) were drawn based on deferential 
interference contrast (DIC) images. Images of the cells were taken using CLSM and are presented as a 
merge of x-y-z scans using maximum intensity projection; Co-localization of SAINT-O-Somes and siRNA 
with acidic compartments (late endosomes/lysosomes) in activated HUVEC was demonstrated using (B) 
LysoTracker. After 4 h of incubation with targeted SAINT-O-Somes labeled with DiD (liposome membrane, 
red), LysoTracker (green) was added to the cells for 20 min. (C) Co-localization with late endolysosomal 
compartments was shown using cells transected with a plasmid expressing Lamp-1-RFP protein (red) prior 
to the experiment as described in ‘Experimental Section’. After 4 h of incubation with targeted SAINT-O-
Somes containing AlexaFluor488 labeled siRNA (green), cells were visualized using CLSM and are presented 
as single z-scans. Presented data set show representative images of tree independent experiments.
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targeted SAINT-O-Somes containing control siRNA. Specific downregulation of VE-
cadherin protein was also confirmed using Western Blot (Fig. 4E, F).
The possibility that targeted siRNA SAINT-O-Somes influence VE-cadherin 
expression by exerting a toxic effect on the cells was excluded by their negligible effect 
on endothelial cell viability (Fig. 5A, B). TNF-α activated HUVEC and HAEC were 
incubated for 48 h with SAINT-O-Somes containing VE-cadherin or control siRNA at 
1 µM concentration. Little or no decrease in cell viability was observed either in cells 
treated with SAINT-O-Somes containing VE-cadherin specific siRNA or in groups 
incubated with SAINT-O-Somes loaded with control siRNA.
Figure 4. Effective downregulation of VE-cadherin in primary endothelial cells via targeted SAINT-O-
Somes siRNA delivery. TNF-α activated HUVEC and HAEC were incubated with targeted SAINT-O-Somes 
containing VE-cadherin (VE) or control siRNA (CS) at 1 µM concentration for 48 h. After incubation, RNA 
or cell lysates were used for RT-qPCR (A,B) respectively ELISA (C,D) and Western blot (E,F) as described in 
‘Experimental Section’. (A-B) Data are presented as relative expression ± SD, compared to cells treated only 
with TNF-α (Ctr), of a minimum of three independent experiments. * P < 0.05. (C-D) Data are presented as 
VE-cadherin protein expression ± SD of three independent experiments. (E-F) Images show a representative 
Western Blot.





Inflamed endothelial cells play a significant role in the pathology of cancer and 
inflammatory diseases and present an accessible target for systemically applied drug 
carriers [13]. As such, development of siRNA delivery devices for pharmacological 
intervention at the level of inflamed or angiogenic endothelium holds clinical potential. 
Development of a carrier which selectively delivers siRNA into endothelial cells at 
the site of inflammation or angiogenesis can enhance pharmacological efficacy and 
limit possible side effects of the treatment. In the current work we demonstrated that, 
by using SAINT-C18 based liposomes (SAINT-O-Somes) surface-modified with 
antibodies specific for the inflammatory adhesion molecules E-selectin or VCAM-1, 
we were able to selectively deliver siRNA into activated primary endothelial cells. We 
found that E-selectin and VCAM-1 mediated internalization guided SAINT-O-Somes 
to endolysosomal compartments and allowed the release of the encapsulated siRNA. 
Targeted SAINT-O-Somes containing VE-cadherin specific siRNA showed significant 
downregulation of both the target gene mRNA and protein without exerting cellular 
toxicity. Furthermore, we demonstrated that the physicochemical properties and in 
vivo pharmacokinetic behavior of SAINT-O-Somes renders them suitable for in vivo 
delivery of siRNA. From this study we conclude that anti-E-selectin and anti-VCAM-1 
SAINT-O-Somes have the features that allows specific and effective delivery of siRNA 
to inflamed endothelial cells in vivo, which justifies further in vivo studies on the use of 
siRNA SAINT-O-Somes to interfere with inflammatory diseases.
SAINT-O-Somes formulated with siRNA and 18 mol% of SAINT-C18 in the 
liposomal bilayer form small and unilamellar particles. Reported disc-like micelles 
are not expected to contribute significantly to the physicochemical properties and 
Figure 5. Targeted SAINT-O-Somes delivered siRNA do not affect cell viability. TNF-α activated HUVEC 
(A) and HAEC (B) were incubated with targeted SAINT-O-Somes containing VE-cadherin or control siRNA 
at 1 µM concentration for 48 h. After the incubation viability of cells was investigated using CellTiter 96® 
AQueous One Solution reagent as described in ‘Experimental Section’. Viability of activated endothelial 
cells without addition of SAINT-O-Somes was considered 100%. Data are presented as mean values ± SD of 
three independent experiments. * P < 0.05.
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findings reported in this manuscript since they comprise <10% of siRNA SAINT-O-
Some preparation, that with a polydispersity index of 0.17 is considered homogenous 
and monodisperse. The here described SAINT-O-Somes are stable in the presence 
of serum and show siRNA encapsulation efficiency of 71%, that is high compared 
to other liposomal delivery platforms incorporating cationic lipids [32, 33]. Good 
stability and encapsulation efficiency are crucial features of in vivo siRNA delivery 
systems. For example, lipoplex formulations can reach > 90% siRNA entrapment 
efficiency [34], but their limited stability under physiological conditions restricts in 
vivo application [35]. Our results indicated that the integrity of siRNA encapsulated 
in SAINT-O-Somes is preserved under conditions that resemble the in vivo situation 
(presence of 50% serum and 37 oC) as well as upon long-term storage. We showed that 
i.v. injected SAINT-O-Somes display a two-phase PK with a long secondary half-life 
> 11 h, comparable to the PK behavior of conventional long circulating liposomes, that 
have been successfully used to target endothelial cells in vivo [18]. Encapsulation of 
siRNA significantly influenced the PK parameters and resulted in delayed clearance 
from the circulation. This could be explained by lower surface charge of SAINT-O-
Somes containing negatively charged siRNA. Coupling of antibody to siRNA SAINT-
O-Somes prolonged the circulation time from approximately 12 to 17 h. Combined, 
our results justify use of siRNA SAINT-O-Somes  in a follow up in vivo studies in the 
future.
In the current study we focused on primary endothelial cells as they more closely 
represent endothelial cells in vivo than cell lines. Previous studies demonstrated that 
these cells are difficult to transfect [24] and show limited processing capabilities [19], 
which makes them a challenging target for our newly designed siRNA carrier. Recently, 
Whitehead et al. [36] demonstrated that in contrast to cell lines, primary cells were 
found to yield the most predictive correlations between in vitro – in vivo siRNA delivery 
efficacy of lipid nanoparticles. Taking into account the well-established heterogeneity 
of endothelial cells in vivo [37], we included primary cells from two distinct vascular 
beds in our investigation (HUVEC – venous, HAEC – arterial). Both VCAM-1 and 
E-selectin have been described as attractive targets for endothelial specific drug 
delivery [13], however use of VCAM-1 as a target for siRNA delivery to activated 
endothelial cells has not been demonstrated before. Here we compared association of 
siRNA encapsulated into E-selectin respectively VCAM-1 targeted SAINT-O-Somes 
with activated HUVEC and HAEC. We demonstrated that both anti-E-selectin and anti-
VCAM-1 SAINT-O-Somes allowed robust and specific siRNA delivery into activated 
cells and showed comparable downregulation of VE-cadherin mRNA without exerting 
any cellular toxicity, as often seen with siRNA delivery systems containing cationic 
amphiphiles [38]. Up to 60% downregulation of VE-cadherin mRNA was reached in 
both cell types which was associated by 50% decrease in protein expression in HUVEC 




and 25 % in HAEC (Fig. 4C-F). Sato et. al [6] demonstrated that 60% downregulation 
of a target gene mRNA and protein by siRNA-bearing liposomes targeted to hepatic 
stellate cells, was sufficient to almost completely resolve liver fibrosis and prolonged 
survival of cirrhotic rats. Thus, demonstrated capacity of targeted SAINT-O-Somes 
for gene silencing could be sufficient to interfere with the expression of disease-
associated genes and requires further investigation in animal models. Differences 
in the efficacy of protein downregulation between HUVEC and HAEC in our study 
could not be attributed to differences in mRNA and protein expression levels (Table 
2, supplementary data). Since HAEC and HUVEC exerted a similar extent of uptake 
of siRNA and siRNA delivered by the SAINT-O-Somes did not affect cell viability, 
possibly the ability of both cells to process SAINT-O-Somes influencing siRNA 
release is responsible for the observed differences. Moreover, the efficacy of the siRNA 
delivery can be affected by different molecular aspects that are part of the concept of 
heterogeneity of endothelial cells [39]. We demonstrated that anti-E-selectin and anti-
VCAM-1 SAINT-O-Somes can effectively deliver siRNA to primary endothelial cells 
originating from different vascular beds, which provides an opportunity for effective 
targeting of disease-associated endothelial cell subsets in different vascular segments.
Target epitopes residing at the membrane of the target cells should internalize upon 
ligand binding and allow intracellular release of the siRNA, which is a prerequisite 
for effective gene downregulation. It was previously shown that both E-selectin 
and VCAM-1 could mediate internalization of immunoliposomes conjugated with 
antibodies targeting these proteins [15, 40]. Nevertheless little is known about the 
intracellular processing of siRNA delivered via this route. Therefore we studied the fate 
of anti-VCAM-1 and anti-E-selectin SAINT-O-Somes containing siRNA after binding 
to the endothelial cell surface applying confocal microscopy. siRNA endocytosed via 
E-selectin and VCAM-1 localized in endolysosomal compartments in the perinuclear 
region within 4 h after the start of incubation of cells with SAINT-O-Somes. Our 
observations are in line with findings describing transport of VCAM-1 and E-selectin 
ligands mainly via clathrin-mediated endocytosis to lysosomes (summarized by Muro 
et al. [41]) although involvement of other pathways, such as macropinocytosis or cell 
adhesion molecule endocytosis cannot be excluded. Adrian et al. [19] reported that at 
low pH (pH<5.5) the SAINT-O-Some bilayer is destabilized, which enhances content 
release. Within the endolysosomal compartments the low pH may thus be able to 
facilitate destabilization of the particles and enhance the release of siRNA. Furthermore, 
cationic lipids such as SAINT can destabilize the endosomal membrane by inducing 
‘flipping’ of anionic lipids in the endosomal bilayer which facilitates release of the 
cargo into the cytoplasm [42]. Under physiological conditions a polyethylene-glycol 
(PEG) coating limits interaction of particles with the cell membrane by masking their 
surface charge [43]. Destabilization of SAINT-O-Some bilayer may reduce the effect 
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of PEG and allow SAINT to interact with the endosomal membrane. Moreover, we 
showed that SAINT-O-Somes and encapsulated siRNA followed the same route of 
internalization and partially dissociated after 24h, which indicates limited release of 
siRNA from the carrier. Up to now, little is known about the relation between siRNA 
disassembly from the carrier and the efficacy of gene silencing. The first tools to study 
intracellular disassembly of siRNA nanocomplexes have been developed only recently 
[44]. Poor processing of liposomes by HUVEC, as reported by Adrian et al. [19], may 
as well contribute to limited release of siRNA. Based on the intracellular trafficking 
of SAINT-O-Somes targeted to VCAM-1 and E-selectin, the inclusion of pH-sensitive 
components in the formulation (e.g. pH-sensitive PEG) might improve the efficacy of 
siRNA release [33, 45]. Further studies focusing on the exact siRNA release mechanism 
involving SAINT-O-Somes will shed more light and facilitate the rational design of 
these SAINT-based carriers.
We here report a liposomal formulation that allows selective and functional siRNA 
delivery into inflammation activated primary endothelial cells, mediates significant 
downregulation of a target gene, and is suitable for in vivo application based on their 
physicochemical and pharmacokinetic features. We demonstrated that both VCAM-1 
and E-selectin can serve as an efficient and specific entry route for siRNA delivery 
to inflamed endothelial cells. Liposomes based on cationic amphiphile SAINT-C18 
(SAINT-O-Somes) are a suitable carrier for siRNA and when harnessed with anti-
VCAM-1 or anti-E-selectin antibodies allow effective delivery of siRNA to activated 
primary endothelial cells from venous and aortic vascular beds. anti-VCAM-1 and 
anti-E-selectin SAINT-O-Somes are thus a novel drug delivery system that provide 
an opportunity for siRNA delivery to disease-associated endothelial cell subsets in 
different vascular segments.
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S1. Blood clearance of empty and siRNA loaded SAINT-O-Somes. 
C57BL/6 mice were injected with 10 μmolTL/kg  of 3H labeled SAINT-O-Somes, empty or containing siRNA. 
3H radioactivity was measured in the plasma to determine clearance kinetic. Data are presented as mean 
values ± SD of 3 mice/group. *P < 0.05 empty vs siRNA; # P < 0.05 empty vs siRNA + Ab (antibody).
Supplementary data
Figure S1 showing blood clearance of empty and siRNA loaded SAINT-O-Somes. 
Figure S2 showing association of non-targeted SAINT-O-Somes with endothelial cells. 
Figure S3 showing CLSM images of intracellular co-localization of SAINT-O-Somes 
and siRNA in activated HUVEC. Figure S4 showing expression of endothelial genes 
CD31 and Tie-2 in HUVEC and HAEC after transfection with anti-E-selectin and 
anti VCAM-1 SAINT-O-Somes containing VE-cadherin specific or control siRNA. 
Supplementary Table 1 showing basal expression of VE-cadherin, CD31 and Tie-2 in 
resting or TNF-α activated cells. This information is available free of charge via the 
Internet at http://pubs.acs.org/.
S2. Association of non-targeted SAINT-O-Somes with endothelial cells. 
Activated and non-activated HUVEC (A) and HAEC (B) were incubated with SAINT-O-Somes containing 
AlexaFluor488 siRNA for 4 h or 24 h at a concentration of 80 nmol TL/ml. The association was quantified 
by flow cytometry as described in ‘Experimental Section’. Data are presented as MFI (mean florescence 
intensity) values ± SD of three independent experiments.




S3. SAINT-O-Somes and siRNA co-localize intracellularly in activated HUVEC. 
Cells were activated with TNF-α for 2 h, and subsequently incubated  for 4 or 24 h with an anti-E-selectin 
SAINT-O-Somes labeled with DiD (red) and containing AlexaFluor488 labeled siRNA (green). Cells 
were visualized live using CLSM. Presented data sets show representative single z-plane images of three 
independent experiments.
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S4. Transfection of HUVEC and HAEC with siRNA specific VE-cadherin does not alter expression of 
unrelated endothelial genes (CD31 and Tie-2). 
TNF-α activated HUVEC (A, C) and HAEC (B, D) incubated with targeted SAINT-O-Somes containing VE-
cadherin or control siRNA at 1 µM concentration for 48 h. After incubation, RNA was isolated from the 
cells for RT-qPCR as described in ‘Experimental Section’. The real-time PCR primers for human CD31 
(Hs00169777_m1) and Tie-2 (Hs00176096_m1) were purchased as Assay-on-Demand from Applied 
Biosystems. Data are presented as mean relative expression ± SD, compared to cells treated only with TNF-α, 
of a minimum of three independent experiments. * P < 0.05.
 VE-cadherin  CD31 Tie-2 
 - TNF-α + TNF-α - TNF-α + TNF-α - TNF-α + TNF-α 
HUVEC 0.37 ± 0.02 0.39 ± 0.01 0.23 ± 0.02 0.17 ± 0.04* 0.011 ± 0.005 0.017 ± 0.005 
HAEC 0.11 ± 0.01 0.12 ± 0.03 0.07 ± 0.02 0.05 ± 0.02 0.010 ± 0.003 0.019 ± 0.006* 
 Basal gene expression levels relative to GAPDH  
 
HUVEC and HAEC were incubated with or without TNF-α for 48 h. After incubation, RNA was isolated from 
the cells for RT-qPCR as described in ‘Experimental Section’. Compared to CD31 and Tie-2, VE-cadherin 
is abundantly expressed in HUVEC and HAEC, and its expression was not affected by TNF-α stimulation. 
mRNA levels are presented as relative to GAPDH ± SD of a minimum of three independent experiments. 
* P < 0.05,  – TNF-α vs. + TNF-α.
Table 1. Basal expression of VE-cadherin, CD31 and Tie-2 in resting or TNF-α activated cells.
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Abstract
The pivotal role of endothelial cells in the pathology of inflammatory diseases 
raised interest in the development of short interfering RNA (siRNA) delivery devices 
for selective pharmacological intervention in the inflamed endothelium. The current 
study demonstrates endothelial specific delivery of siRNAs and downregulation of 
inflammatory genes in activated endothelium in vivo, applying a novel type of targeted 
liposomes based on the cationic amphiphile SAINT-C18 (1-methyl-4-(cis-9-dioleyl)
methyl-pyridinium-chloride). To create specificity for inflamed endothelial cells, 
these so-called SAINT-O-Somes were harnessed with antibodies against vascular cell 
adhesion protein 1 (VCAM-1). In TNFα challenged mice, intravenously administered 
anti-VCAM-1 SAINT-O-Somes exerted long circulation times and homed to VCAM-1 
expressing endothelial cells in inflamed organs. The formulations were devoid of liver 
and kidney toxicity. Using anti-VCAM-1 SAINT-O-Somes we successfully delivered 
siRNA to knock down VE-cadherin mRNA in inflamed renal microvasculature, as 
demonstrated by using laser microdissection of different microvascular beds prior to 
analysis of gene expression. Using the same strategy, we demonstrated local attenuation 
of endothelial inflammatory response towards lipopolysaccharide in kidneys of mice 
treated with anti-VCAM-1 SAINT-O-Somes containing NFκB p65 specific siRNA. 
This study is a first demonstration of a novel, endothelial specific carrier that is suitable 
for selective in vivo delivery of siRNAs into inflamed microvascular segments and 
interference with disease associated endothelial activation.





The interest to therapeutically target inflammatory processes is stirred by widespread 
devastating chronic diseases, including atherosclerosis, type 2 diabetes, and sepsis, that 
share a pathophysiologically important inflammatory component [1, 2]. Endothelium 
is an attractive target for anti-inflammatory therapy by virtue of its active engagement 
in the inflammatory process and its role in the pathophysiology of these (chronic) 
inflammatory diseases [3]. Activated endothelial cells at the site of inflammation play a 
central role in the recruitment of leukocytes from the blood primarily via the production 
of cytokines, chemokines and adhesion molecules [4]. Expression of these molecules 
is often triggered by pro-inflammatory cytokines such as tumor necrosis factor (TNF)α, 
interleukin (IL)-1b or bacterial endotoxins like lipopolysaccharide (LPS). This occurs 
mainly via activation of nuclear factor (NF)κB and p38 mitogen-activated protein 
kinase (MAPK) signaling cascades, as shown for various inflammatory diseases [5-7].
Various pharmacological approaches to counteract (endothelial) cell activation are 
already applied in the clinic, tested in clinical trials, or are in preclinical development. 
These include corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and 
inhibitors of NFκB and p38 MAPK signaling (reviewed by Kuldo et al. [8]). Although 
existing therapies improve disease status, they often evoke adverse effects due to 
the lack of cellular and molecular specificity and carry a substantial risk of systemic 
toxicity [9]. New molecular drugs such as small interfering RNAs (siRNAs) offer high 
molecular specificity and potent gene silencing of disease associated genes [10]. The 
physicochemical properties of siRNAs demand their formulation into a delivery system 
that allows modification of the pharmacokinetic profile of the siRNA, reduces off-
target toxicity, and improves the therapeutic index, thereby creating potent therapeutics 
[11, 12]. siRNA nano-carriers targeted to subsets of inflammatory leukocytes and 
monocytes have already shown their anti-inflammatory potential of gene silencing 
and their ability to attenuate disease progression in mouse models of intestinal 
inflammation [13], atherosclerosis, and myocardial infarction [14]. Development of 
siRNA based drug delivery approaches to inhibit endothelial activation in inflammation 
may create an additional translational avenue to therapeutically address inflammatory 
diseases and offer improvement over existing therapies. Attractive molecular targets for 
selective gene silencing in the endothelial cells are the members of the NFκB and p38 
MAPK family [6, 15] or enzymes generating reactive oxygen species (e.g. NADPH 
oxidase) [16], based on their inherent association with inflammatory activation of the 
endothelium.
Upon inflammatory stimulation, each organ displays a vascular bed specific pattern 
of cell adhesion molecules expression including E-selectin and vascular cell adhesion 
protein 1 (VCAM-1) [4], providing a challenging gateway to deliver small RNAs to 
Thesis Piotr Kowalski 2014.indb   90 04-04-14   07:48
91
Endothelial-specific delivery of siRNA in vivo
5
organ-specific (micro)vascular endothelial subsets [17]. To this end, we developed 
a new generation of liposomes called SAINT-O-Somes by combining cationic 
SAINT-C18 (1-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chloride) amphiphile with 
conventional liposome technology, that showed superior intracellular release of their 
content in endothelial cells compared to conventional liposomes [18]. We furthermore 
recently demonstrated that SAINT-O-Somes targeted to VCAM-1 and E-selectin can 
selectively and functionally deliver siRNA into inflammation activated endothelial cells 
in vitro, and are suitable for in vivo application based on their physicochemical and 
pharmacokinetic features [19]. E-selectin has been previously applied as a molecular 
target to direct liposomes and viruses to glomerular endothelium in mouse kidney 
inflammatory disease [20, 21], but the data regarding the use of VCAM-1 as a target on 
inflamed endothelium in vivo are scarce [22].
In the current study we aimed to show that anti-VCAM-1 (Ab
VCAM-1
) targeted 
SAINT-O-Somes carrying siRNA enable cell specific gene downregulation in inflamed 
endothelium in vivo. We studied the pharmacokinetic (PK) behavior, biodistribution, 
and in vivo toxicity of Ab
VCAM-1 
SAINT-O-Somes in TNFα challenged mice. Focusing 
on kidneys as our organ of interest, we investigated the potential of Ab
VCAM-1 
SAINT-O-
Somes to deliver VE-cadherin and NFκB p65 (RelA) specific siRNAs to the inflamed 
renal vasculature of those mice. Using SAINT-O-Somes containing RelA specific 
siRNA we demonstrated both in vitro and in vivo proof-of-concept of attenuation 
of an endothelial inflammatory response towards LPS by knocking down the signal 
transduction pathway, which is pivotal in endothelial cell activation. In addition, we 
provide new insights into the use of VCAM-1 as a target for drug delivery to inflamed 
endothelium in vivo. Taking all data together, we demonstrate here that Ab
VCAM-1 
SAINT-
O-Somes can be used for selective delivery of siRNA into inflamed microvascular 




Lipids, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-distearo-
yl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]-ma-
leimide (DSPE-PEG2000-Mal), and 2-distearoyl-sn-glycero-3-phosphoethanolamine-N 
[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Avanti 
Polar Lipids (Alabaster AL, USA). The cationic lipid 1-methyl-4-(cis-9-dioleyl)methyl-
pyridinium-chloride (SAINT-C18) was obtained from Synvolux Therapeutics (Gron-
ingen, The Netherlands). Cholesterol (Chol) and N-succinimidyl-S-acetylthioacetate 
(SATA) were obtained from Sigma (St. Louis, MO, USA). Radioactive tracer [3H]Cho-




lesteryl Hexadecyl Ether [Cholesteryl-1,2-3H(N)] was purchased from PerkinElmer 
(Shelton, CT, USA). Nucleic acid stain DAPI was obtained from Roche Diagnostics 
(Manheim, Germany). LipofectamineTM 2000 transfection reagent was purchased from 
Invitrogen (Breda, The Netherlands). All siRNAs were purchased from Qiagen (Venlo, 
The Netherlands).
The M/K-2.7 (rat IgG1a anti-mouse VCAM-1) producing hybridoma was obtained 
from American Type Culture Collection (ATCC, Manassas, VA, USA). Rat IgG antibody 
(irrelevant IgG) was purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Preparation of siRNA containing SAINT-O-Somes
SAINT-O-Somes were prepared as described previously with slight modifications 
[19]. In brief, lipids from stock solutions of POPC, SAINT-C18, Chol, DSPE-
PEG2000 and DSPE-PEG2000-Mal in chloroform:methanol (9:1) were mixed in a molar 
ratio of 37:18:40:4:1. Radioactively labeled SAINT-O-Somes were prepared by 
adding a trace amount (2.5 mCi/mmol of total lipid) of [3H]Cholesteryl Hexadecyl 
Ether ([3H]CHE) to the formulation. SAINT-O-Somes were prepared containing 
siRNA specific for VE-cadherin (Mm_Cdh5_2 FlexiTube siRNA, target sequence 
5’-AAGGATCAAGTCCAATCTAAA-3’), RelA (Hs_RELA_7 FlexiTube siRNA, 
5’-CCGGATTGAGGAGAAACGTAA-3’; Mm_Rela_3 FlexiTube siRNA, 
5’-CACCATCAAGATCAATGGCTA-3’) or control siRNA (AllStars Negative Control, 
cat No. 1027281), with no homology to any known mammalian gene. VE-cadherin 
respectively RelA specific siRNAs used for the experiments were selected from a 
pool of four pre-designed siRNAs based on the specificity and efficacy of target gene 
downregulation. siRNA was dissolved according to the protocol of the manufacturer 
and mixed with dried lipids at a ratio of 1 nmol siRNA per 1 μmol total lipid (TL). 
After extrusion through polycarbonate filters (50 nm pore size) nonencapsulated siRNA 
was removed by ion exchange chromatography on a DEAE Sepharose CL-6B column 
(Sigma, The Netherlands) using HN buffer (135 mM NaCl, 10 mM HEPES) pH 6.7 as 
an eluent. The concentration of siRNA encapsulated in liposomes was measured using 
the Quant-iT™ Ribo-Green® assay (Invitrogen, Breda, The Netherlands) according to 
the protocol of the manufacturer. The efficiency of siRNA encapsulation into liposomes 
was calculated based on the measurements of encapsulated siRNA in the presence or 
absence of 1% (v/v) Triton X-100 (Sigma-Aldrich, Zwijndrecht, The Netherlands). 
The anti-VCAM-1 and irrelevant IgG antibodies were thiolated by means of SATA 
and coupled to a maleimide group at the distal end of the polyethylene glycol chain 
by sulfhydryl-maleimide coupling as described before for albumin [23]. SAINT-O-
Somes without an antibody were prepared from the same lipid mixture, but instead 
of being conjugated to the antibody, they were allowed to react with cysteine in a 
molar ratio twice that of DSPE-PEG2000-Mal to block reactive maleimide groups. The 
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SAINT-O-Somes were characterized by determining the protein concentration using 
rat IgG as a standard and measuring the total lipid concentration by phosphorus assay 
[24]. Particle size and Zeta-potential were analyzed using a Nicomp model 380 ZLS 
submicron particle analyzer. Particle size was measured using dynamic light scattering 
(DLS) in the volume weighing mode (NICOMP particle sizing systems, Santa Barbara, 
CA, USA). The Polydispersity index (PDI) was analyzed using a Malvern Zetasizer 
Nano ZSP (Malvern Instruments ltd., Worcestershire, UK). The number of antibody 
molecules coupled per liposome was calculated as described before [25]. SAINT-O-
Somes were stored at 4 °C under argon gas and were used within 4 weeks.
Cell cultures
Human umbilical vein endothelial cells (HUVEC) were obtained from Lonza 
(Breda, The Netherlands). Cells were cultured in EBM-2 medium supplemented 
with EGM-2 MV SingleQuot Kit Supplements & Growth Factors (cat No. CC-
3202, Lonza). In all experiments, cells from passage 5 to 7 were used. Cells were 
plated on culture plates (Costar, Corning, NY) at a density of 1.8 x 104 cells/
cm2 one day before the experiment unless stated differently. Before seeding 
the cells, culture plates were incubated with EGM2 MV medium for 30 min. 
Cell cultures were maintained by the Endothelial Cell Facility of UMCG.
Animals
Male C57bl/6OlaHsd mice (18-23 g) were purchased from Harlan (Zeist, The 
Netherlands) and randomly divided into experimental groups. Animals were group 
housed and maintained on a mouse chow diet, in a temperature and light-dark cycle 
controlled environment (24 °C, 12:12 h). All intravenous (i.v.) injections were performed 
in the orbital plexus under anesthesia (inhalation of isoflurane/O2). To induce acute 
systemic inflammation mice received i.v. 0.2 mg recombinant mouse TNFα (rmTNFα; 
Gibco, Camarilo, CA, USA) in sterile 0.9% NaCl. For induction of endotoxemia, mice 
were intraperitoneally (i.p) injected with LPS (Escherichia coli, serotype 0.26:B6l; 
Sigma, St. Louis, MO, USA) in 0.9% NaCl at 1.5 mg/kg (450 EU/g). At the end of 
the experiment mice were sacrificed under anesthesia, blood was collected via heart 
puncture and organs were immediately snap frozen in liquid nitrogen or embedded in 
paraffin. Frozen organs were stored at -80 oC until analysis. All animal experiments 
were performed according to national guidelines and upon approval of the local Animal 
Care and Use Committee of Groningen University (DEC 6150B).
Pharmacokinetics and biodistribution of SAINT-O-Somes
2 h prior to injection of liposomes, mice were challenged with rmTNFα. Subsequently, 
animals received i.v. a single dose (10 mmol TL/kg, 3 mice/group) of [3H]CHE-labeled 




SAINT-O-Somes containing control siRNA (~ 0.12 mg siRNA/kg), conjugated with 
either anti-VCAM-1 or irrelevant IgG antibody (Ab
VCAM-1
 or IgG siRNA SAINT-O-
Somes). Blood was sampled at 10 min, 30 min, 1 h, 6 h, and 24 h. At 24 h mice were 
sacrificed and liver, spleen, kidney, lungs, heart and brain were removed and processed 
for measurement of radioactivity as described previously [23]. 3H radioactivity was 
measured using a Packard Tri-Carb 2500 TR liquid scintillation analyzer (PerkinElmer 
Life And Analytical Sciences, Waltham, MA). The total amount of radioactivity in 
the serum was calculated as described previously [20]. Pharmacokinetic parameters 
were calculated according to population analysis and the Interactive Two-Stage 
Bayesian approach [26] using the Multifit program (Dr J.H. Proost, Department of 
Pharmacokinetics and Drug Delivery, University Center for Pharmacy, University of 
Groningen).
Immunohistochemical and immunofluorescent detection of VCAM-1 protein and 
localization of AbVCAM-1 siRNA SAINT-O-Somes in mouse tissues
Tissue cryo-sections (5 mm) were fixed in acetone for 10 min, non-specific binding 
was blocked by 1 h incubation with PBS containing 1% BSA (Bovine Serum Albumin; 
Sigma-Aldrich, Zwijndrecht, The Netherlands) and 2% FCS (Fetal Calf Serum; Thermo 
Scientific HyClone, Cramlington, UK). For detection of VCAM-1 protein tissues were 
incubated for 60 min with rat anti-mouse VCAM-1 antibody (10 mg/ml) diluted in 
PBS/1% BSA supplemented with 2% FCS. Endogenous peroxidase activity was blocked 
using the EnVision kit (EnVision + System-HRP (AEC), DAKO, Carpinteria, CA, 
USA). Subsequently, sections were incubated for 30 min with rabbit anti-rat antibody 
(Vector Laboratories, Burlingame, CA, USA) at 10 mg/ml in PBS supplemented with 
5% normal mouse serum (NMS; DAKO). Detection was performed with anti-rabbit 
labeled polymer-HRP antibody from the EnVision kit. Peroxidase activity was detected 
with 3-amino-9-ethylcarbazole (AEC; DAKO) and sections were counterstained with 
Mayer’s hematoxylin (Merck, Darmstadt, Germany). Isotype-matched controls were 
consistently found to be devoid of staining. Immunohistochemical detection of Ab
VCAM-1
 
and IgG siRNA SAINT-O-Somes after i.v. administration was performed on the cryo-
sections with rabbit anti-rat antibody (Vector) in PBS/5% NMS and using EnVision kit 
to detect peroxidase activity as described above.
Immunofluorescence double staining for immunoliposomes and CD31 was 
performed as previously described [20]. Endogenous biotin was blocked by a Biotin 
Blocking System (Dako, Glostrup, Denmark). Ab
VCAM-1
 and IgG siRNA liposomes were 
detected with AlexaFluor
546
-conjugated goat anti-rat antibodies (1 h incubation, 20 µg/
ml PBS; Molecular Probes, Leiden, The Netherlands). CD31 was detected with biotin-
labeled rat anti-mouse CD31 (clone 390, 5 µg/ml PBS; eBioscience, San Diego, CA), 
followed by AlexaFluor
488
-conjugated streptavidin (50 µg/ml PBS Molecular Probes). 
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All incubation steps were carried out in the presence of 5% NMS. Sections were mounted 
with Citi-Fluor AF1 (Citifluor Ltd, London, UK) and examined using a confocal laser 
scanning microscope (CLSM) equipped with a true confocal scanner (TCS SP2-AOBS; 
Leica, Heidelberg, Germany) coupled to a LeicaDM RXE microscope with an HCXPL 
APO CS 63 x 1.40 oil immersion objective. Sequential scans were obtained to avoid 
bleed through. AlexaFluor
488 
was excited using the 488 nm Ar laser line, AlexaFluor
546 
was excited using the 543 nm HeNe laser line. All images were recorded in the linear 
range, avoiding local saturation, at an image resolution of 1024x1024 pixels and with 
pinhole size of 1 Airy unit. A series of xyz-scans with a 0.3 µm step size were taken 
along the z-axis from top to bottom of the tissue. Presented images show a single z-scan 
from a single series. Images were analyzed and processed using ImageJ V1.45s.
Investigation of NFκB p65 (RelA) downregulation in vitro
For downregulation of RelA using targeted siRNA SAINT-O-Somes, HUVEC 
were activated with 10 ng/ml TNFα (Boehringer, Ingelheim, Germany) for 6 h prior 
to addition of liposomes. Ab
VCAM-1
 SAINT-O-Somes containing RelA specific siRNA 
or control siRNA were added to the cells at 1 or 1.5 µM siRNA concentration, and 
incubated for 24 h. TNFα was present in the medium during the entire incubation 
period. Subsequently, cells were washed and cultured for an additional 24 h in the 
absence of TNFα. At the 48 h time point cells were re-challenged with LPS (1 mg/ml) 
for 4 h. Subsequently cells were washed twice with PBS and total RNA was isolated 
for gene expression analysis.
For protein analysis, HUVEC were seeded in 6-well plates, challenged with TNFα 
and  incubated with Ab
VCAM-1
 siRNA SAINT-O-Somes as described above. After 48 h 
of incubation cells were lysed using RIPA buffer (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and lysates were used for Western blot performed as described previously 
[27], with slight modifications. The membrane was horizontally cut through the 50 kDa 
pre-stained marker and the upper part of the blot was incubated overnight at 4 °C with 
rabbit anti-RelA antibody (Cell Signaling Technology). For loading control the lower 
part of the blot was incubated overnight at 4 °C with rabbit anti-GAPDH antibody (cat 
No. sc-25778, Santa Cruz Biotechnology, Dallas, TX, USA). Antibody binding was 
visualized by horseradish peroxidase-conjugated anti-rabbit IgG (cat No. #7074, Cell 
Signaling Technology, Inc, Leiden, The Netherlands). Chemiluminescence (Thermo 
Scientific, Rockford, IL, USA) signals were quantified by densitometric analysis using 
Quantity One software (Bio-Rad, Hercules, CA, USA). A representative Western Blot 
of two independent experiments is presented.
For immunofluorescent staining of RelA, HUVEC were cultured on sterile cover 
glasses (Menzel-Gläser, Braunschweig, Germany) placed into the wells of a 12-well 
plate. Cells were challenged with TNFα and incubated with Ab
VCAM-1
 siRNA SAINT-O-




Somes as described above. After 48 h, cell were challenged LPS for 25 min and fixed 
with 1 % formaldehyde in PBS for 20 min. Subsequently, cells were permeabilized by 
5 min incubation with 0.25% TritonX-100 in PBS, then blocked with PBS/3% BSA for 
30 min at RT and later incubated with rabbit anti-RelA antibody (cat No. #8242, Cell 
Signaling Technology) diluted 1:50 in PBS/0.5 % BSA/0.05% Tween 20 (Sigma, St. 
Louis, MO, USA). Next, coverslips were washed with PBS and incubated for 1 h with 
20 µg/ml of AlexaFluor
488
-conjugated goat anti-rabbit antibody (Molecular Probes, 
Eugene, Oregon, USA). At the end of the incubation, coverslips were washed with PBS 
and mounted using Aqua Poly/Mount medium (Polysciences, Warrington, PA, USA) 
containing DAPI, air dried for 24 h, and stored in the dark at 4 oC. Fluorescence images 
were taken with a Leica DM/RXA fluorescence microscope (Wetzlar, Germany) using 
Quantimet HR600 image analysis software (Leica). Images were taken at excitation/
emission wavelengths 490/520 nm for AlexaFluor
488
, and 350/460 nm for DAPI.
In vivo gene downregulation using anti-VCAM-1 siRNA SAINT-O-Somes
2 h prior to administration of SAINT-O-Somes mice were challenged with rmTNFα 
(treatment group; 3 mice/group), while untreated animals (n=3) received 0.9% NaCl. 
Subsequently, treatment groups received a single i.v. dose (50 mmol TL/kg) of Ab
VCAM-1
 
SAINT-O-Somes containing either VE-cadherin specific siRNA (VE-cadherin group) 
or RelA specific siRNA (RelA group) at a dose of 0.6 mg siRNA/kg. Control mice were 
i.v. injected either with an equivalent dose of Ab
VCAM-1
 SAINT-O-Somes containing 
control siRNA or with sterile HN buffer pH 7.4 (vehicle). 48 h after injection of the 
liposomes, the VE-cadherin group and corresponding control groups were sacrificed, 
while the RelA group and corresponding control groups received an i.p. LPS challenge 
and were sacrificed 4 h later. Blood and organs were collected for further analysis.
Examination of liver and kidney toxicity
Toxicity parameters were measured in EDTA-treated plasma obtained from 
peripheral blood of rmTNFα challenged mice treated with targeted siRNA SAINT-
O-Somes (50 mmol TL/kg, 0.6 mg siRNA/kg) and control mice. Liver toxicity was 
analyzed by determining levels of liver enzymes ALAT (alanine aminotransferase) 
and ALP (alkaline phosphatase), kidney toxicity by urea and creatinine measurements. 
All tests were performed with assays from Roche Diagnostics (Mannheim, Germany), 
and were measured using a Hitachi automatic analyzer (Modular Analytics, Roche 
diagnostics, Mannheim, Germany).
Laser dissection microscopy of renal microvascular segments
9 mm cryo-sections were mounted on 1.35 mm polyethylene-naphthalene membranes 
attached to normal 1-mm slides (P.A.L.M. Microlaser Technologies GmbH, Bernried, 
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Germany). Sections were fixed in a cold acetone, air-dried and stained with Mayer’s 
hematoxylin. Stained sections were briefly washed with diethyl pyrocarbonate-
treated tapwater, air-dried and stored at 4°C. Endothelial cells from arterioles (area 
5 x 105 mm2), postcapillary venules (area 1 x 106 mm2), and glomeruli (area 1 x 106 
mm2) were dissected using the Leica LMD6500 Laser Microdissection System 
(Leica Microsystems, Wetzlar, Germany). Microdissected material was collected 
directly in AdhesiveCap 0.5 ml tubes (Carl Zeiss, Göttingen, Germany) and stored at 
-80 oC prior to RNA isolation. 
Gene expression analysis by RT-qPCR
Total RNA from in vitro experiments was isolated using the RNeasy® Mini Plus Kit 
(Qiagen, Venlo, The Netherlands) and total RNA from laser microdissected material 
was isolated using RNeasy® Micro Plus Kit (Qiagen) according to manufacturer’s 
protocols. The integrity of RNA isolated from whole tissue, LMD samples and cell 
culture material was analyzed by qualitative gel electrophoresis and was consistently 
found intact. cDNA synthesis and real-time PCR, including data analysis, were 
performed as described previously [18]. The real-time PCR primers (supplementary 
Table 1) were purchased as Assay-on-Demand from Applied Biosystems (Nieuwekerk 
a/d IJssel, The Netherlands). Gene expression levels were normalized to the expression 
of the reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which 
was not influenced by the experimental conditions. Enrichment of the endothelial 
marker gene CD31 in the laser microdissected material as compared to the whole tissue 
was found to be consistent for each vascular compartment (enrichment in arterioles ~ 
65 fold, glomeruli ~ 11 fold, venules ~ 3 fold).
Analysis of leukocyte attraction to kidney venules





SAINT-O-Somes were administered as described above (paragraph 2.8) were used for 
immunohistochemical detection of CD45 positive cells. 5 µm paraffin sections were 
de-paraffinized and microwaved (300 W) for 15 min in citrate buffer (10 mM, pH 6) 
for antigen retrieval. Subsequently, endogenous peroxidase activity was blocked using 
the EnVision kit (DAKO) and sections were incubated for 1 h with 3.5 µg/ml of rat 
anti-mouse CD45 antibody in PBS/1% BSA (cat No. #550539, BD Pharmingen, San 
Diego, CA, USA). Next sections were incubated with rabbit anti-rat antibody (Vector) 
in PBS/5% NMS for 30 min. Peroxidase activity was detected using the EnVision kit 
as described above. Sections were counterstained with Mayer’s hematoxylin and slides 
were scanned using NanoZoomer (Hamamatsu Photonics, Higashi-ku, Hamamatsu, 
Japan) with 40x magnification. Isotype-matched controls were consistently found to 
be devoid of staining. Leukocyte attraction to the postcapillary venules was scored by 




3 independent researchers. CD45+ cells that were in direct contact with the endothelial 
cells at the luminal or basal site of postcapillary venules were counted in 10 randomly 
selected kidney venules, for all mice, and values were arranged per group.
Statistical analysis
Statistical analysis of the results was performed by a two-tailed unpaired Student’s 
t-test, assuming equal variances to compare two replicate means, or One-Way ANOVA 
followed by Bonferroni post-hoc analysis to compare multiple replicate means. 
Differences were considered significant when p < 0.05.
Results
Characterization of TNFα induced VCAM-1 expression in vivo.
TNFα is a well characterized cytokine and a potent inducer of the inflammatory 
response in the vasculature. We therefore used mice systemically challenged with 
TNFα as a model to study VCAM-1 mediated siRNA delivery to inflammation activated 
endothelial cells in vivo. I.v. injection of TNFα resulted in induction of VCAM-1 
mRNA in main organs (kidneys ~ 27 fold, brain ~ 6 fold, heart ~ 32 fold, liver ~ 
20 fold, lungs ~ 39 fold) [28] and consequent elevated protein expression at 2 h post 
challenge, as compared to untreated mice. 2 h after administration of TNFα, VCAM-1 
was abundantly expressed in arterioles and venules of all organs. Furthermore, liver 
sinusoidal endothelium and kidney peritubular capillary endothelium as well as some 
scattered capillaries in the brain expressed VCAM-1 protein (Fig. 1).
Figure 1. Adhesion molecule expression in vivo 2 h after systemic administration of TNFα 
VCAM-1 protein expression (red staining) in mouse organs 2 h after i.v. injection of mTNFα and in untreated 
controls, assessed by immunohistochemistry as described in ‘Materials and Methods’.
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Pharmacokinetic properties and tissue distribution of AbVCAM-1 siRNA SAINT-O-Somes 
in TNFα challenged mice.
The physicochemical properties of targeted siRNA SAINT-O-Somes that were 
administered to mice are presented in Table 1. Ab
VCAM-1
 and IgG SAINT-O-Somes 
containing control siRNA were i.v. injected into mice 2 h after administration of TNFα. 
SAINT-O-Somes plasma concentration curves showed two-phase disappearance 
kinetics (Fig. 2A) with a short initial half-life (8 min for IgG and 10 min for Ab
VCAM-1
) 
and a long secondary half-life (11 h for IgG and 25 h for Ab
VCAM-1
) (Table 2). Plasma 
clearance and steady state volume of distribution for AbVCAM-1 siRNA SAINT-O-Somes 
were approximately 1.5 fold higher than those of IgG siRNA SAINT-O-Somes.
At 24 h, the whole body distribution of Ab
VCAM-1
 siRNA SAINT-O-Somes showed 
increased accumulation in tissues of TNFα challenged mice as reflected by the targeting 
ratio (% of injected dose/gram tissue of Ab
VCAM-1
 divided by % of injected dose/gram 
tissue of IgG siRNA SAINT-O-Somes) (Fig. 2B). Accumulation of Ab
VCAM-1
 siRNA 
SAINT-O-Somes in TNFα activated kidneys, heart and lungs was more than 3 times 
higher than that of IgG siRNA SAINT-O-Somes, while in the brain this accumulation 
was 7.3 times higher. The accumulation of both preparations in the liver was comparable, 
whereas in the spleen Ab
VCAM-1
 siRNA SAINT-O-Somes accumulated to a somewhat 
higher extent than IgG siRNA SAINT-O-Somes. The total recovery of the radioactivity 
from the collected tissues ranged from 75-80% for both preparations (data not shown).
Localization of AbVCAM-1 siRNA SAINT-O-Somes in the tissues of TNFα challenged 
mice follows VCAM-1 expression.
Immunohistochemical staining was performed to determine the intra-organ 
localization of the Ab
VCAM-1
 and IgG siRNA SAINT-O-Somes in the tissues of TNFα 
challenged mice, 6 h after i.v. injection of liposomes (Fig. 3A). Homing of Ab
VCAM-1
 
siRNA SAINT-O-Somes followed the heterogenic VCAM-1 expression in the kidneys, 
Table 1. Characterization of antibody conjugated SAINT-O-Somes containing siRNA.
Data are presented as means of 3-6 preparations ± SD.
Formulation	  
POPC	  :	  SAINT	  :	  Chol	  	  :	  DSPE-­‐PEG	  :	  DSPE-­‐PEG-­‐Mal	  














AbVCAM-­‐1	   116	  ±	  49	   0.16	  ±	  0.02	   3.8	  ±	  5	   26	  ±	  8	   74	  ±	  14	  
IgG	   118	  ±	  48	   0.16	  ±	  0.03	   2.1	  ±	  7	   22	  ±	  10	   74	  ±	  16	  
	  




Figure 2. Tissue distribution and pharmacokinetic properties of targeted siRNA SAINT-O-Somes in TNFα 
challenged mice. C57BL/6 mice were i.v. challenged with 0.2 µg rmTNFα 2 h later 10 µmol TL/kg of [3H]
cholesteryl hexadecyl ether-labeled siRNA SAINT-O-Somes conjugated with anti-VCAM-1 (AbVCAM-1) or 
irrelevant IgG antibodies (IgG) were administered i.v.. (A) Disappearance from blood in time. (B) Tissue 
distribution 24 h after administration of targeted siRNA SAINT-O-Somes. Fold-increase in accumulation of 
AbVCAM-1 versus IgG siRNA SAINT-O-Somes is represented by the targeting ratio. Data are presented as mean 
values ± SD of 3 mice/group. * p < 0.05.




AbVCAM-1 IgGCL, ml/h 3.41 ± 0.11 2.89 ± 0.25*Vss, ml/g    58.6 ± 3.6    35.8 ± 2.1*
t1/2 (1), h 0.13 ± 0.01 0.17 ± 0.03*
t1/2 (2), h    25.7 ± 4.5    11.5 ± 0.4*
Data are presented as mean values ± SD of 3 mice/group. CL, 
plasma clearance; Vss, steady-state volume of distribution; 
t1/2 (1), initial half-life; t1/2 (2), secondary half-life. * p < 0.05 
AbVCAM-1 vs IgG.
heart and lungs (Fig. 3B), whereas IgG siRNA SAINT-O-Somes mainly accumulated 
in the glomerular compartment of the kidneys and were not detected in lungs and heart. 
Both Ab
VCAM-1
 and IgG SAINT-O-Somes furthermore accumulated in liver and spleen 
(Fig. 3B). In these latter organs Ab
VCAM-1 
siRNA SAINT-O-Somes localized mainly in 
the vascular compartments, in venules and sinusoidal endothelium in the liver, and 
in the red pulp of the spleen. In contrast, IgG siRNA SAINT-O-Somes were mostly 
found in the Kupffer cells and in the white pulp, respectively (Fig. 3B). In addition, 
with CLSM we could show that Ab
VCAM-1 
siRNA SAINT-O-Somes co-localized with 
endothelial cells (stained for endothelial marker CD31) in the venules and arterioles 
of TNFα challenged mouse kidneys (Fig. 3C). No co-localization with those vascular 
compartments was observed for IgG siRNA SAINT-O-Somes.
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Figure 3. Homing of Ab
VCAM-1 
siRNA SAINT-O-Somes follows heterogenic VCAM-1 expression in the 
different organs. (A) Schematic representation of the experimental setup. (B) Immunohistochemical detection 
of VCAM-1 protein expression and AbVCAM-1 and IgG siRNA SAINT-O-Somes localization (red staining) in 
tissues of TNFα challenged mice, 6 h after i.v. injection of SAINT-O-Somes. Original magnification 200x, 
scale bar represents 50 µm. (C) Confocal microscopy images of double immunofluorescent staining for 
endothelial marker CD31 (green) and AbVCAM-1 siRNA SAINT-O-Somes (red) in kidney of TNFα challenged 
mice. White arrowheads point at venules and arrows at arterioles. Presented data sets show representative 
images of 2 mice/group.




AbVCAM-1 siRNA SAINT-O-Somes are not toxic and enable effective siRNA delivery to 
specific vascular segments in mouse kidneys.
No significant changes in the plasma levels of ureum, creatinine, ALAT and ALP 
(kidney and liver toxicity parameters) or in the weight of the animals (data not shown) 
were detected after a single dose (50 µmol TL/kg, 0.6 mg/kg siRNA) of Ab
VCAM-1
 
siRNA SAINT-O-Somes, as compared to TNFα challenged mice (Table 3). Although 
a significant decrease in the ALP levels was found in the group treated with control 
siRNA, the levels of all the parameters presented in Table 3, including ALP, were not 
significantly different from untreated healthy mice.
In a previous study we used VE-cadherin as a model gene for studying the effects 
of the targeted SAINT-O-Somes in endothelial cells in vitro, since its expression is 
restricted to endothelial cells and maintained under TNFα stimulation [19]. In the 




 SAINT-O-Somes we also chose the VE-
cadherin as a target gene in mouse microvessels and validated endothelial specific 
gene downregulation in vivo. TNFα challenged mice were i.v. injected with a single 
dose of Ab
VCAM-1
 SAINT-O-Somes containing VE-cadherin specific or control siRNA 
(0.6 mg/kg) and were sacrificed after 48 h. Downregulation of VE-cadherin in the 
vascular compartments, as demonstrated using laser microdissection, corroborated the 
accumulation of Ab
VCAM-1
 siRNA SAINT-O-Somes in these compartments (Fig. 4A). 
The VE-cadherin siRNA treated group showed 40% downregulation of VE-cadherin 
mRNA in postcapillary venules and 30% downregulation in arterioles, as compared 
to the group that received control siRNA (Fig. 4B-D). No difference in VE-cadherin 
expression was detected in the glomerular compartment, which corroborated the minor 
accumulation of SAINT-O-Somes in that compartment.
Parameter - TNFα +TNFα
AbVCAM-1 SAINT-O-Somes
VE-cadherin Control siRNAUreum (mmol/l)     7.7 ± 0.7    7.3 ± 0.1   8.3 ± 1.7   8.5 ± 1.1Creatinine (µmol/l)       9 ± 2.5       7 ± 1      7.9 ± 1          6 ± 1ALAT (U/l)     23.1 ± 5    30.3 ± 2.9    24.3 ± 5.7    20.7 ± 3.8ALP (U/l)       70 ± 11.4       80 ± 5.7       70 ± 4.7       61 ± 7.8*
Table 3. Kidney and liver toxicity parameters measured in plasma after treatment with Ab
VCAM-1
 
SAINT-O-Somes (50 µmol TL/kg) containing (0.6 mg/kg) VE-cadherin specific or control siRNA.
Data are presented as mean values ± SD of 3 mice/group. ALAT, alanine aminotransferase; ALP, alkaline 
phosphatase. * p < 0.05 vs TNFα
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Downregulation of RelA gene expression by siRNA attenuates endothelial 
inflammatory response to TNFα and LPS in vitro.
To demonstrate proof of concept of endothelial specific siRNA delivery based 
therapeutic intervention we chose RelA as a target gene to inhibit endothelial activation 
in inflammation. We first investigated in vitro the consequences of RelA downregulation 
on the inflammatory status of endothelial cells after TNFα and LPS challenge. In 
HUVEC transfected with RelA specific siRNA and exposed to TNFα or LPS, 98% 
downregulation of RelA mRNA was achieved (Fig. S1A), which was paralleled by 
nearly complete inhibition of RelA protein expression (Fig. S1B) and absence of RelA 
in the nucleus after the challenge (Fig. S1C), while transfection with control siRNA 
was devoid of such effects. Interference with NFκB signaling led to attenuation of the 
inflammatory response towards TNFα and LPS as demonstrated by robust inhibition 
of expression of the pro-inflammatory genes E-selectin, VCAM-1, ICAM-1, IL-8 and 
IL-6, and MCP-1 (Fig. S1D, E). Moreover, downregulation of RelA resulted in 70-
80% inhibition of IL-8 protein and 50-60% inhibition of IL-6 protein production by 
endothelial cells exposed to TNFα resp. LPS (Fig. S2). Comparable effects of RelA 
downregulation were found in the mouse heart endothelial cell line (H5V), implying 
that attenuation of the inflammatory response using RelA siRNA can also be achieved 





 SAINT-O-Somes downregulate target gene VE-cedherin in 
specific vascular segments. TNFα challenged mice were injected with AbVCAM-1 SAINT-O-Somes containing 
(0.6 mg/kg) VE-cadherin or control siRNA and sacrificed 48 h later. (A) Accumulation of AbVCAM-1 siRNA 
SAINT-O-Somes in the kidney. (B-D) VE-cadherin gene expression in specific vascular segments, laser 
microdissected from kidney cryo-sections prior to analysis by RT-qPCR. Data of 3 mice/group and mean 
values are presented. * p < 0.05.








 SAINT-O-Somes reduce the expression of pro-inflammatory genes in LPS 
activated endothelial cells. (A) Schematic representation of the experimental setup. HUVEC were activated 
with TNFα (10 ng/ml) and subsequently incubated with AbVCAM-1 SAINT-O-Somes containing RelA specific 
or control siRNA (CS) for 24 h. After an additional 24 h incubation period, cells were stimulated with LPS 
(1 mg/ml) for the last 4 h of the experiment. (B) siRNA concentration dependent downregulation of RelA 
mRNA. (C) Downregulation of RelA protein expression by AbVCAM-1 siRNARelA SAINT-O-Somes at 1.5 mM 
resulted in (D) decreased nuclear translocation of RelA in LPS stimulated HUVEC and (E) attenuation of 
pro-inflammatory gene expression upon LPS stimulation. (B, E) Data are presented as mean values ± SD of 
three independent experiments. *p < 0.05, # p < 0.05 RelA vs LPS; (C) Image shows a representative Western 
Blot; (D) Immunofluorescence data set shows representative images of one of three independent experiments, 
original magnification 400x. Scale bar represents 50 µm.
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AbVCAM-1 SAINT-O-Somes containing siRNA against RelA attenuate the endothelial 
inflammatory response to LPS in vitro and in vivo.
HUVEC were challenged with TNFα for 6 h to induce expression of VCAM-1 and 




SAINT-O-Somes for 24 h. After an 





O-Somes showed a dose dependent downregulation of RelA mRNA up to 60 % at 1.5 
µM of siRNA, as compared to control siRNA (Fig. 5B). Inhibition of gene expression 
was corroborated by downregulation of RelA protein expression (Fig. 5C) and led to 
a decrease in RelA nuclear translocation upon LPS stimulation (Fig. 5D). In parallel, 
a 40-50 % downregulation of adhesion molecules (E-selectin, VCAM-1, ICAM-1), 
35 % downregulation of MCP-1, and 30-40 % downregulation of IL-8 and IL-6 was 
observed (Fig. 5E). Non-targeted siRNA
RelA
 SAINT-O-Somes were devoid of the above 
effect (data not shown).




SAINT-O-Somes can attenuate the 
endothelial inflammatory response to LPS in vivo, we used the TNFα challenged mouse 
model, to allow SAINT-O-Somes homing, followed by LPS challenge. TNFα challenged 
mice were injected with a single dose of Ab
VCAM-1
 SAINT-O-Somes containing (0.6 
mg/kg) RelA specific or control siRNA and re-challenged with LPS after 48 h. Local 
pharmacological effects of the siRNA treatment were analyzed in laser microdissected 
vascular compartments of the kidneys (Fig. 6A). The extent of RelA downregulation 
was analyzed in mice sacrificed prior to LPS treatment (at 48 h time point). 48 h after 
an acute TNFα challenge the expression of most pro-inflammatory genes is restored to 
basal (low) levels, therefore, to show the consequences of RelA downregulation on the 
expression of downstream pro-inflammatory genes, the second challenge was required. 
As previously observed for VE-cadherin, the major effects of siRNA treatment were 
observed in postcapillary venules. We found 46% downregulation of RelA mRNA 










SAINT-O-Somes further showed a significant downregulation of E-selectin, MCP-1, 
and IL-6 gene expression in the venules to approx. 40%, as compared to LPS challenged 
group that received control siRNA (Fig. 6C-E). We did not observe significant 
differences in the expression of the these genes in glomeruli and renal arterioles (Fig. 
S4). Furthermore, no significant differences were found in the expression of VCAM-





 SAINT-O-Somes (data not shown). The molecular effects in the venules 
were accompanied by a significantly reduced number of adhering/infiltrating CD45+ 




 SAINT-O-Somes, as compared to LPS 
re-challenged control mice (Fig. 6F). The effect on leukocyte attraction was though not 
significantly different from mice treated with control siRNA.




Figure 6. Local attenuation of endothelial inflammatory response towards LPS challenge in vivo by 
endothelial specific RelA downregulation. (A) Schematic representation of the experimental setup. (B) 
RelA mRNA expression in kidney venules of TNFα challenged mice 48 h after administration of AbVCAM-1 
SAINT-O-Somes containing (0.6 mg/kg) RelA specific or control siRNA. (C-E) Inhibition of pro-inflammatory 
gene expression in renal postcapillary venules of TNFα / LPS challenged mice by AbVCAM-1 siRNARelA SAINT-
O-Somes. Kidney venules were laser microdissected prior to analysis by RT-qPCR. Data of 3 mice/group 
and mean values are presented. * p < 0.05. (F-G) Leukocyte (CD45+ cells) attraction to kidney venules. 
Number of CD45+ cells in contact with vessel wall (black arrows (G)) was scored in 10 randomly selected 
postcapillary venules per kidney as described in ‘Material and Methods’. Data are presented as mean values 
of 3-5 mice/group. * p < 0.05. Scale bar represents 50 µm.
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Discussion
Microvascular endothelial cells at a site of inflammation are both active participants 
and regulators of acute and chronic inflammatory processes, thus endothelial specific 
delivery of therapeutics presents a promising approach for anti-inflammatory 
intervention. In the current work we demonstrate that it is feasible to selectively deliver 
siRNAs to inflamed endothelial cells in vivo using SAINT-C18 based liposomes 
(SAINT-O-Somes), surface-modified with antibodies specific for the inflammatory 
adhesion protein VCAM-1, and we show their potential to interfere with disease 
associated endothelial cell activation. Ab
VCAM-1
 SAINT-O-Somes selectively homed to 
VCAM-1 expressing endothelial cells in specific microvascular segments in organs of 
TNFα challenged mice and effectively delivered VE-cadherin and NFκB p65 (RelA) 
specific siRNAs to the renal vasculature without exerting liver and kidney toxicity. 
The resulting knock down of RelA led to attenuation of the endothelial inflammatory 
response towards LPS and exerted local therapeutic effects represented by inhibition 
of pro-inflammatory gene expression and leukocyte attraction to kidney venules. From 
this study we conclude that Ab
VCAM-1
 SAINT-O-Somes are suitable for functional 
delivery of siRNAs to inflamed microvascular segments and attenuation of endothelial 
inflammatory responses in vivo.
NFκB is a key regulator of the inflammatory response in endothelial cells, and 
its activation is involved in the pathogenesis of many diseases with an underlying 
inflammatory component such as sepsis and atherosclerosis [29, 30]. Activation 
of NFκB by pro-inflammatory cytokines, free radicals or pathogens, leads to the 
expression of a variety of pro-inflammatory genes encoding cytokines, chemokines 
and adhesion molecules [31]. Targeting members of the NFκB signaling pathway is 
a promising therapeutic strategy, yet a specific intervention is an important requisite 
as systemic inhibition of its biological function has for example detrimental effects 
on the performance of the immune system and the maintenance of liver homeostasis 
upon acute inflammation [32, 33]. Many currently used small molecule inhibitors 
of NFκB lack cellular and molecular specificity and exert systemic toxicity [8]. 
Endothelial specific inhibition of NFκB activity may therefore enhance the efficacy of 
anti-inflammatory treatment by attenuating the inflammation while reducing adverse 
effects of the intervention. For example, Ye et al. showed that mice with genetically 
engineered endothelial-selective blockade of NFκB activation were resistant to septic 
shock and sepsis-related death yet retained a normal capacity to clear pathogenic 
bacteria [6]. Other studies in transgenic mice with endothelial cell-restricted depletion 
of NFκB demonstrated its protective role in the development of atherosclerosis [31] 
and hypertension-induced renal damage [5].




Targeting inflamed vasculature has been attempted using a variety of targets including 
PECAM-1, ICAM-1, and E-selectin, each representing different vascular specificity 
and heterogeneity of expression in quiescence and inflammatory diseases (reviewed by 
Simone et. al. [34]). VCAM-1 presents an attractive target for endothelial specific drug 
delivery as it is expressed at low levels by resting endothelium and is strongly induced 
by inflammatory stimuli, such as pro-inflammatory cytokines or growth factors [4]. 
TNFα challenged mice showed induced VCAM-1 mRNA and protein expression in all 
vascular segments of major organs at 2-8 h post challenge. In the kidney VCAM-1 protein 
was expressed in arterioles and venules but not in glomeruli, corroborating findings 
in models of hemorrhagic shock [35] and LPS induced sepsis [36]. Our data indeed 
indicate limited use of VCAM-1 for targeting glomerular endothelium, whereas venous 
and arteriolar endothelial cells were accessible through VCAM-1. Strong induction 
of VCAM-1 expression was also found at the sites of pathological inflammation in 
atherosclerosis [37], autoimmune diseases [38], and on tumor vasculature [39], offering 
multiple applications for siRNA delivery devices targeted to VCAM-1.
We showed that Ab
VCAM-1
 siRNA SAINT-O-Somes display the required 
physicochemical properties and pharmacokinetic behavior to target VCAM-1 expressing 
microvascular endothelial cells in TNFα challenged mice. Circulation kinetics of i.v. 
injected siRNA SAINT-O-Somes were comparable to long circulating liposomes that 
do not contain the cationic SAINT-C18 [20]. Ab
VCAM-1 
siRNA SAINT-O-Somes showed 
higher plasma clearance than IgG conjugated SAINT-O-Somes, which is likely due to 
specific binding to VCAM-1 on activated endothelial cells. Compared to IgG SAINT-
O-Somes, a significantly higher accumulation of Ab
VCAM-1
 SAINT-O-Somes was found 
in the inflamed microvasculature of kidneys, heart and lungs and brain. In all organs, 
the localization of Ab
VCAM-1
 SAINT-O-Somes corroborated the TNFα induced VCAM-1 
expression on the endothelium, whereas IgG SAINT-O-Somes were mainly associated 
with the phagocytic cells of the reticuloendothelial system (RES) in the liver and spleen. 
The glomerular presence of IgG SAINT-O-Somes possibly occurred due to uptake by 
mesangial cells possessing phagocytic properties [40].
We previously showed that targeted SAINT-O-Somes containing siRNA at 1 µM 
concentration had no influence on the viability of endothelial cells in vitro, after 48 h 
exposure [19]. In vivo, no toxicity was observed after administration of a single dose 
(50 µmol TL/kg, 0.6 mg/kg siRNA) of Ab
VCAM-1
 siRNA SAINT-O-Somes to mice, as 
indicated by the absence of weight loss or unchanged plasma levels of the indicators of 
liver and kidney damage. The toxicity of lipid based formulations is often attributed to 
their positive surface charge, determined by the type and the content of cationic lipid, 
as well as presence of the helper lipids facilitating endosomal escape such as DOPE 
(reviewed by Borja et al. [41]). It is highly likely that the absence of toxic effects 
of SAINT-O-Somes in our study is a consequence of the relatively low SAINT-C18 
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content (18 mol%), in combination with PEG shielding of the surface charge, and the 
absence of DOPE in the formulation.
Upon pro-inflammatory stimulation, the kidney vasculature displays a heterogeneous 
expression of VCAM-1 in distinct vascular beds (Fig 1 and 3B), which allowed us to 
study the local effects of Ab
VCAM-1
 siRNA SAINT-O-Somes in kidney vasculature. The 
tool of laser microdissection in combination with quantitative RT-PCR enabled analysis 
of vascular bed-specific pharmacological effects, that were masked when whole kidney 
homogenates were analyzed (data not shown). Whole organ effects of Ab
VCAM-1
 SAINT-
O-Somes delivered VE-cadherin and RelA specific siRNAs were also investigated 
in lungs and liver but no downregulation of the targeted genes was found (data not 
shown). Likely the siRNA effects in these organs are also restricted to the endothelium 
which comprises a small part of the whole tissue but have not been studied yet. Targeted 
delivery of VE-cadherin or RelA specific siRNAs by Ab
VCAM-1
 SAINT-O-Somes 
resulted in downregulation of VE-cadherin and RelA mRNA expression predominantly 
in renal venules, whereas gene expression in glomeruli was unaltered. This local effects 
of siRNA can be explained by the fact that a majority of Ab
VCAM-1 
siRNA SAINT-O-
Somes accumulated in the kidney venules, while only minor amounts were found in the 
glomeruli. Interestingly, despite detectable accumulation of Ab
VCAM-1 
siRNA SAINT-
O-Somes in the kidney arterioles, we did not observe a significant downregulation of 
VE-cadherin and RelA gene expression. Possibly insufficient accumulation of Ab
VCAM-1
 
SAINT-O-Somes at the highly endothelial-dense arterial wall is underlying this effect, 
which is also experimentally reflected by the immunofluorescent data (Fig. 3C). Recent 
studies demonstrated the effects of flow related shear stress on endothelial endocytosis 
of nanocarriers targeted to PECAM-1 [42] and ICAM-1 [43], showing a higher rate 
of endocytosis in vascular segments with lower shear stress. It may be possible that 
hydrodynamic differences between the vascular segments may also play a role in 
differential uptake and concomitant effects of Ab
VCAM-1
 siRNA SAINT-O-Somes. The 
differences between arterial and venous endothelial cells with regard to siRNA release 
such as the ability to intra-cellularly process Ab
VCAM-1
 SAINT-O-Somes, as implied by 
data in our previous study [19], may also contribute to the observed preferential gene 
silencing capacity in vivo in the venous segments.
A single dose of Ab
VCAM-1
 SAINT-O-Somes (0.6 mg/kg siRNA) was sufficient to 
achieve approximately 40% reduction of the VE-cadherin and RelA mRNA expression 
in vivo, 48 h post administration. This result corroborates downregulation of mRNA 
expression of the above genes found in HUVEC, which in vitro was followed by 
inhibition of protein expression ([19] and Fig 5 A-D). In vivo, however, we did not 
detect changes in protein expression in whole kidney protein extracts (data not shown). 
Lack of the differences in RelA protein expression may be explained by the fact that 




 SAINT-O-Somes are localized in a minority of cells 









 SAINT-O-Somes in kidney venules, represented by inhibition of 
LPS induced E-selectin, MCP-1, and IL-6 gene expression, and a decrease in leukocyte 
attraction to kidney venules. Absence of VCAM-1 and ICAM-1 downregulation in vivo 
may possibly be explained by a more complex regulation of the inflammatory gene 
expression in subsets of microvascular endothelium in vivo than described for in vitro 
cell culture systems [4]. The inhibitory effect of RelA siRNA on leukocyte attraction in 
the venules may be a result of both inhibition of gene expression and binding of Ab
VCAM-1
 
conjugated to SAINT-O-Somes to its target that may affect leukocyte interaction with 
the vessel wall. The contribution of the latter is however not likely, as Ab
VCAM-1
 SAINT-
O-Somes were hardly detectable in kidney venules 48 h after administration, being the 
time point at which the LPS challenge took place (data not shown).
Until now drug delivery based selective NFκB interference with activated 
endothelium has only been demonstrated using adenoviral gene therapy [21, 44], 
whereas only a few non-viral carriers are currently available for in vivo siRNA 
delivery into endothelial cells [17, 45]. Most studies regarding those carriers focus 
on siRNA delivery to tumor vasculature that is markedly transformed by the tumor 
microenvironment, often leaky and not considered normal vasculature [46]. It is 
therefore difficult to compare gene silencing efficacy of Ab
VCAM-1
 siRNA SAINT-
O-Somes with those systems. siRNA delivery into the vasculature was previously 
demonstrated using non-targeted lipoplexes that were taken up via interaction of 
positively charged cationic lipids with the endothelial cells [47]. With those lipoplexes, 
based on cationic lipid AtuFECT01, Santel et. al. demonstrated silencing of gene and 
protein expression of endothelial specific genes PECAM-1 and Tie-2 in liver, lungs, 
and heart vasculature. Mice were treated i.v. with a daily siRNA dose of 1.88 mg/kg 
for 4 consecutive days [47]. Contrary to cationic lipoplexes, Ab
VCAM-1
 SAINT-O-Somes 
facilitate selective siRNA delivery via antibody/antigen specific interaction solely to 
disease associated endothelial cell subsets. Future studies need to evaluate the duration 
of in vivo gene silencing and the influence of multiple dosing on silencing efficiency 
and duration, as well as the maintenance of VCAM-1 specificity to vascular segments.
In summary, this study reports on a novel, endothelial specific carrier suitable for 
selective delivery of siRNAs to inflamed microvascular endothelial cells and interference 
with disease associated endothelial activation. We showed that VCAM-1 can serve 
as a specific entry route for this delivery and we demonstrated proof-of-concept of 
pharmacological effects represented by attenuation of the endothelial inflammatory 




 SAINT-O-Somes mediated inhibition of 





O-Somes in relevant models of inflammatory diseases will disclose more details on the 
potential of this system for broad therapeutic application.
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S1. Downregulation of NFkB p65 (RelA) using siRNA attenuates the inflammatory response to TNFα 
and LPS in human endothelial cells. HUVEC were transfected with 60 nM of RelA specific or control 
siRNA (CS) using Lipofectamine 2000, according to the manufacturer’s protocol. After 48 h, cells were 
challenged with either TNFα (10 ng/ml; Boehringer) or LPS (1 mg/ml) for the following 4 h or 25 min for 
immunofluorescent detection of RelA. Subsequent analysis of gene and protein expression was performed as 
described in ‘Materials and Methods’. siRNA mediated downregulation of RelA (A) mRNA and (B) protein 
expression. Image shows a representative Western Blot of two independent experiments; (C) Absence of RelA 
in the nucleus upon pro-inflammatory activation. (D, E) Attenuation of pro-inflammatory gene expression 
in TNFα or LPS stimulated HUVEC upon downregulation of RelA. All RT-qPCR data are presented as 
mean values ± SD, n=3. * p < 0.05; (C) Presented immunofluorescence data set show images from three 
independent experiments, original magnification 400x. Scale bar represents 50 µm.
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S3. Downregulation of RelA using siRNA attenuates inflammatory response to TNFα and LPS in mouse 
endothelial cells. H5V mouse heart endothelial cells were transfected with RelA or control siRNA using 
Lipofectamine 2000 and after 48 h they were exposed to mrTNFα (100 ng/ml) or LPS (1 µg/ml) for 4 h. (A) 
siRNA mediated downregulation of RelA mRNA. (B, C) Attenuation of pro-inflammatory gene expression in 
TNFα or LPS stimulated cells upon downregulation of RelA. All RT-qPCR data are presented as mean values 
± SD, n=3. * p < 0.05.
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Adhesion moleculesE-selectin Hs00174057_m1Mm00441278_m1VCAM-1 Hs00365486_m1Mm00449197_m1ICAM-1 Hs00164932_m1Mm00516023_m1PECAM-1 (CD31) Hs00169777_m1Mm00476702_m1P-selectin Mm00441295_m1
Cytokines/chemokinesMCP-1 Hs00234140_m1Mm00446190_m1IL-6 Hs00174131_m1Mm00433859_m1IL-8 Hs00174131_m1Mm00433859_m1
OthersRelA (NFκB p65) Hs00153294_m1Mm00501346_m1VE-cadherin Mm00486938_m1
Table 1. qPCR primers used for gene expression analysis
Species - Human (Hs), mouse (Mm).
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Abstract
Interference with acute and chronic inflammatory processes by means of delivery of 
siRNAs into microvascular endothelial cells at a site of inflammation demands specific, 
non-toxic and effective siRNA delivery system. In the current work we describe the 
design and characterization of siRNA carriers based on cationic pyridinium-derived 
lipid 1-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chloride) (SAINT-C18) and the 
transfection enhancer protamine, complexed with siRNA/carrier DNA or siRNA 
only. These carriers, called SAINT-liposome-polycation-DNA (S-LPD) and SAINT-
liposome-polycation (S-LP), have a high efficiency of siRNA encapsulation, low 
cellular toxicity, and superior efficacy of gene downregulation in endothelial cells in 
vitro as compared to DOTAP-LPD. Incorporation of 10 mol% PEG and anti-E-selectin 
antibody in these formulations resulted in selective siRNA delivery into activated 
endothelial cells. Furthermore, we showed that the physicochemical characteristics of 
S-LPD and S-LP, including size-stability and maintenance of the siRNA integrity in the 
presence of serum at 37 oC, comply with requirements for in vivo application.





Nucleic acids such as short interfering RNAs (siRNA) are a promising new class 
of therapeutics, enabling specific interference with gene expression [1]. They can be 
therapeutically exploited for the inhibition of disease associated genes and provide 
the opportunity to address so far unmet therapeutic needs. However, unmodified or 
uncomplexed siRNAs (so-called “naked” siRNAs) are subjected to rapid clearance 
from the circulation by the liver and renal filtration, and are sensitive to degradation by 
serum RNases, which limits their application in vivo [2]. Therefore for the development 
of clinically suitable siRNA therapeutics, safe and effective delivery systems that are 
specifically taken up by diseased cells, are crucial.
The pivotal role of endothelial cells in the pathology of inflammatory diseases 





-integrins) on the endothelial cells [3] raised interest in the 
development of siRNA delivery devices for selective pharmacological intervention in 
the diseased endothelium. Systemic administration of siRNA via the bloodstream is a 
feasible route to reach the vascular endothelium, though only a few types of carriers 
suitable for in vivo siRNA delivery into endothelial cells have been developed so far 
[4]. We recently demonstrated specific delivery of siRNA to inflamed endothelial cells 
using two types of carriers based on cationic pyridinium-derived lipid 1-methyl-4-
(cis-9-dioleyl)methyl-pyridinium-chloride) (SAINT-C18), called SAINT-O-Somes 
and SAINTargs [4-6]. SAINT-C18 by itself is capable of delivering nucleic acids, and 
in combination with the helper-lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) it forms complexes with nucleic acids that are characterized by high transfection 
efficiency in the presence of serum and low toxicity in vitro [7]. Notably, administration 
of SAINT:DOPE (SD) also did not elicit any immune response or toxicity in mice 
[8, 9]. For in vivo application addition of polyethylene-glycol (PEG) to an siRNA 
carrier is often essential, to avoid RES and improve carrier stability in the serum [10]. 
However, PEGylation of SD lipoplexes significantly reduces their transfection efficacy 
[5] and enforces formulation of the particles only with a low amount of PEG (2 mol%), 
resulting in short blood circulation times (personal communication with N.G.J. Leus). 
A major advantage of SD is the capacity to transfect not only siRNA or DNA but 
also proteins. Van der Gun et al. demonstrated that SD enables serum-insensitive protein 
delivery to various cell types, in contrast to other commercially available profection 
compounds [11]. Protamine is a small cationic protein with high arginine content that 
is FDA approved for parenteral administration [12]. Protamine aids DNA condensation 
and stabilization in sperm cells [13]  and has attracted much attention as a nucleic acid 
transfection enhancer for gene delivery [12]. It was employed by Huang and coworkers 
to develop siRNA delivery systems called liposome-polycation-DNA (LPD) [14], that 
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comprise of siRNA and carrier DNA complexed with protamine and lipids. These 
formulations show gene silencing at relatively low doses (0.15-0.45 mg siRNA/kg), 
display a more uniform size than lipoplexes, and could be grafted with up to 20 mol% 
of PEG allowing a substantial reduction of clearance by the RES [15]. 
In order to improve the efficacy of gene silencing in endothelial cells and in vivo 
suitability of SAINT-based carriers, we formulated and characterized particles composed 
of a protamine complexed with siRNA/ctDNA or siRNA only, and encapsulated by SD 
liposomes, called SAINT-liposome-polycation-DNA (S-LPD) and SAINT-liposome-
polycation (S-LP). These particles were examined for size, stability and influence of 
PEG grafting. Toxicity and VE-cadherin gene silencing efficacy in endothelial cells 
of S-LPD and S-LP  was compared to liposome-polycation-DNA particles based on 
DOTAP : Cholesterol liposomes.  When conjugated with anti-E-selectin antibodies, 
S-LPD and S-LP demonstrated selective siRNA delivery to activated endothelium. 
We showed that this novel SAINT-based systems allow efficient and specific siRNA 
delivery to inflamed endothelial cells and have physicochemical features that comply 
with demands for in vivo application.
Materials and methods
Materials
Lipids, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE), 1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine-N-[methoxy(polyethylene glycol)-2000]-maleimide (DSPE-PEG2000-Mal), 
and 2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene gly-
col)-2000] (DSPE-PEG2000) were purchased from Avanti Polar Lipids (Alabaster 
AL, USA). The cationic lipid 1-methyl-4-(cis-9-dioleyl)methyl-pyridinium-chloride 
(SAINT-C18) was obtained from Synvolux Therapeutics (Groningen, The Nether-
lands). Cholesterol (Chol), protamine (sulphate salt from Salmon), calf-thymus DNA 
(ct-DNA) and N-succinimidyl-S-acetylthioacetate (SATA) were purchased from Sigma 
(St. Louis, MO, USA). Nucleic acid stain DAPI was obtained from Roche Diagnostics 
(Manheim, Germany). All siRNAs were purchased from Qiagen (Venlo, The Nether-
lands). 
The H18/7-acb (mouse IgG2a anti-human E-selectin) producing hybridoma was 
kindly provided by Dr. M. Gimbrone from Harvard Medical School (Boston, MA, 
USA).





Liposomes composed of SAINT and DOPE or DOTAP and Cholesterol in a molar 
ratio of 1:1 were prepared by lipid film hydration. Lipids were dissolved in chloroform/
methanol (9:1, v/v) and dried under reduced nitrogen pressure and vacuum for 30 
minutes. The dried lipid film was hydrated with RNase free water (Qiagen) for 10 
minutes. Liposome size was reduced by repeated extrusion through a polycarbonate 
membrane (Whatman, Maidstone Kent, UK), pore size 100 nm, using a high pressure 
extruder (Lipex, Vancouver, Canada). The liposomes were stored at 4 °C under Argon 
gas.
Preparation of LPD and LP particles
To prepare SAINT : DOPE based LPD and LP, referred to as S-LPD respectively 
S-LP, protamine (1 mg/ml) and nucleic acids (NA) were mixed at a ratio of 0.75 (w/w) 
and incubated for 10 minutes at room temperature (RT). A 1:1 (w/w) mixture of siRNA 
(0.3 mg/ml) and calf thymus DNA (1 mg/ml) in RNase free water was used to form 
LPD, while an equivalent total NA amount of siRNA only was used for LP. Liposomes 
(10 mM) were added to the mixture at a ratio of 0.025 (µmol TL/µg NA). Samples were 
vortexed and incubated for 30 min at RT. DOTAP : Cholesterol based LPD were 
prepared as described by Li et al. [16] and are here referred to as DOTAP-
LPD. Particles were PEGylated by post insertion of DSPE-PEG2000  micelles (3.56 
mM) for 10 min at 50 oC. DSPE-PEG2000 micelles were prepared by lipid film hydration, 
as descried for liposomes in paragraph 2.2., and added to the particles at indicated mol% 
PEG ratios. LPD and LP were used for the experiments within 1 hour after preparation.
Targeted S-LPD and S-LP were prepared by simultaneous post insertion of anti-E-
selectin DSPE-PEG2000 micelles in a 1:4,000 molar ratio of protein/TL and non-targeted 
DSPE-PEG2000 micelles at indicated mol% PEG ratio. To prepare anti-E-selectin 
DSPE-PEG2000 micelles, antibodies were thiolated by means of SATA and coupled to 
the maleimide group at the distal end of the polyethylene glycol (DSPE-PEG2000-Mal) 
chain by sulfhydryl-maleimide coupling [17]. In brief, SATA-modified antibodies 
containing free sulfhydryl groups were added to DSPE-PEG2000-Mal micelles at a molar 
ratio of 1:20 and incubated at room temperature for 1 h. Excess of free DSPE-PEG2000-
Mal micelles was removed by Zeba™ Desalt Spin Columns, 7K MWCO (Thermo 
Fisher Scientific, Rockford, IL, USA). Protein concentration of the anti-E-selectin 
DSPE-PEG2000 micelles was determined by measuring absorbance at 280 nm using 
NanoDrop® ND 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, 
USA).
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Characterization of S-LPD and S-LP particles
Particle size and ζ-potential were analyzed using a Nicomp 380 ZLS submicron 
particle analyzer (NICOMP particle sizing systems, Santa Barbara, CA, USA). Particle 
size was measured using dynamic light scattering (DLS) in the volume weighing mode. 
The Polydispersity index (PDI) was analyzed using a Malvern Zetasizer Nano ZSP 
(Malvern Instruments ltd., Worcestershire, UK). S-LPD and S-LP particles were freshly 
prepared using control siRNA (Qiagen, AllStars Negative Control, cat No. 1027281) 
and, when indicated, formulated with various amounts of PEG-DSPE2000. The siRNA 
encapsulation efficiency was measured using the Quant-iT™ Ribo-Green® assay 
(Invitrogen, Breda, The Netherlands). For gel retardation, particles containing 200 ng 
siRNA were mixed with 1 % (v/v) Triton X-100 and 1% (v/v) SDS, and subsequently 
loaded on 2% agarose gel containing ethidium bromide (60 µg/ml). Electrophoresis 
was performed at 15 min at 110 V. Images of the gel were taken using the ChemiDoc 
XRS system (Bio-rad, Veenendaal, The Netherlands).
Cryo-transmission electron microscopy (Cryo-TEM)
The morphology of S-LPD and S-LP particles was determined by transmission cryo-
EM. Samples were applied on glow discharged holey carbon-coated grids (Quantifoil 
3.5/1), and the excess of liquid was blotted away by filter paper. The specimens were 
frozen in liquid ethane using a vitrobot (FEI, Eindhoven, The, Netherlands) the frozen 
hydrated samples were mounted in a Gatan (mol 626) CRYOSTAGE and examined in 
a Philips CM 120 cryo-electron microscope, operating at 120 kV or in a FEI Tecnai 20 
cryo-electron microscope operating at 200 kV. Images were recorded under low-dose 
conditions wth a slow-scan CCD camera.
Cell cultures
Human umbilical vein endothelial cells (HUVEC) were obtained from Lonza 
(Breda, The Netherlands) and the Endothelial Cell Facility of UMCG. HUVEC obtained 
from Lonza  were used for functional and uptake studies. Cells were cultured in EBM-
2 medium supplemented with EGM-2 MV SingleQuote Kit Supplements & Growth 
Factors (cat No. CC-3202, Lonza). In all experiments, cells from passage 5 to 7 were 
used. Cells were plated on culture plates (Costar, Corning, NY) at a density of 1.8 x 104 
cells/cm2 one day before the experiment unless stated otherwise. Before seeding the 
cells, culture plates were coated with EGM2 MV medium for 30 min. Primary HUVEC 
isolated from two umbilical cords, to circumvent donor bias, were used to demonstrate 
siRNA delivery capacity of anti-E-selectin targeted LP particles. Isolated HUVEC 
showed higher induction of  E-selectin expression upon TNFα stimulation, as compared 
to one obtained from Lonza. Cells were plated one day before the experiment at a density 
of 2.2 x 104 cells/cm2 on 1% gelatin-precoated culture plates (Costar) and cultured in 




EC-medium consisting of RPMI 1640 (Lonza, Verviers, Belgium) supplemented with 
20% (v/v) heat inactivated fetal calf serum (FCS, Hyclone, Logan, UT, USA), 2 mM 
L-glutamine (GIBCO-BRL), 5 U/ml heparin (Leo Pharma, Breda, the Netherlands), 
100 IU/ml penicillin (Yamanouchi Pharma, Leiderdorp, the Netherlands), 100 μg/ml 
streptomycin (Radiumfarma-Fisiopharma, Milano, Italy), and 20 μg/ml endothelial 
cell growth factor (ECGF) extracted from bovine brain (Maciag et al., 1982). Freshly 
isolated HUVEC were used between passage 1 and 4. All cell cultures were maintained 
by the Endothelial Cell Facility of UMCG. 
Influence of serum on particles size-stability and siRNA integrity 
To determine the effect of serum and temperature on size of the S-LPD and S-LP, 
particles were formulated with 10% DSPE-PEG2000 and incubated for 1, 4, and 24 h at 
37 °C in the presence or absence of 50% human serum. The size of the particles was 
measured by DLS as described above. 
To investigate the ability of S-LPD and S-LP to protect siRNA from degradation by 
serum RNases, particles containing 200 ng of control siRNA (Qiagen) were incubated 
in the presence of 50% human serum for different time periods up to 24 h at 37 °C. An 
equal amount of naked control siRNA was incubated with 50% human serum for the 
same period of time. siRNA integrity was analyzed by agarose gel electrophoresis as 
described above.
Cellular uptake of S-LPD and S-LP by endothelial cells
For the flow cytometry experiments, HUVEC were seeded in 24-well plates at a 
density of 2.2 x 104 cells/cm2. 2 hours prior siRNA delivery cells were activated with 
TNFα (10 ng/ml), that remained present in the medium during the experiment. S-LPD 
and S-LP or DOTAP-LPD particles complexed with AlexaFluor
488
 labeled control 
siRNA (Qiagen) were added to the cells for 4 hours at 50 nM siRNA. To demonstrate 
specificity of E-selectin mediated uptake cells were pre-incubated for 5 min with 75- 
fold excess of anti-E-selectin antibody. At 4 after transfection, cells were washed twice 
with PBS and detached from the surface using trypsin/EDTA (Sigma,Ayrshire, UK), 
subsequently they were transferred to tubes containing 5% FBS (fetal bovine serum, 
Thermo Scientific HyClone, Cramlington, UK) in PBS and kept on ice. Next, samples 
were centrifuged for 5 min at 500 g at 4 °C, washed twice with 5% FBS in PBS and 
resuspended in 0.5% paraformaldehyde/PBS. Cells were stored at 4 °C until flow 
cytometry (Calibur, BD Biosciences, Franklin Lakes, NJ). The results were analyzed 
using FlowJo software v7.6.5.
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Gene expression analysis by RT-qPCR
For gene expression analysis, HUVEC were seeded in 24-well plates. After 2 h of 
activation with TNFα (10 ng/mL), S-LPD and S-LP or DOTAP-LPD particles containing 
VE-cadherin specific siRNA (Hs_CDH5_2 FlexiTube siRNA, target sequence 
5’-ACGTATTATTATCACAATAACGAA-3’) or control siRNA, with no homology to 
any known mammalian gene, were added to the cells at 25-300 nM and incubated for 4 
h. TNFα was present in the medium during the entire incubation period. After 48 h total 
RNA was isolated using the RNeasy Mini Plus Kit (Qiagen, Venlo, The Netherlands) 
according to the protocol of the manufacturer. The concentration of RNA was measured 
by a NanoDrop ND-1000 spectrophotometer, and qualitative gel electrophoresis 
consistently showed intact RNA integrity. cDNA synthesis and quantitative (q) PCR, 
including data analysis, were performed as described previously [18]. The real-time 
PCR primers for human VE-cadherin (Hs00174344_m1) and GAPDH (Hs99999905_
m1) were purchased as Assay-on-Demand from Applied Biosystems (Nieuwekerk a/d 
IJssel, The Netherlands). Gene expression levels were normalized to the expression of 
the reference gene GAPDH.
Investigation of cellular toxicity by MTS assay
HUVEC were seeded in 96-well plates. Incubations with TNFα and particles were 
performed as described in 2.9. After 48 h, cells were washed with PBS and incubated 
with CellTiter 96® AQueous One Solution reagent (Promega, Leiden, The Netherlands) 
diluted 1:5 (v/v) in culture medium. After 1.5 h, the absorbance at 490 nm was recorded 
with a Varioskan Flash Multimode reader (Thermo Scientific, Breda, The Netherlands). 
Absorbance of the activated endothelial cells without the addition of particles was set 
as 100%.
Statistical analysis
Statistical analysis of the results was performed by a two-tailed unpaired Student’s 
t-test, assuming equal variances to compare two replicate means, or One-Way ANOVA 
followed by Bonferroni post-hoc analysis to compare multiple replicate means. 
Differences were considered significant when p < 0.05. 





Preparation and optimization of SAINT-LPD and LP particles
In the present study we aimed to formulate SAINT-based LPD and LP particles 
composed of a protamine/nucleic acids (NA) core complex encapsulated by 
SAINT:DOPE liposomes, called S-LPD and S-LP (Fig. 1). Prior to formulation of the 
S-LPD and S-LP, core complexes were prepared with varying ratios of protamine, calf 
thymus DNA and siRNA to study the influence on the core size and z-potential (Fig 
2). Cores including siRNA and ctDNA showed a smaller mean size and increase in 
z-potential with an increasing ratio of protamine/NA (Fig. 2A, B). Cores containing 
only siRNA  exhibited an increase in z-potential but no change in mean particle sizes 
upon increasing the ratio of protamine/NA (Fig. 2C, D). A protamine/NA ratio of 0.75 
resulted in cores with a mean size of approximately 200 nm, z-potential close to -10 mV 
and good NA complexation (Fig. S1), and was considered optimal to formulate S-LPD 
and S-LP particles. Core complexes prepared using the selected ratio of protamine/NA 
ratio were subsequently complexed with SAINT:DOPE liposomes forming S-LPD and 
S-LP particles. S-LP based on protamine/siRNA formed significantly smaller particles, 
of approximately 150 nm, with lower z-potential as compared to S-LPD, prepared 
using protamine/ctDNA + siRNA (Table 1).
Figure 1. Hypothetical schematic overview of SAINT-LPD and LP particle formulation.
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Figure 2. Optimization of the particle core by varying protamine/NA ratios. Mean size and ζ-potential of 
the particle cores prepared with varying ratios of protamine/nucleic acid (NA). (A, B) Protamine/ctDNA + 
siRNA based particle core, (C, D) protamine/siRNA based particle core. Data are presented as mean values 









S-­‐LP	  5%	  PEG	  
S-­‐LP	  10%	  PEG 
S-­‐LP	  20%	  PEG 
144	  ±	  8@ 
155	  ±	  14@ 
199	  ±	  3∗@ 
256	  ±	  16∗@ 
0.17	  ±	  0.02	  
0.16	  ±	  0.02	  
0.19	  ±	  0.04	  
	  	  0.26	  ±	  0.05∗@ 
25.6	  ±	  5@ 
27.8	  ±	  10 
11.2	  ±	  5∗@ 
0.5	  ±	  4∗ 
S-­‐LPD 
S-­‐LPD	  5%	  PEG 
S-­‐LPD	  10%	  PEG 
S-­‐LPD	  20%	  PEG 
202	  ±	  7 
216	  ±	  6 
225	  ±	  13∗ 
285	  ±	  8∗ 
0.19	  ±	  0.02	  
0.18	  ±	  0.01	  
0.19	  ±	  0.02	  
	  	  0.39	  ±	  0.04∗ 
37.3	  ±	  5 
17.3	  ±	  3∗ 
23.3	  ±	  8∗ 
2.6	  ±	  5∗ 
	  
Data are presented as means of 3 preparations ± SD. *P < 0.05 vs 0% PEG; 
@ P < 0.05 vs S-LPD.
Table 1. Physicochemical properties of SAINT-LPD (S-LPD) 
and SAINT-LP (S-LP) particles containing various amounts of PEG




Steric stabilization of S-LPD and S-LP particles by PEGylation
Particles were PEGyated by the post-insertion method with 5-20 mol% PEG-
DSPE2000. Increasing PEG in the formulation resulted in a significant decrease in 
z-potential of both S-LPD and S-LP particles down to 0.5-2.6 mV with 20 mol% PEG 
(Table 1). The siRNA delivery capacity of S-LPD and S-LP to endothelial cells was 
hampered by an increasing amount of PEG in the formulation (Fig. S2) up to 10 mol% 
PEG. Formulations with 20 mol% PEG showed an increase in size and polydispersity 
compared to one with 10 mol% PEG (Table 1). 10% surface density of PEG was thus 
considered optimal for PEGylated formulations. 10% PEG S-LP and S-LPD presented 
comparable siRNA delivery capacity to endothelial cells, while S-LP displayed 
significantly smaller mean particle size (199 ± 3 nm) and lower z-potential (11.2 ± 5 
mV) than S-LPD (Table 1).
Characterization of the nanoparticles
The morphology of S-LPD and S-LP nanoparticles was characterized using Cryo-
EM microscopy (Fig. 3A). Both S-LPD and S-LP formed uniform particles with a lipid 
bilayer surrounding an irregularly shaped core (Fig. 3A a1, a2). A few particles with a 
typical electron-dense fingerprint structure, which reflects a hexagonal organization of 
the lipid bilayer (H
II
), were seen in the populations. The Influence of 10% PEG on the 
morphology of particles is currently being investigate (data not shown).
Both non-PEGylated and 10% PEG S-LPD and S-LP displayed a high efficiency 
of siRNA encapsulation, as demonstrated in the gel retardation assay (Fig. 3B, C). 
Figure 3. Characterization of the S-LPD and S-LP particles. (A) Cryo-EM images of S-LPD and S-LP 
particles formulated without PEG (a1, a2). The ability of non-PEGylated and PEGylated (B) S-LPD and (C) 
S-LP particles to encapsulate siRNA was investigated by 2% agarose gel electrophoresis.
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Based on the RiboGreen assay, the siRNA encapsulation efficiency of S-LP was 98% 
(data not shown), while exact siRNA encapsulation efficiencies of S-LPD could not be 
determined due to interference of ctDNA with the assay.
To investigate the Influence of serum on size-stability and maintenance of siRNA 
integrity by 10% PEG S-LPD and S-LP, particles were incubated with 50% human 
serum at 37 oC (Fig. 4). Both 10% PEG S-LPD and S-LP showed good size stability in 
the presence of serum for 24 h (Fig. 4A, B). Additionally, nonencapsulated siRNA was 
entirely degraded in the serum within 4 h, whereas formulation into S-LPD and S-LP 
preserved the integrity of siRNA for 24 h (Fig. 4C).
10% PEG S-LPD and S-LP show low toxicity and high efficacy of gene 
downregulation in endothelial cells.
We used VE-cadherin, the expression of which is restricted to endothelial cells 
and maintained under TNFα stimulation [4, 19], as a model gene to investigate the 
capacity of gene downregulation by S-LPD and S-LP. HUVEC cells were incubated 
for 4 h with non-PEGylated respectively 10% PEG S-LPD or S-LP or DOTAP-LPD 
particles containing VE-cadherin specific or control siRNA at siRNA concentrations 
ranging from 25-300 nM. Non-PEGylated S-LP had the least effect on cell viability as 
compared to S-LPD and DOTAP-LPD particles (Fig. 5A-C) and showed efficient VE-
cadherin gene silencing with an approximated IC50 of 34 nM siRNA, which is a 3-fold 
Figure 4. Influence of serum on particle size-stability and siRNA integrity. Size stability of (A) S-LPD and 
(B) S-LP formulated with 10 mol% PEG-DSPE2000 was determined in the (●) presence or (○) absence of 
50% serum at diferent time points at 37 oC. Data are presented as the mean diameter (nm) ± SD of three 
preparations. (C) Maintenance of siRNA integrity encapsulated in the particles was studied by agarose gel 
electrophoresis of equal amounts of nonencapsulated and encapsulated siRNA incubated in 50% human 
serum at 37 °C.




lower than the IC50 of DOTAP-LPD (108 nM) (Fig. 5D-F). The IC50 of S-LPD could 
not be determined in the selected concentration range, moreover siRNA delivery at 
siRNA concentrations higher than 25 nM resulted in a profound decrease in endothelial 
cell viability (Fig. 5A). Post insertion of 10 mol% PEG diminished toxicity associated 
with S-LPD and S-LP siRNA delivery (Fig. 5A, B) but led to a decrease in efficacy of 
gene downregulation (Fig. 5D, E). 10% PEG S-LPD had an estimated IC50 of 62 nM, 
while the IC50 of 10% PEG S-LP was 92 nM.
Selective siRNA delivery to activated primary endothelial cells by anti-E-selectin 
10% PEG S-LPD and S-LP particles.
To achieve specific delivery of siRNA to activated endothelial cells, 10% PEG 
S-LPD and 10% PEG S-LP particles were conjugated with antibodies directed 
against E-selectin. Uptake of the particles formulated with AlexaFluor
488
 siRNA was 
investigated in resting and TNFα activated HUVEC by flow cytometry. As compared 
to the resting cells, both anti-E-selectin 10% PEG S-LPD and anti-E-selectin 10% PEG 
S-LP showed a 8-10 fold increase in siRNA uptake in TNFα activated HUVEC (Fig. 
6A, B), while uptake of IgG and non-targeted particles in quiescent and in activated cell 
Figure 5. Toxicity of S-LPD and S-LP particles and their capacity to downregulate VE-cadherin in 
endothelial cells. HUVEC were incubated for 4 h with non-PEGylated S-LPD, S-LP and DOTAP LPD 
particles (●) or S-LPD and S-LP formulated with 10 mol% PEG-DSPE2000 (○), containing VE-cadherin 
specific or control siRNA at siRNA concentrations ranging from 25-300 nM. (A - C). Viability of the cells 
was analyzed after 48 h as described in M&M section. Viability of the cells without addition of the particles 
was set at 100%. Data are presented as mean values ± SD (n=3). * P< 0.05 vs control; (D-E) VE-cadherin 
downregulation by (●) non-PEGylated or (○) 10% PEG S-LPD, S-LP or DOTAP-LPD particles. 48 h after 
incubation with the particles RNA was isolated and VE-cadherin gene expression was determined by RT-
qPCR. Data are presented as mean values ± SD of three independent experiments. Dotted lines indicate 
estimated IC50.
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was comparable. Specificity of association was demonstrated by blocking E-selectin 
with an excess of anti-E-selectin antibodies prior to incubation with the particles. This 
resulted in an almost complete decrease in the uptake of siRNA by activated endothelial 
cells (Fig. 6A, B). 
Discussion
Specific and effective delivery without exerting toxicity is a key challenge and the 
most significant barrier for siRNA technology to become therapeutically applicable. 
Interference with acute and chronic inflammatory processes by means of downregulation 
of key controllers of endothelial cells activation at a site of inflammation demands, 
therefore, a suitable siRNA delivery system. In the current work we describe the 
design and characterization of siRNA carriers which combine SAINT-technology with 
protamine as a transfection enhancer, and show their ability for the delivery of siRNA 
into inflammation-activated endothelial cells. These so called, S-LPD and S-LP particles 
showed high efficacy of siRNA encapsulation, low in vitro toxicity and efficient gene 
downregulation in endothelial cells, that were compared to conventional LPD particles 
based on DOTAP : Cholesterol [14]. Incorporation of 10 mol% PEG and anti-E-selectin 
antibody in the formulation of the carriers resulted in selective siRNA delivery into 
TNFα activated endothelial cells. Furthermore, we showed that the physicochemical 
characteristics of S-LPD and S-LP, including size-stability and maintenance of siRNA 
Figure 6. Selective delivery of siRNA to activated primary endothelial cells by anti-E-selectin targeted 
S-LPD and S-LP particles. Quiescent and TNFα activated HUVEC were incubated for 4 h with anti-E-selectin 
10 mol% PEG (A) S-LPD and (B) S-LP particles containing AlexaFluor488 siRNA. Specificity of association 
to E-selectin, was shown by co-incubation of the cells with excess of anti-E-selectin monoclonal antibodies 
together with the particles. The association of siRNA with the cells was quantified by flow cytometry. Data 
are presented as mean florescence intensity (MFI) values ± SD of three independent experiments. * P < 0.05, 
# P < 0.05 - TNFα vs + TNFα.




integrity in the presence of serum at 37 oC, comply with demands for in vivo application.
LPD particles originally formulated by the group of Huang et al, with DOTAP : 
Cholesterol liposomes, offer several advantages for in vivo siRNA delivery over 
conventional lipoplexes such as good stability in physiological milieu and low RES 
uptake [20]. Due to the above properties, LPD were primary applied in experimental 
RNAi-based tumor therapy. Several studies demonstrated high tumor targeting using 
anisamide-coated PEGylated LPD [1, 16], and recently RGD-targeted PEGylated LPD 
formulations were used to silence expression of VEGFR-2 receptor in angiogenic 
endothelial cells in vitro [21]. Still, these particles demonstrated moderate cellular 
toxicity as well as  moderate efficacy of gene silencing due to poor intracellular release 
of siRNA [15]. Toxicity of LPD formulation was reduced by replacement of carrier 
DNA with hyaluronic acid [22], but efficacy of intracellular siRNA release still remains 
an issue. Here we prepared targeted S-LPD and S-LP based on protamine-siRNA/carrier 
DNA or protamine-siRNA core, that were complexed with SAINT : DOPE liposomes 
and engrafted with DSPE-PEG2000. The optimized protamine/NA ratios for S-LPD and 
S-LP was 0.75 (Fig. 2). Further increasing these ratio resulted in core formulations 
with positive net charge that would interfere in the interaction with cationic lipids and 
hamper the core complexation by the liposomes. Addition of SD liposomes to the cores 
yielded uniform particles with a diameter of 150-200 nm and a double lipid bilayer 
structure, as revealed by Cryo-TEM, comparable to DOTAP-LPD [20]. We further 
demonstrated that S-LPD and S-LP formulations displayed higher gene silencing 
potency than DOTAP-LPD, reflected by a 3-fold lower siRNA concentration required 
to silence a target gene VE-cadherin mRNA to 50% of control expression. Since 
DOTAP-LPD delivered more siRNA to the endothelial cells than S-LPD and S-LP 
(Fig. S2) and all particles displayed comparable sizes (120 - 200 nm), the observed 
differences in VE-cadherin silencing were likely related to the ability of the particles 
to intracellulary release the siRNA. It has been shown that SD lipoplexes facilitate 
intermembrane interactions by adopting a hexagnonal phase at physiological conditions 
[7, 23], promoted by the lipid membrane destabilizing effect of DOPE [24]. Therefore, 
the use of SAINT : DOPE in the formulation of S-LPD and S-LP could significantly 
improve siRNA release from the carrier and the endosomes [25] by allowing more 
effective hexagonal phase transition than DOTAP : Cholesterol formulations. Further 
studies focusing on the intracellular siRNA release mechanism involving S-LPD and 
S-LP are needed to validate this hypothesis.
S-LPD were approximately 4-fold more potent in VE-cadherin silencing than S-LP 
(Fig. 5B). This increase in potency may result from the weaker interaction of the siRNA 
with the protamine caused by the presence of high molecular weight ctDNA, enabling 
more efficient siRNA release, or improved particle stability enabled by higher core 
compaction as advocated by Li et al. [14]. S-LPD on the other hand caused a dose 
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dependent decrease in the endothelial cell viability, starting at 50 nM siRNA, while S-LP 
affected the cell viability starting at 3-fold higher siRNA concentrations. S-LP were 
also less harmful for the cells than DOTAP-LPD (Fig 5A). Greater toxicity of S-LPD 
and DOTAP-LPD likely results from the presence of ctDNA in the formulation, which 
as a foreign DNA may elicit toxicity related to the presence of immunostimulatory CpG 
motifs [26]. Toxicity of the S-LPD and S-LP particles was reduced by addition of 10 
mol% PEG to the formulation, however, that decreased delivery of siRNA and ctDNA 
to the cells.
In many studies, lipoplexes containing DOPE showed reduced stability and activity 
in vivo [27]. DOPE also significantly decreased the in vivo activity of DOTAP-LPD 
by decreasing the stability of lipid bilayer, resulting in high association with the serum 
proteins and increase in particle size [28]. In our study S-LPD and S-LP were grafted with 
10% PEG to limit their toxicity and increase the stability in physiological conditions. 
10% PEG S-LPD did not show any increase in size, while the size of S-LP only slightly 
increased after 24 h incubation with serum at 37 oC. Moreover, both particles were able 
to maintain siRNA integrity for the whole incubation period. Demonstrated particle 
and siRNA stability in the presence of serum indicates that S-LPD and S-LP comply 
with demands for in vivo application. In contrast, SD lipoplexes significantly lose their 
siRNA delivery capacity to HUVEC when grafted with 2 mol% PEG [5],  S-LPD 
and S-LP maintained their siRNA delivery ability even with 10 mol% PEG (Fig 5). 
Comparison of the morphology of PEGylated SD lipoplexes with PEGylated S-LPD 
and S-LP using Cryo-TEM and studying their phase transition with differential scanning 
calorimetry may shed more light on the distinct influence of PEGylation on both types 
of particles. While addition of 10 mol% PEG hampered interaction of the S-LPD and 
S-LP particles with activated endothelial cells (Fig. 6 and S2), the combination with 
post insertion of anti-E-selectin DSPE-PEG2000 micelles allowed us to create specificity 
for these cells via interaction with E-selectin. 8 to 10 fold more siRNA was delivered to 
activated HUVEC by anti-E-selectin S-LPD and S-LP as compared to IgG conjugated 
particles. Specificity to E-selectin was demonstrated by co-incubation of the cells with 
an excess of anti-E-selectin antibodies together with the anti-E-selectin S-LPD and 
S-LP.
Other siRNA delivery systems based  on SAINT-C18, such as SAINT-O-Somes 
and SAINTarg are already in the later stage of development and have been tested in 
vivo, thus for an adequate comparison further in vivo studies with S-LP and S-LPD 
need to be performed. Based on our in vitro result, S-LPD and S-LP were more 
potent in VE-cadherin silencing than SAINT-O-Somes (approx. 10–fold) and could 
accommodate more PEG on the particle surface without substantial loss of silencing 
potency as compared to SAINTargs. Moreover, anti-E-selectin S-LPD and S-LP 
showed comparable selectivity of siRNA delivery to activated endothelial cells as other 




SAINT-based systems. High silencing potency and 98% siRNA encapsulation efficacy 
presented by S-LPD and S-LP allows the use of multiple therapeutic siRNAs in one 
formulation without the need for substantial dose increase, in order to reach the effective 
siRNA concentration in the target cells. Targeted LPD co-formulated with combination 
of siRNAs against c-Myc, MDM2, and vascular endothelial growth factor (VEGF) 
significantly reduced the lung metastasis and increased the survival time of the tumor-
bearing animals [29]. Attractive molecular targets for simultaneous gene silencing in 
the endothelial cells may be the members of the NFκB and p38 MAPK families, based 
on their inherent association with inflammatory activation of the endothelium.
In summary, this study reports on new SAINT-based carriers formulated with 
protamine, that allow selective and functional siRNA delivery into inflammation 
activated endothelial cells, mediate potent downregulation of a target gene, and are 
suitable for in vivo application based on their physicochemical and features. S-LPD 
and S-LP are thus novel SAINT-based siRNA delivery systems that can offer an 
improvement in in vivo siRNA delivery to disease-associated endothelial cell subsets 
in different vascular segments, although thorough validation of this system in animal 
models is essential.
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Figure S1. Gel retardation of protamine/ NA particle cores. Cores composed of (A) protamine/ctDNA+siRNA 
and (B) protamine/siRNA were prepared with various ratios of protamine/ NA (w/w) and were resolved on 
2% arose gel by electrophoresis. Arrows indicate positions of the core in the gel. Data show a representative 
image of the gel.
Figure S2. Delivery of siRNA by S-LPD a S-LP particles to endothelial cells. HUVEC were incubated for 
4 h with S-LP, S-LPD or DOTAP LPD particles formulated with various amounts of PEG-DSPE2000 and 
containing AlexaFluor488 siRNA at 50 nM concentration. The uptake of siRNA by the cells was quantified by 
flow cytometry. Data are presented as mean florescence intensity (MFI) values ± SD (n=3).
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Summary
The discovery and application of RNA interference (RNAi) has transformed basic 
research and markedly advanced our understanding of eukaryotic gene regulation and 
function. Until now, short interfering RNAs (siRNAs) have proven to be the most 
effective and widely used tool for specific inhibition of gene expression, and as a result 
they are being translated into the clinic with an unprecedented speed [1]. The ultimate 
goal, achieving siRNA-based therapies for life-threatening or debilitating diseases, 
can, however, not be attained without improving the safety, efficiency and target 
specificity of siRNA delivery systems. This thesis focuses on the development of a 
lipid-based carrier suitable for endothelial-specific in vivo delivery of siRNA. Our aims 
were to design and characterize a liposomal targeted siRNA carrier system based on 
the cationic amphiphile SAINT-C18, study suitability of E-selectin and VCAM-1 for 
specific siRNA delivery into inflamed endothelium and validate molecular targets for 
siRNA mediated anti-inflammatory intervention, and finally to investigate the potential 
of this system for interference with disease associated endothelial activation in vivo. 
Microvascular endothelial cells at the site of inflammation are both active participants 
and regulators of acute and chronic inflammatory processes, thus endothelial specific 
delivery of siRNA presents a promising approach for anti-inflammatory intervention 
and for a better understanding of the role of endothelial cells in inflammatory diseases. 
In chapter 2 we reviewed recent developments in the design of siRNA delivery 
strategies aiming to therapeutically affect diseased endothelium and introduced the 
general consideration of endothelial heterogeneity in relation to disease state and its 
consequences for targeted therapeutic interventions. We discussed obstacles central to 
our work that are limiting the clinical application of siRNA for treatment of chronic 
inflammatory diseases. This includes intracellular fate of endothelium targeted delivery 
systems and microvascular bed dependent heterogeneity of endothelial responses to 
pro-inflammatory stimuli or pharmacological treatment. Upon inflammatory challenge, 
different vascular beds display a heterogeneous expression of adhesion molecules, 
including e.g., E-selectin, VCAM-1, and ICAM-1 [2]. Thus identification of the 
disease-specific makeup of potential target epitopes in vascular segments is crucial for 
the outcome of endothelial targeted treatment. Ideally, target epitope expression should 
be restricted to diseased endothelium and the protein becomes internalized upon ligand 
binding, allowing internalization of the carrier and cytoplasmic release of siRNA. 
Knowledge about the intracellular processing of carriers internalized by endothelial 
adhesion molecules is still limited. Finally, we discussed novel technologies that may 
aid further development of targeted delivery systems toward clinical application such 
as the use of tissue slices and application of laser microdissection (LMD). Tissue slices 
enable analysis of the pharmacological effects in the complexity of the whole human 




organ [3] while LMD allows studying local pharmacological effects by enrichment of 
endothelial cells from (micro)vascular segments prior to analysis [4], which can be an 
essential strategy to provide proof of concept of in vivo siRNA delivery effects.
Lack of suitable animal models to study gene function in relevant diseases is a major 
problem for researchers, often embarked upon by generating transgenic animals at a vast 
expense of time and money. RNAi tools combined with a proper delivery system can 
aid investigations into gene function and identification/validation of therapeutic targets 
in vivo. In chapter 3 we formulated catalytic oligodeoxynucleotides (DNAzymes) that 
bind to target RNA sequences resulting in specific RNA degradation [5], with cationic 
lipid, to study the role of early growth response protein 1 (Egr-1) in a rat model of 
pulmonary arterial hypertension (PAH). Pulmonary arterial hypertension (PAH) is 
characterized by the development of unique neointimal lesions in small pulmonary 
arteries, leading to increased right ventricular (RV) afterload and heart failure. PAH is 
regarded incurable when neointimal lesions have formed, thus therapeutic strategies are 
needed to prevent formation of these lesions. We intravenously administred DNAzymes 
formulated with cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) 
to rats with experimental flow-associated PAH. This resulted in downregulation of 
Egr-1 in pulmonary vasculature and attenuated pulmonary vascular remodeling, 
including the development of occlusive neointimal lesions, and subsequent reduction of 
pulmonary vascular resistance, RV systolic pressure, and RV hypertrophy. We showed 
that hampered expression of Egr-1 target genes (PDGF-B, TGF-β, IL-6 and p53) and 
concomitant decrease in vascular proliferation and increased apoptosis was associated 
with the attenuation of neointimal development. These data imply that Egr-1 plays a 
critical role during vascular remodeling in PAH, and as indicated by our results, that it 
can serve as a therapeutic target for biologics such as DNAzymes or siRNAs. Such a 
pharmacological approach can benefit from improved specific delivery into pulmonary 
endothelium using targeted delivery systems.
In chapter 4 we set out on an attempt to develop a targeted carrier for selective 
delivery of siRNA into inflamed endothelial cells. For this purpose we employed a 
new type of liposomes called SAINT-O-Somes, which are based on formulation of 
conventional long circulating liposomes with the cationic lipid 1-methyl-4-(cis-9-
dioleyl)methyl-pyridiniumchloride (SAINT-C18). SAINT-O-Somes showed superior 
intracellular release of small molecules in endothelial cells as compared to conventional 
liposomes and displayed good siRNA encapsulation efficacy due to the presence of 20 
mol% of cationic SAINT-C18 [6]. In line with our aims, we confirmed the suitability 
of vascular cell adhesion protein 1 (VCAM-1) respectively E-selectin as targets for 
selective siRNA delivery into inflamed endothelium by studying the uptake and the 
intracellular trafficking of SAINT-O-Somes harnessed with antibodies against these 
adhesion molecules in TNFα activated primary endothelial cells. Both VCAM-1 and 
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E-selectin guided SAINT-O-Somes to endolysosomal compartments where (a limited) 
release of the encapsulated siRNA from the carrier was found after 24h. We showed 
that anti-VCAM-1 and anti-E-selectin SAINT-O-Somes carrying siRNA against the 
endothelial gene VE-cadherin specifically downregulated its target mRNA and protein 
expression without exerting cellular toxicity. Notably, SAINT-O-Somes were stable in 
the presence of serum and protected siRNA from degradation by serum RNases, and 
when i.v. injected displayed a pharmacokinetic profile comparable to conventional long 
circulating immunoliposomes, with a circulation half-life of approximately 17 h. This 
study demonstrated the capacity of anti-VCAM-1 and anti-E-selectin SAINT-O-Somes 
to selectively deliver siRNA into inflamed endothelial cells and their suitability for in 
vivo application. 
Our findings from chapter 4 prompted the in vivo study on the use of anti-VCAM-1 
(Ab
VCAM-1
) siRNA SAINT-O-Somes to interfere with disease associated endothelial 
activation, which is described in chapter 5. To demonstrate proof of concept of 
endothelial specific siRNA based therapeutic intervention we chose NFκB p65 (RelA), 
which is a key component of a signal transduction pathway pivotal in endothelial 
cell activation, as a target gene to inhibit endothelial activation in inflammation. I.v. 
administered Ab
VCAM-1
 SAINT-O-Somes selectively homed to VCAM-1 expressing 
endothelial cells in specific microvascular segments in inflamed organs of TNFα 
challenged mice. In the renal vasculature they effectively delivered VE-cadherin and 
RelA specific siRNAs without exerting liver and kidney toxicity. The resulting knock 
down of RelA led to attenuation of the endothelial inflammatory response in kidney 
venules towards LPS and exerted local therapeutic effects represented by inhibition 
of pro-inflammatory gene expression (E-selectin, IL-6, MCP-1) and leukocyte 
attraction. Employing laser microdissection allowed to unravel vascular bed-specific 
pharmacological effects of siRNA, that were masked when whole kidney homogenates 




 SAINT-O-Somes are suitable 
for functional in vivo delivery of siRNAs to inflamed microvascular segments leading 
to attenuation of endothelial inflammatory responses and provides proof-of concept that 
siRNA-based approaches directed to inflamed endothelium may create new prospects 
to therapeutically address (chronic) inflammatory diseases.
Finally in chapter 6, we described the design of, and characterized new SAINT-based 
siRNA carriers incorporating protamine, a small cationic protein used as a transfection 
enhancer, with the aim to improve the efficacy of in vivo gene silencing. The concept 
for the design of these carriers was based on the ability of SAINT-C18, formulated with 
the helper-lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), to efficiently 
deliver DNA, siRNA as well as proteins into cells in the presence of serum and with low 
toxicity in vitro, thus being potentially interesting for in vivo application [7]. So called 
SAINT-liposome-polycation-DNA (S-LPD) and SAINT-liposome-polycation (S-LP) 




were formulated by complexing protamine with siRNA and carrier DNA or siRNA only 
and subsequent addition of SAINT:DOPE liposomes allowing encapsulation of the 
protamine assemblies. S-LPD and S-LP had high efficiency of siRNA encapsulation, 
low in vitro toxicity and superior efficacy of gene downregulation in endothelial cells as 
compared to liposome-polycation-DNA based on DOTAP : Cholesterol, developed by 
Huang and coworkers [8]. Incorporation of 10 mol% PEG and anti-E-selectin antibody 
in the formulation of the carriers enabled selective siRNA delivery into activated 
endothelial cells. Furthermore, the physicochemical characteristics of S-LPD and S-LP, 
including size-stability and maintenance of siRNA integrity in the presence of serum at 
37 oC, complied with in vivo application demands, thus encouraging further validation 
of this system in vivo.
Conclusions
 Since the discovery of RNAi more than a decade ago, many efforts have been 
undertaken to harness gene silencing for application to endothelium engaged in 
widespread (chronic) diseases, e.g., in age related macular degeneration and cancer [9]. 
Endothelium is regarded as a relevant therapeutic target that is directly accessible for 
intravenously administered compounds, though, so far only a few non-viral carriers for 
in vivo siRNA delivery into endothelial cells are in pre-clinical development [9, 10]. 
Our work has yielded novel SAINT-C18 lipid-based carriers called SAINT-O-Somes, 
S-LPD, and S-LP, that we characterized and optimized for selective in vivo delivery 
of siRNA into inflammation activated endothelium [11]. The in vivo study performed 
with anti-VCAM-1 SAINT-O-Somes containing RelA specific siRNA provided 
proof of concept of microvascular specific siRNA delivery based anti-inflammatory 
intervention [12]. We showed that selective interference with NFκB signaling in 
endothelium by means of siRNA, until now only demonstrated using adenoviral gene 
therapy or modular fusion protein SCL1 [13, 14], can offer an alternative approach 
to therapeutically address inflammatory diseases. Even though the downregulation of 
RelA was not complete, a ~50% inhibition of upregulation of RelA controlled pro-
inflammatory genes was found upon LPS challenge, which had an impact on one 
of the key processes in inflammation, namely the recruitment of leukocytes. Dose 
finding and efficacy studies in more clinically relevant animal models are necessary to 
investigate the real therapeutic impact of the our siRNA delivery approaches for further 
development into broad therapeutic applications in inflammatory diseases.
Thesis Piotr Kowalski 2014.indb   144 04-04-14   07:48
145
Summary, Conclusions and Future perspectives
7
Future perspectives
The last decade also brought an unprecedented expansion in development of new 
nanoparticles for treatment of numerous diseases. This development was largely driven 
by the discovery of RNAi and the expenditure on application of RNAi-based therapies 
assisted by the advancement in the design of new materials and technologies, e.g., 
lipidoids, microfluidics, and biomimetics. Although the full therapeutic potential of 
RNAi has not yet been exploited, it ensures new RNAi-based therapies. The future 
demand for multifunctional nanoparticles featuring targeting ligands, auxiliary moieties, 
and gene silencing capability, will grow stirred by implementation of personalized 
approaches towards treatment of diseases and development of affordable clinical scale 
manufacturing methods for nanoparticles [15]. 
Disease models for validation of endothelial specific siRNA-based 
anti-inflammatory intervention
Our experiments provided the first evidence that inflamed endothelial cells that 
actively engage in the pathology of widespread chronic diseases may benefit from 




 SAINT-O-Somes in relevant 
animal models of disease is necessary to prove their therapeutic potential. Specifically, 
diseases with a strong inflammatory component underlying their pathology such as 
atherosclerosis or sepsis, are rational choices for this validation. Atherosclerotic 
plaques exhibit strong induction of VCAM-1 and endothelial-restricted depletion of 
NFκB signaling was demonstrated to reduce the atherosclerotic plaque formation 
[16]. Atherosclerosis models such as ApoE-/- or ApoE/LdL-/- mice may therefore be of 




 SAINT-O-Somes on the plaque 
formation or their inversion in developed atherosclerosis. Also experimental sepsis 
mouse models such as cecal ligation and puncture or systemic injection of bacterial 





 SAINT-O-Somes. During septic shock VCAM-1 is overexpressed 
on the surface of endothelial cells in all major organs [17] and genetically engineered 
mice with an endothelial selective blockade of NFκB activation show resistance to 
septic shock and sepsis-related death [18]. Importantly, a great deal of clinical research 
in sepsis, including more than 40 human clinical trials, so far did not result in FDA-
approved drugs for use in sepsis [19]. Development of effective siRNA-based anti-
inflammatory therapeutics may thus significantly aid the treatment of sepsis.
Pulmonary arterial hypertension (PAH) may also benefit from a targeted siRNA 
delivery approach. As demonstrated in this thesis, formation of neointimal lesions in 
a PAH model can be attenuated by inhibition of Egr-1 expression in the pulmonary 
vasculature, where Egr-1 downregulation restricts vascular remodeling by increase of 




apoptosis and reduction of proliferation in endothelial and smooth muscle cells. Egr-1 
is expressed in remodeled vessels, also in human end-stage PAH, and could therefore 
very well be a target in established disease. Identification of suitable target epitopes 
on remodeled vessels in neointimal lesions of PAH patients enabling specific delivery 
of biologics targeting Egr-1 in the lesions is a perquisite for treatment of established 
PAH. So far, no studies described potential targets for such approach. However, 
inflammation has been suggested to play a role in PAH as well as in the development of 
neointimal lesions [20], that was also reflected in our study by elevated IL-6 expression 
in remodeled vessels. This suggest that elevated expression of endothelial activation 
markers such as E-selectin, VCAM-1, or ICAM-1 may also be present in those lesions 
and could be exploited for target drug delivery. Reducing inflammation has also been 
shown to attenuate the development of PAH [21] justifying future exploration of the 
anti-inflammatory therapies for PAH next to, or in combination with Egr-1 inhibition.
Improving gene silencing efficacy of SAINT-O-Somes
Our data showed that micromolar concentrations of siRNA encapsulated into 
SAINT-O-Somes were required to downregulate the target genes in endothelial cells. 
This was in line with our observations that limited intracellular release of siRNA from 
the carrier is taking place [11]. Using high concentrations of siRNA carrier for target 
gene silencing in not cost effective and may lead to toxicity [22], therefore improvement 
of the siRNA release properties of SAINT-O-Somes should be a key subject for the 
further development of this system. The enhancements introduced should, however, not 
radically challenge the carrier properties such as size, siRNA encapsulation efficacy, 
capacity of antibody conjugation, or stability in vivo. Modification of these properties 
may influence the pharmacokinetic behavior of SAINT-O-Some and may result in 
decrease of their specificity for inflamed endothelial cells. Based on our knowledge on 
the intracellular trafficking of SAINT-O-Somes targeted to VCAM-1 and E-selectin, 
inclusion of pH responsive components in the formulation (e.g., pH-sensitive PEG or 
cell-penetrating peptides) might improve the intracellular efficacy of siRNA release 
[23]. At low endolysosomal pH, the liposomes will lose their PEG coating and will 
protrude the endolysosomal membrane more efficiently via exposed cationic lipid 
head groups or cell-penetrating peptide moieties. Those modification will increase 
the complexity of the system, thus for clinical purpose the benefit of introduced pH-
sensitivity should compensate for the higher development and production costs of the 
particles.
The silencing efficacy could also be improved by refining the payload of siRNA. 
Recently developed RNAi-microsponges present a means of rapidly generating large 
amounts of siRNA densely packed into crystalline particles of 2 µm in size, using 
rolling circle transcription and RNA polymerization [24]. By encapsulation into a 
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positively charged polycation such as polyethylenimine (PEI), RNAi-microsponges 
can be condensed to a size of 200 nm. Using RNAi-microsponge/PEI particles, roughly 
three orders of magnitude less carrier was required to achieve the same degree of 
gene silencing as with conventional particle-based vehicle [25]. Given the high cost 
of therapeutic siRNA and the need for high silencing efficiency, this approach can 
significantly reduce the difficulties of achieving high loading efficiency for siRNA, 
which in combination with enhanced siRNA efficacy and low cytotoxicity may 
synergize to improve the overall delivery system performance. Furthermore, the ease 
of modification of the polymeric RNA composition enables the introduction of multiple 
RNA species into a single RNAi-microsponge for combination therapies.
Alternative approaches for silencing endothelial activation
A number of mediators and overlapping signaling pathways contribute to the control 
of the inflammatory response in the endothelial cells. As a result many agents that 
target proteins in distinct signaling pathways, including NFkB, p38 MAPK, COX2, and 
mTOR, have been developed to inhibit endothelial activation in inflammation [26]. The 
complexity of this regulatory mechanism is also associated with microvascular segment 
specific engagement of the endothelial cells in disease and their heterogenous response 
to treatment [2]. Therefore, using a single target to efficiently inhibit inflammatory 
processes in the endothelium is likely not feasible. In this thesis we demonstrated that 
Ab
VCAM-1
 SAINT-O-Somes mediated delivery of RelA specific siRNA attenuated the 
expression of pro-inflammatory genes in endothelial cells and reduced attraction of the 
leukocytes via the kidney venules [12]. Not all inflammatory molecules were however 
inhibited by the RelA downregulation. Combination of multiple siRNA species against 
several inflammatory targets may enhance the therapeutic potential of siRNA anti-
inflammatory therapy. Simultaneous inhibition of NFκB and p38MAPK would block 
many downstream effector molecules [27], which from a pharmacological point of view 
is beneficial compared to mono-target therapy against a single inflammatory signaling 
protein. SiRNA encapsulation and release efficacy are the limiting factors for suitability 
of the carrier for such an approach as the amount of intracellularly released siRNAs 
should reach the concentration required for effective gene silencing. S-LPD and S-LP 
developed and described in this thesis display a higher siRNA encapsulation efficacy 
and 10-fold greater gene silencing potency in HUVEC than SAINT-O-Somes, thus they 
meet the requirements for combined siRNA therapies.
MicroRNAs (miRNAs) have emerged as a novel class of endogenous, noncoding 
short RNA molecules (about 22 nt) that regulate gene expression at the post-
transcriptional level, via degradation or translational inhibition of their target mRNAs 
[28]. In contrast to siRNA, miRNA recognition of the target mRNA is imperfect, that 
results in binding of many target mRNAs and silencing of multiple target genes by 




one single miRNA [1]. Recent studies indicate the contribution of specific miRNAs, 
including e.g., miR-10a and miR-126, to vascular inflammation and diseases [29, 30]. 
Elevated levels of miR-10a have been shown to inhibit the pro-inflammatory phenotype 
in atherosusceptible endothelium in vivo and in vitro by regulating the IkB/NFkB 
signaling pathway [31], while miR-126 negatively regulates the expression of VCAM-
1 protein, which mediates leukocyte adherence to ECs in vascular inflammation [32]. 
Delivery of anti-inflammatory miRNAs that are deficient in diseased endothelial cells, 
to increase their presence to a similar or higher level than found in healthy cells, may 
present an alternative approach to address the complexity of the inflammatory diseases. 
Double stranded miRNA equivalent to the dicer products, which is a structural analogues 
of siRNA, can be delivered directly to the cytoplasm of the cells for loading into the 
RNA-induced silencing complex (RISC) [33]. miRNA mimics siRNA in most of its 
features and the delivery challenges met for siRNA are the same for miRNA (reviewed 
by [34]). Although functionality of the miRNA may have more advantages for treatment 
of complex inflammatory diseases, efficacy of target suppression by miRNA molecules 
has yet to be verified in animal models of clinically relevant diseases.
The fact that endothelial cells exhibit different proliferation rates ranging from days 
to years [35] is an important aspect of rational application of a post-transcriptional 
silencing mechanism for target gene inhibition. Silencing effects of siRNA can last 
from 3-7 days in rapidly dividing cells and up to 3 weeks in slow/non-dividing cells. 
The duration of the effect will also depend on the target gene expression kinetics, the 
level of expression, delivered dose and the treatment frequency [36]. Resolution of 
inflammation in chronic diseases may thus require repeated intravenous administration 
of the siRNA therapeutics on a weekly to monthly basis. Advanced genome editing 
technologies such as zinc finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and clustered regularly interspaced short palindromic repeat 
(CRISPR)-based systems will complement gene silencing methods and broaden our 
toolkit to understand and treat diseases [37]. These chimeric nucleases enable efficient, 
precise and irreversible genome modification by inducing targeted DNA double-strand 
breaks that stimulate the cellular DNA repair mechanisms [38]. This approach allows 
correcting the underlying cause of the disease, therefore permanently eliminating the 
disease symptoms. So far, there is no evidence that this would be a desired therapy for 
attenuation of endothelial activation in chronic inflammatory diseases though, lack of 
understanding of the underlying causes of many inflammatory diseases will be the key 
factor that limits therapeutic use of genome engineering tools. To date, ZFNs have been 
used to correct the disease-causing mutations in X-linked severe combined immune 
deficiency (SCID) [39], hemophilia B [40], and α1-antitrypsin deficiency [41]. Unlike 
ZFNs and TALENs that are protein-guided, the specificity of CRISPR/Cas9 targeting 
is RNA-guided [42]. Early studies indicate that CRISPR/Cas9 can been used to edit 
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genomes in human cells, zebrafish [43] and bacteria [44] with comparable activity to 
TALENS, but show higher off-target effects [45]. Delivery of those tools to the cells is 
achieved by transfection/transduction of DNA, but RNA delivery is also an on-going 
area of investigation. Overall, utility of site-specific nucleases is currently limited 
mainly to production and manipulation of induced pluripotent stem cells but further 
development of this technology will ultimately open numerous new directions for gene 
therapy. Specificity of target recognition of each nuclease platform and the optimal 
methods for delivering DNA or mRNA sequences encoding these nucleases into cells 
and organisms are a critical areas of future research. So far, the packaging capacity of 
large DNA fragments into viral vectors is limited, while efficacy of DNA delivery by 
non-viral vectors is insufficient.
New technologies facilitating clinical translation of siRNA nanoparticles
Despite great progress in nanoparticle development, their translation to the clinic 
has been slow compared with small molecule drugs. New applications require tailoring 
of the properties of the carrier such as size, shape, surface charge, and its content, that 
are important parameters for optimizing cellular delivery and in vivo pharmacokinetics. 
Therefore upscalable formulation methods yielding tunable carriers at limited costs, 
displaying well-defined and reproducible features, will aid the design of effective 
nanoparticle-based therapies. Particle fabrication by the so called Particle Replication 
in Non-wetting Templates (PRINT) process is a robust, well-established, and scalable 
approach for rapidly manufacturing particles with exquisite control over particle 
geometry and composition [46]. Also recent advances in microfluidics are expected to 
improve the synthesis of nanoparticles and accelerate their transition to the clinic [47]. 
Formulation of Lipid nanoparticles (LNP), that are at present the leading systems for 
in vivo delivery of siRNA, employs microfluidic mixing techniques to produce systems 
of 20-100 nm diameter or larger, that have variable siRNA encapsulation efficiencies 
and homogeneity [48]. Moreover, biomimetic microfluidic technologies are capable of 
representing organ-level functions on a chip such as those observed in the lung, liver 
and kidneys [49]. These technologies could serve the evaluation of particle toxicity and 
its therapeutic efficacy, and screen for the most potent formulations prior to entering in 
vivo trials. 
The versatile fabrication methods using nucleic acids as building blocks make 
nucleic acids one of the most popular construction materials for nano-scale objects [50]. 
Nanoobjects formed from DNA, such as DNA origami, may be designed in almost any 
3D shape [51]. The geometry and size of DNA assemblies can be accurately designed 
due to the well-known self-recognition properties of DNA and the knowledge of the 
exact structure of the double helix at the atomic level. Moreover, DNA nanostructures 
composed of nucleic acid hybrid materials, e.g, DNA-gold nanoparticles or DNA block 




copolymer micelles, permit to implement extra functionalities (including imaging 
agents), and offer multiple possibilities for drug incorporation with control over the 
payload release [52, 53]. For example, anticancer drugs, e.g., doxorubicin, paclitaxel, 
and cisplatin (reviewed by de Vries [50]) or antisense DNA have been successfully 
conjugated to these nanoparticles. Similarly, gold-nanoconjugates functionalized with 
densely packed RNA are a potent material for siRNA delivery due to high serum stability 
without the need for chemical modification of RNA and efficient gene silencing [54].
Above mentioned carrier systems composed of high density DNA or RNA show 
low immunogenicity and can be taken up by the cells without the need for a transfection 
agents, mainly via scavenger-receptor-dependent endocytosis [50, 55]. These system 
may therefore in the near future become the new frontier in the field of biomedicine. 
To date, use of DNA and RNA nanostructures for drug delivery is in pre-clinical stage 
and more effort is necessary to achieve the pharmaceutical grade and manufacturing 
scale established in pharmaceutical industry for other delivery platforms, such as lipid 
based carriers.
In summary, many new technologies are now available to assist in the design and 
development of superior siRNA delivery systems for clinical application, that may or 
may not be made endothelial-specific, and their potential needs further exploration.
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Algemene inleiding (hoofdstuk 1)
De ontdekking en de toepassing van “RNA interferentie” (RNAi) heeft het 
fundamentele onderzoek naar functie en regulatie van eukaryote genen in een 
stroomversnelling gebracht en onze inzichten daarin aanzienlijk vergroot.Tot nu toe 
zijn “short interfering RNAs” (siRNAs) de meest effectieve instrumenten gebleken 
voor het specifiek onderdrukken van gen expressie met als gevolg dat hun klinische 
toepassing in snel tempo toeneemt [1].Het uiteindelijke doel hiervan, dat wil zeggen 
het ontwerpen van effectieve op siRNA gebaseerde therapieën voor levensbedreigende 
of ernstige invaliderende ziekten, zal echter niet worden bereikt zonder de efficiëntie, 
target specificiteit en veiligheid van siRNA afgifte systemen verder te verbeteren.
Het in dit proefschrift beschreven onderzoek richt zich op de ontwikkeling van 
een op lipiden gebaseerd siRNA drager systeem dat geschikt is voor de specifieke 
in vivo aflevering van siRNAs in de endotheelcellen van bloedvaten. Voor dat doel 
werd een dragersysteem voor siRNA ontwikkeld op basis van het kationische amfifiele 
lipide SAINT-18 met als potentiële targets de endotheel-specifieke eiwitten E-selectine 
en vasculair cel adhesie molecuul (VCAM)-1, die met name tot expressie komen 
op ontstoken bloedvatendotheel. Vervolgens werd nagegaan of, en in hoeverre dit 
systeem kan worden toegepast om de ontstekingsreactie in vivo met specifiek siRNA 
te onderdrukken. 
Het is bekend dat microvasculaire endotheelcellen niet slechts participant zijn in 
zowel acute als chronische ontstekingen maar ook een belangrijke rol als regulator in 
ontstekingsprocesen vervullen. We verwachtten daarom dat de mogelijkheid om siRNA 
specifiek aan deze cellen af te leveren zou kunnen leiden tot een beter begrip van de rol 
van endotheliale cellen in het ontstekingsproces.
In hoofdstuk 2 wordt een overzicht gegeven van recente ontwikkelingen in het 
ontwerpen van verschillende strategieën gericht op de (therapeutische) behandeling 
van (chronische) ontstekingen via interventie op het niveau van het vaatendotheel. 
In dit verband wordt het concept geïntroduceerd van endotheliale heterogeniteit met 
betrekking tot het betreffende ziektebeeld en de typen bloedvaten die betrokken zijn, en 
de consequenties daarvan voor doel-specifieke therapeutische interventies.
Obstakels die een belemmering vormen voor de klinische toepassing van siRNA 
voor de behandeling van chronische ontstekingsprocessen (inflammatie) staan centraal 
in deze discussie. Daarbij komen met name de intracellulaire afhandeling van de naar 
het microvasculaire endotheel gestuurde afgiftesystemen aan de orde, evenals de 
heterogeniteit van dat endotheel met betrekking tot zijn respons op pro-inflammatoire 
prikkels en farmacologisch ingrijpen.





In reactie op een inflammatoire prikkel brengen vaatendotheelcellen verschillende 
adhesie eiwitten zoals E-selectine, VCAM-1 en intercellulair adhesie molecuul (ICAM)-
1 in verschillende mate tot expressie op het celoppervlak. De exacte opmaak van 
adhesie-eiwit expressie is afhankelijk van het type endotheel dat reageert[2]. Daarom 
is inzicht in en kennis van de mogelijke target epitopen op het aangedane endotheel 
van essentieel belang voor het resultaat van een endotheel-specifieke therapie. Idealiter 
komt het beoogde target epitoop uitsluitend tot expressie op het aangedane endotheel 
en wordt het betreffende eiwit in de cel opgenomen na interactie met het ligand dat 
bindt aan het eiwit. De kennis hierover en over de intracellulaire verwerking van aldus 
opgenomen carriersystemen is echter nog zeer beperkt.
In samenhang hiermee worden nieuwe technologieën besproken die de verdere 
ontwikkeling van cel- of weefselspecifieke afgiftesystemen tot aan de klinische 
toepassing kunnen bevorderen, zoals de toepassing van dunne weefselplakjes en de 
zogenaamde laser microdissectie (LMD). Het gebruik van weefselplakjes maakt het 
mogelijk de farmacologische effecten van een behandeling te analyseren in een systeem 
waarin de complexiteit van het intacte organisme (d.w.z. het proefdier of de mens) 
dicht benaderd wordt. LMD op zijn beurt maakt het mogelijk lokale farmacologische 
effecten op het endotheel te analyseren in geslecteerde (micro)vasculaire segmenten.
Het ontbreken van geschikte diermodellen is een probleem voor het onderzoeken van 
de betrokkenheid van bepaalde genen bij het ontstaan van pathologische afwijkingen. 
Bij gebrek aan beter wordt hierbij vaak gebruik gemaakt van transgene proefdieren, een 
zeer kostbare en tijdrovende benadering. Het gebruik van RNA interferentie technieken 
in combinatie met geschikte cel-specifieke afgiftesystemen zou een aantrekkelijk 
alternatief daarvoor kunnen vormen en kunnen bijdragen aan de identificatie van 
geschikte therapeutische targetmoleculen voor in vivo toepassing.
Hoofdstuk 3 gaat over de formulering van katalytische oligodeoxynucleotiden 
(“DNAzymes”), in complexen met kationische lipiden met als doel de rol van het “early 
growth response protein-1” (Egr-1) te onderzoeken in een rattenmodel voor pulmonaire 
arteriële hypertensie (PAH). DNAzymes kunnen binden aan bepaalde target RNA 
sequenties met als resultaat specifieke afbraak van (m)RNA en dus onderdrukking van 
de expressie van bepaalde genen. 
PAH wordt getypeerd door de vorming van unieke beschadigingen in de intima 
van kleine arteriën in de long die leiden tot een toename van de afterload van het 
rechter ventrikel (RV) met als ultiem gevolg hartfalen. De aandoening is niet meer 
behandelbaar als de laesies eenmaal zijn gevormd en dus is er een dringende behoefte 
aan een strategie die de vorming van deze laesies kan voorkomen.
Complexen van Egr-1-specifiek DNAzyme met het kationische lipide 1,2-dioleoyl-
3-trimethylammonium-propaan (DOTAP) werden intraveneus toegediend aan ratten 





met een experimentele flow-geïnduceerde PAH. Dit resulteerde in een down-regulatie 
van Egr-1 in  de pulmonale vasculatuur en onderdrukte de pulmonaire vasculaire 
remodellering, inclusief de vorming van afsluitende neo-intima laesies. Dit ging 
gepaard met afnames van de pulmonaire vaatweerstand, de RV systolische druk en RV 
hypertrofie.
Aangetoond werd dat de onderdrukte expressie van de Egr-1 target genen PDGF-B, 
TGF-β, IL-6 en p53 en de daarmee gepaard gaande afname in vaatproliferatie en 
toegenomen apoptose samen gaat met een verminderde neo-intima vorming. Deze 
waarneming impliceert dat Egr-1 een belangrijke rol speelt tijdens de bij PAH 
optredende vasculaire remodellering. 
In hoofdstuk 4 worden pogingen beschreven een carrier systeem te ontwerpen 
voor de selectieve afgifte van siRNA in aan inflammatie onderhevige endotheelcellen. 
Voor dat doel werd een nieuw type liposomen gebruikt, genaamd SAINT-O-Somen, 
gebaseerd op de combinatie van conventionele lang-circulerende liposomen en het 
kationische lipide 1-methyl-4-(cis-9-dioleyl)methyl-pyridiniumchloride (SAINT-C18).
SAINT-O-Somen met 20% SAINT-C18 lieten zien niet alleen een goede siRNA 
insluitingsefficientie te bezitten maar daarnaast ook superieur te zijn aan conventionele 
liposomen wat betreft effectiviteit van intracellulaire afgifte van kleine moleculen. 
Geheel in overeenstemming met de gestelde doelen kon worden aangetoond dat de 
adhesie eiwitten VCAM-1 en E-selectine geschikt zijn als targets voor de selectieve 
afgifte van siRNA in ontstoken endotheel. Daartoe werden siRNA-bevattende SAINT-
O-Somen, die aan hun oppervlak waren voorzien van antilichamen tegen deze 
adhesie eiwitten, geïncubeerd met tumornecrosefactor (TNF)-α geactiveerde primaire 
endotheelcellen. Zowel met anti-VCAM-1 als met anti-E-selectine gemodificeerde 
SAINT-O-Somen werden na opname door de cellen aangetroffen in endolysosomale 
compartimenten, van waaruit over een periode van 24 uur het ingesloten siRNA ten dele 
in het cytosol werd vrijgemaakt. Er kon worden aangetoond dat beide SAINT-O-Somen 
met daarin ingesloten een siRNA dat specifiek is voor het endotheliale VE-cadherine 
gen het betreffende target mRNA en daarmee de expressie van het VE-cadherine kunnen 
down-reguleren zonder enige toxiciteit. Met het oog op de in vivo toepassing van dit 
carrier systeem is het voorts van belang dat kon worden vastgesteld dat de SAINT-O-Somen 
stabiel zijn in aanwezigheid van serum en het ingesloten siRNA volledig beschermen tegen 
afbraak door serum Rnases. Na intraveneuze toediening in de muis lieten de SAINT-O-
Somen een farmacokinetisch profiel zien dat vergelijkbaar is met dat van conventionele 
lang-circulerende liposomen met een halfwaarde tijd van ca. 17 uur. Samenvattend: 
deze waarnemingen laten zien dat de met anti-VCAM-1 of anti-E-selectine antilichaam 
gemodificeerde SAINT-O-Somen een in principe geschikt dragersysteem vormen voor de 
selectieve en functionele in vivo afgifte van siRNA in ontstoken endotheelcellen.





Hoofdstuk 5 toont de conceptuele bruikbaarheid aan van siRNA-bevattende anti-
VCAM-1 (Ab
VCAM-1
) SAINT-O-Somen in met TNF-α behandelde muizen als in vivo 
model voor ziekte-gerelateerde endotheel activatie. Als anti-inflammatoir target gen 
voor endotheel-specifieke therapeutische interventie werd NFκB p65 (ReIA) gekozen. 
Dit is een sleutel component van een signaal transductie pad dat een essentiële rol speelt 
in endotheel activering. Intraveneus toegediende Ab
VCAM-1
 SAINT-O-Somen bleken 
selectief te worden afgeleverd aan endotheelcellen die VCAM-1 tot expressie brengen in 
specifieke microvasculaire segmenten in ontstoken organen van met TNF-α behandelde 
muizen. SiRNAs specifiek voor ReIA werden effectief afgeleverd in de vasculatuur 
van de nier zonder noemenswaardige toxiciteit voor lever en nier. De daarmee gepaard 
gaande onderdrukking van ReIA expressie veroorzaakte in renale microvasculatuur 
een vermindering van de inflammatoire respons na LPS toediening. Bovendien werden 
lokale therapeutische effecten vastgesteld in de vorm van remming van expressie van 
de pro-inflammatoire genen E-selectine, interleukine-6 en macrofagen aantrekkend 
eiwit (MCP)-1 en van leukocyten mobilisatie. Met behulp van laser microdissectie 
konden we vaatbed-specifieke farmacologische effecten onderscheiden die gemaskeerd 
werden wanneer hele-nier homogenaten werden geanalyseerd. Deze studie laat zien dat 
op siRNA gebaseerde therapeutische behandeling van ontstoken endotheel zeer wel 
mogelijk is en biedt goede vooruitzichten op bruikbare strategieën voor de behandeling 
van (chronische) inflammatoire aandoeningen. 
Tenslotte wordt in hoofdstuk 6 een nieuw op SAINT gebaseerd siRNA carrier 
systeem beschreven met daarin ingebouwd een klein kationisch eiwit, protamine, als 
transfectie versterker, met als doel verbetering van de efficiëntie van in vivo siRNA 
vrijmaking uit het carriersysteem en onderdrukking van gen expressie.
Het concept voor dit type carrier is gebaseerd op het vermogen van SAINT-18 om, 
in combinatie met het helper lipide 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) en in aanwezigheid van serum, op efficiente wijze DNA en siRNA, maar ook 
eiwitten in cellen binnen te brengen zonder toxiciteitsverschijnselen te veroorzaken7]. 
Dergelijke zogenaamde SAINT-liposoom-polykation-DNA (S-LPD) en SAINT-
liposoom-polykation (S-LP) complexen werden gemaakt door protamine met siRNA, 
en eventueel carrier DNA, te complexeren en vervolgens SAINT-DOPE liposomen toe 
te voegen, met als gevolg dat de protamine/siRNA(/DNA) complexen hierin worden 
ingebouwd. Deze S-LP(D) complexen blijken siRNA met hoge efficientie in te bouwen, 
vertonen geringe toxiciteit op cellulair niveau en een superieur vermogen tot gen down-
regulatie in endotheelcellen in vergelijking met de op DOTAP/cholesterol gebaseerde 
liposoom-polycation-DNA (LPD) partikels ontwikkeld door Huang en medewerkers 
[8].





Aangetoond werd dat inbouw van 10 mol% PEG en koppeling van het anti-E-
selectine antilichaam in de S-LP(D) partikels selectieve siRNA afgifte in geactiveerde 
endotheelcellen mogelijk maakten. Meting van fysicochemische parameters van deze 
S-LPD en S-LP partikels, zoals stabiliteit in partikel afmeting en siRNA structuur in 
aanwezigheid van serum bij 37 oC, laat zien dat de eigenschappen van deze partikels 
compatibel zijn met in vivo vigerende omstandigheden. Dit rechtvaardigt verdere 
validering van deze systemen voor in vivo toepassingen.
Samengevat laten de studies in dit promotieonderzoek zien dat op SAINT-gebaseerde 
siRNA carriersystemen uitermate geschikt zijn voor in vivo aflevering van siRNA in 
endotheelcellen in ontstekingsweefsel. Vervolgonderzoek zal duidelijk moeten maken 
in hoeverre deze nieuwe benadering therapeutisch gewin oplevert voor de behandeling 
van (chronische) ontstekingsziekten in hiervoor relevante proefdiermodellen.










Odkrycie zjawiska interferencji RNA (ang. RNA interference, RNAi) i jego 
zastosowanie w badaniach podstawowych zmieniły dotychczasowe poglądy na 
mechanizmy regulacji ekspresji genów oraz przyspieszyły poznawanie funkcji genów. 
Jak dotąd małe interferujące RNA (ang. small interfering RNA, siRNA) stanowią 
najbardziej efektywne narzędzie pozwalające w precyzyjny sposób wyciszyć ekspresję 
dowolnego genu poprzez degradację cząsteczek mRNA, co skutkuje obniżoną 
produkcją białka. siRNA są małymi, około 22-nukleotydowymi, dwuniciowymi 
cząsteczkami RNA o 100%-owej homologii do docelowego mRNA, powstałymi 
w wyniku syntezy chemicznej. Terapeutyczny potencjał siRNA wzbudza ogromne 
zainteresowanie, jednak skuteczne terapie z użyciem siRNA wymagają zastosowania 
wydajnych oraz bezpiecznych nośników umożliwiających użycie siRNA wewnątrz 
żywego organizmu (in vivo). Aplikacja tzw. „nagiego siRNA” –  bez użycia nośnika 
–  skutkuje jego degradacją przez enzymy odpowiedzialne za rozkład RNA oraz jego 
niemal natychmiastowym (5-10 min) wydaleniem z krwiobiegu.
Komorki śródbłonka naczyń stanowią wysoce wyspecjalizowaną wyściółkę naczyń 
krwionośnych i pełnią kluczowa rolę w utrzymywaniu wewnętrznej homeostazy 
organizmu poprzez regulację ważnych procesów biologicznych takich jak np. 
krzepnięcie krwi, angiogeneza, odpowiedź zapalna oraz regulacja ciśnienia tętniczego 
i ukrwienia tkanek. Szczególnie istotną rolą komórek śródbłonka naczyń jest regulacja 
odpowiedzi zapalnej, gdzie odpowiadają one za rekrutację leukocytów z krwiobiegu 
do ogniska zapalnego oraz pośredniczą w ich migracji do przyległych tkanek. Kontrola 
odpowiedzi prozapalnej przez komórki śródbłonka naczyń odbywa się poprzez ich 
aktywacje pod wpływem bodźców prozapalnych np. bakteryjnych lipopolisacharydow 
(LPS), co indukuje produkcję białek z rodziny selektyn (P-selektyny, E-selektyny), 
białek adhezyjnych (ang. Vascular cell adhesion protein 1; VCAM-1, Intercellular 
Adhesion Molecule 1; ICAM-1) oraz wydzielanie cytokin prozapalnych (m.in. 
interleukiny-6 i 8; IL-6, IL-8). Selektyny i białka adhezyjne uczestniczą w adhezji 
leukocytów do aktywowanych komórek śródbłonka, podczas gdy interleukiny 
odpowiadzają za pobudzanie procesu zapalnego i aktywację leukocytów.
Terapie przeciwzapale, stosowane obecnie w leczeniu przewlekłych lub ostrych 
stanów zapalnych towarzyszących np. miażdżycy, cukrzycy typu 2 czy sepsie, 
charakteryzuje brak selektywności molekularnej i komórkowej. Działają one 
systemowo na wiele komórek organizmu oraz blokują wiele różny mechanizmy 
wewnątrzkomórkomórkowych, co prowadzi do niepożądanych efektów ubocznych 
takich jak obniżenie odporności biologicznej organizmu, osteoporoza, zwiększone 
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ryzyko zawału mięśnia sercowego i problemy z układem pokarmowym. Opracowanie 
nowego typu nośników pozwalających na selektywne dostarczanie siRNA do 
aktywowanych komórek śródbłonka naczyń, w celu obniżenia ekspresji czynników 
prozapalnych, umożliwiłoby terapię przeciwzapalną o wysokiej specificzności 
molekularnej i komórkowej. Szczególnie obiecujące pod tym względem są nośniki 
lipidowe, ze względu na ich niską toksycznością w próbach klinicznych oraz wysoką 
wydajnoscią w transfekcji siRNA in vivo.
Cele badań opisanych w niniejszej pracy były nastepujące:
• Zaprojektowanie oraz scharakteryzownie nośnika lipidowego opartego na 
lipidzie kationowym SAINT-C18, który umożliwiłby efektywne i specyficzne 
dostarczanie siRNA do komórek sródbłonka naczyń w stanie zapalnym. 
• Zbadanie przydatności białek adhezyjnych (VCAM-1 oraz E-selektyny) do 
selektynego wprowadzania nośników siRNA do aktywowanych komórek 
śródbłonka naczyń.
• Zbadanie potencjału opracowanych nośnikow z siRNA do selektywnego 
wyciszania prozapalnych genów w komórkach sródbłonka naczyń w stanie 
zapalnym oraz  zademonstrowanie ich efektów przeciwzapalnych in vivo.
Rozdzial 1 zawiera ogólne wprowadzenie do podjętej tematyki badań oraz 
informacje dotyczące celów badawczych niniejszej pracy.
Rozdzial 2 zawiera przegląd literatury dotyczącej aktualnie dostępnych nośników 
umożliwiających dostarczanie siRNA do komórek sródbłonka naczyń oraz porusza 
kwestie istotne dla terapii z użyciam siRNA, takie jak właściwości nośnika siRNA 
wpływające na wydajność transfekcji oraz na uwalnianie siRNA wewnątrz komórki. 
Rozdział ten prezentuje także koncept zróżnicowania komórek sródbłonka naczyń w 
poszczególnych organach pod względem ich odpowiedzi prozapalnej oraz dyskutuje 
konsekwencje tego zjawiska dla potencjalnych terapii z użyciem siRNA celowanych w 
komórki sródbłonka naczyń. W rozdziale 2 podejmujemy również dyskusję dotyczącą 
wykorzystania nowych technologii, takich jak  laserowe pozyskiwanie mikroskrawków 
(ang. laser microdissection, LMD) oraz plastrów tkankowych do badań nad nośnikami 
siRNA w celu przyspieszenia ich zastosowania klinicznego. 
Celem rozdziału 3 było zbadanie funkcji czynnika transkrypcyjnego early 
growth response protein-1 (Egr-1) w rozwoju nadciśnienia płucnego (ang. pulmonary 
arterial hypertension, PAH). Chorobę tę cechują charakterystyczne zmiany w błonie 
wewnętrznej naczyń płucnych (ang. neointimal lesions)  prowadzące do podwyższenia 
ciśnienia w krążeniu płucnym oraz przerostu prawego przedsionka serca, a z czasem 
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do jego niewydylności i śmierci pacjenta. Obecnie nie istnieją skuteczne sposoby 
leczenia pacjetów z PAH, dlatego niezbędne są badania nad przyczynami rozwoju i 
nowymi terapiami tej choroby. Dostarczenie do komórek śródbłonka naczyń płucnych 
katalitycznych nukleotydów (DNAzymów) degradujących mRNA genu Egr-1, w 
połączeniu z nośnikiem lipidowym 1,2-dioleoilo-3-trimetyloamoniopropan (DOTAP), 
umożliwiło  wyciszenie ekpresji tego genu w naczyniach płucnych szczurów z PAH. 
Wyciszenie ekspresji Egr-1 zahamowało powstawanie zmian w naczyniach płucnych 
oraz zaskutkowało zmniejszeniem ciśnienia płucnego i utrzymaniem prawidłowej 
funkcji prawego przedsionka. Zaobserwowano także związek pomiędzy zmniejszoną 
ekpresją Egr-1 oraz obniżoną ekspresją genów bedących pod kontrolą Egr-1 (PDGF-B, 
TGF-β, IL-6 and p53), co mogło mieć wpływ na obniżenie proliferacji i  zwiększenie 
apoptozy komórek w naczyniach płucnych. Wyniki te zostały również potwierdzone z 
użyciem pioglitazonu – leku, kóry poprzez aktywację PPARγ hamuje ekspresję Egr-1. 
Wyniki te wskazują, że Egr-1 pełni istotną rolę w rozwoju PAH i może posłużyć jako 
cel dla przyszłych terapii, zarówno genowych, opartych na siRNA lub  DNAzymach, 
lub też farmakologicznych, z użyciem aktywatorów PPARγ (np. pioglitazonu).
W rozdziale 4 stworzono oraz scharakteryzowno nośnik lipidowy oparty na 
lipidzie kationowym SAINT-C18, tzw. SAINT-O-Somes, oraz zbadano jego potencjał 
do efektywnego i specyficznego dostarczania siRNA do komórek sródbłonka naczyń 
w stanie zapalnym. Konstrukja nośnika opierała się na wykorzystaniu liposomów: 
pęcherzyków powstających samoistnie z fosfolipidów w środowisku wodnym, 
mających formę podwójnej warstwy lipidowej otaczającej hydrofilowe wnętrze. 
Dodanie lipidu kationowego SAINT-C18 do kompozycji konwencjonalnych liposomów 
nadało im właściwości niezbędne dla nośnika siRNA, m.in. umożliwiło wydajne 
inkorporowanie siRNA do wnętrza liposomów. W rozdziale tym scharakteryzowano 
właściwości fizykochemiczne nośnika zawierającego siRNA takie jak rozmiar, 
stabilność w obecności surowicy, wydajność inkorporowania siRNA oraz jego 
ochrona przed degradacją. Potwierdzono także przydatność VCAM-1 oraz E-selektyny 
jako białek, które mogą służyć do specyficznego dostarczania siRNA do komórek 
śródbłonka naczyń aktywowanych przez TNFα (czynnik nekrozy nowotworów; ang. 
tumor necrosis factor). W tym celu nośnik wyposażono w przeciwciała specyficznie 
rozpoznające VCAM-1 lub E-selektynę na powierzchni aktywowanych komórek 
śródbłonka naczyń i badano specyficzność i efektywność dostarczania siRNA do 
tych komórek. Inkubacja aktywowanych komórek z nośnikiem zawierającym siRNA 
specyficznym dla VE-kadheryny (ang. VE-cadherin) skutkowało 60% wyciszeniem 
ekpresji mRNA oraz białka tego genu. Zbadano też właściwości farmakokinetyczne 
radioaktywnie wyznakowanego nośnika poprzez jego dożylną iniekcje u myszy. Wyniki 
potwierdziły, że SAINT-O-Somes umożliwiają  specyficzne i efektywne wyciszanie 
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genów w komórkach śródbłonka naczyń oraz spełniają wymogi stawiane nośnikom 
siRNA przeznaczonym do aplikacji in vivo. 
W rozdziale 5 kontynuowano badania nad SAINT-O-Somes w mysim modelu 
stanu zapalnego. Celem badań było ustalenie czy SAINT-O-Somes wyposażone w 
przeciwciała rozpoznające VCAM-1 oraz zawierające siRNA przeciwko podjednostce 
p65 (RelA) czynnika transkrypcyjnego NFκB są w stanie zahamować aktywację 
komórek śródbłonka naczyń przez bodźce prozapalne (np. LPS). Wykazano, iż 
nośniki wyposażone w przeciwciała rozpoznające VCAM-1 umożliwiają specyficzne 
dostarczanie siRNA do mysich komórek śródbłonka naczyń wykazujących podwyższoną 
ekspresję VCAM-1, wywołaną dożylnym podaniem TNFα. Zastosowanie technologii 
laserowego pozyskiwania mikroskrawków do izolacji  komórek śródbłonka naczyń 
żylnych nerek umożliwiło  zlokalizowaną analizę ekspresji genów i wykazanie 
lokalnego efektu siRNA w tych naczyniach. Nośniki zawierające siRNA specyficzne 
dla VE-kadheryny lub p65 pozwoliły na 40% wyciszenie ich ekspresji. Zahamowanie 
ekspresji p65 spowodowało osłabienie odpowiedzi prozapalną komórek śródbłonka 
naczyń żylnych nerek stymulowanych LPS, objawiające się zmniejszoną ekspresją 
mRNA dla E-selektyny, MCP-1 i IL-6 oraz zmniejszoną adhezją leukocytów do ścian 
tych naczyń. Wyniki te pokazały, że SAINT-O-Somes wyposażone w przeciwciała 
rozpoznające VCAM-1 oraz zawierające siRNA przeciwko p65 są zdolne do 
specyficznego zahamowania ekspresji genu p65 w aktywowanych komórkach 
śródbłonka naczyń oraz do zahamowania odpowiedzi prozapalnej in vivo. Jest to także 
pierwsza prezentacja zastosowania siRNA do terapii przeciwzapalnej celowanej w 
komórki śródbłonka naczyń.
Rozdział 6 przedstawia konstrukję nośnika siRNA z wykorzystaniem lipidu 
kationowego SAINT-C18 oraz białka protaminy. Celem badań było stworzenie nośnika 
odznaczającego się wysoką wydajnością transfekcji siRNA do komórkek śródbłonka 
naczyń. Idea konstrukcji tego nośnika została oparta na zdolności SAINT-C18, w 
kombinacji z lipidem 1,2- dioleoilo-sn-glicero-3-fosfatydyloetanoloamina (DOPE) w 
stosunku molowym 1:1, do efektywnej transfekcji DNA, siRNA oraz białka do komórek 
z niską toksycznością. Protamina to białko o niskiej masie cząsteczkowej bogate w 
argininę i wspomagjące upakowanie DNA w plemnikach u niektórych ssaków. Silna 
kationowość protaminy sprawia, że jest ona stosowana w warunkach klinicznych do 
osłabiania właściwości antykoagulacyjnych heparyny oraz do konstrukcji nośników 
transportujących kwasy nukleinowe (np. DNA). Skonstruowane przez nas nośniki 
SAINT-liposome-polycation-DNA (S-LPD) and SAINT-liposome-polycation (S-LP) 
powstały w wyniku tworzenia kompleksów protaminy z siRNA oraz DNA, lub jedynie z 
siRNA, a następnie inkorporacji powstałych kompleków przez liposomy o kompozycji 
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SAINT:DOPE. S-LPD i S-LP wykazywały się wysoką wydajnością inkorporacji 
siRNA, niską toksycznością oraz wysoką wydajnością transfekcji siRNA do komórkek 
śródbłonka naczyń. Dodanie do mieszaniny nośników 10 mol% poli(tleneku etylenu) 
(PEG) oraz wyposażenie ich w przeciwciała rozpoznające E-selektynę umożliwiło 
specyficzne dostarczanie siRNA do komórek sródbłonka naczyń aktywowanych przez 
TNFα. Ponadto pokazano, że właściwości fizykochemiczne prezentowane przez S-LPD 
i S-LP spełniają wymogi stawiane nośnikom siRNA przeznaczonym do zastosowania 
in vivo.
Rozdział 7 podsumowuje wyniki opisane w poprzedzających rozdziałach oraz 
przedstawia perspektywy przyszłych badań.
Podsumowując, wyniki badań niniejszej pracy demonstrują, że zaprezentowane 
nośniki siRNA oparte na lipidzie kationowym SAINT-C18 umożliwiają specyficzne 
dostarczanie siRNA in vivo do komórek śródbłonka naczyń w stanie zapalnym. Przyszłe 
badania w stosownych modelach zwierzęcych pozwolą ocenic korzyści płynące z 
zastosowania terapii opartych na siRNA w leczeniu przewlekłych chorób zapalnych.
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